US20200115389A1 - Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors - Google Patents

Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors Download PDF

Info

Publication number
US20200115389A1
US20200115389A1 US16/573,900 US201916573900A US2020115389A1 US 20200115389 A1 US20200115389 A1 US 20200115389A1 US 201916573900 A US201916573900 A US 201916573900A US 2020115389 A1 US2020115389 A1 US 2020115389A1
Authority
US
United States
Prior art keywords
methyl
amino
pyrido
tetrahydro
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/573,900
Inventor
Jiping Fu
Yan Lou
Yigang HE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikang Therapeutics Inc
Original Assignee
Nikang Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikang Therapeutics Inc filed Critical Nikang Therapeutics Inc
Priority to US16/573,900 priority Critical patent/US20200115389A1/en
Assigned to NIKANG THERAPEUTICS, INC. reassignment NIKANG THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FU, JIPING, HE, YIGANG, LOU, YAN
Publication of US20200115389A1 publication Critical patent/US20200115389A1/en
Priority to US15/930,309 priority patent/US10894797B2/en
Priority to US17/025,790 priority patent/US11518772B2/en
Priority to US17/074,337 priority patent/US11034705B2/en
Priority to US18/051,679 priority patent/US20230167134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Definitions

  • the present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
  • SHP2 Src Homology-2 phosphatase
  • SHP2 is a non-receptor protein phosphatase ubiquitously expressed in various tissues and cell types (see reviews: Tajan M et al., Eur J Med Genet 2016 58(10):509-25; Grossmann K S et al., Adv Cancer Res 2010 106:53-89). SHP2 is composed of two Src homology 2 (N—SH2 and C—SH2) domains in its NH2-terminus, a catalytic PTP (protein-tyrosine phosphatase) domain, and a C-terminal tail with regulatory properties.
  • N—SH2 and C—SH2 Src homology 2 domains in its NH2-terminus
  • catalytic PTP protein-tyrosine phosphatase domain
  • C-terminal tail with regulatory properties.
  • SHP2 plays important roles in fundamental cellular functions including proliferation, differentiation, cell cycle maintenance and motility. By dephosphorylating its associated signaling molecules, SHP2 regulates multiple intracellular signaling pathways in response to a wide range of growth factors, cytokines, and hormones.
  • Cell signaling processes in which SHP2 participates include the RAS-MAPK (mitogen-activated protein kinase), the PI3K (phosphoinositol 3-kinase)-AKT, and the JAK-STAT pathways.
  • the RAS-MAPK signaling pathway is crucial for tumor formation and maintenance. Genes encoding various components of this pathway, including RTKs (receptor tyrosine kinases), SHP2, NF1, RAS, or RAF are mutated in cancers, leading to upregulation of MAPK signaling. SHP2 also plays a signal-enhancing role on this pathway, acting downstream of RTKs and upstream of RAS. RTK-driven cancer cells were demonstrated to depend on SHP2 for survival. Thus, SHP2 inhibitor has been proposed as a valid treatment for RTK-driven cancers (see Prahallad, A. et al. Cell Reports 12, 1978-1985 (2015); Chen Y N, Nature 535, 148-152(2016)).
  • SHP2 Given the essential physiological functions SHP2 plays, targeting deregulation of SHP2 is expected to have broad therapeutic applications.
  • Gain of function mutations in PTPN11 the gene that encodes SHP2 have been causally linked to several human diseases, including Noonan Syndrome, juvenile myelomonocytic leukemias, acute myeloid leukemia, myelodysplastic syndrome, and acute B lymphoblastic leukemia.
  • SHP2 functions as an oncogene, and its overexpression and/or activating mutations are reported in various solid tumors, such as neuroblastoma, breast cancer, colon cancer, lung cancer, melanoma, and hepatocellular carcinoma.
  • SHP-2 is believed to mediate inhibitory immune checkpoint signaling of multiple receptors (e.g. PD-1) by dephosphorylating CD28.
  • multiple receptors e.g. PD-1
  • IO Immune-Oncolocy
  • SHP2 systemic lupus erythematosus
  • rheumatoid arthritis see Stanford S. M et al. Arthritis Rheum. 2013 May; 65(5):1171-80; Maeshima K et al. JCI Insight. 2016 May 19; 1(7)).
  • SHP2 has also been characterized as a molecular checkpoint for TGF ⁇ -induced JAK2/STAT3 signaling, suggesting that SHP2 inhibition may offer therapeutic benefit for the treatment of fibrosis (see Zehender A et al. Nat Commun. 2018 Aug. 14; 9(1):3259). Accordingly, SHP2 represents a highly attractive target for the development of novel therapies to treat various diseases.
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or one of R 5 and R 6 is optionally substituted heterocyclyl and the other of R 5 and R 6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 7 R 8 where R 7 and R 8 are independently hydrogen or alkyl;
  • Z 1 is a group of formula (a) or (b):
  • R 9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R 13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 14 is hydrogen, alkyl, or haloalkyl
  • R 11 and R 15 are selected from amino and aminoalkyl
  • R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • e 0, 1, or 2;
  • k 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q 0, 1, or 2, or 3;
  • R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl, and haloalkyl;
  • each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • ring D is absent or present;
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 1 and R 2 , and R 3 and R 4 when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R 5 and R 6 is optionally substituted heterocyclyl and the other of R 5 and R 6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 7 R 8 where R 7 and R 8 are independently hydrogen or alkyl;
  • Z 1 is a group of formula (a) or (b):
  • R 9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R 13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 14 is hydrogen, alkyl, or haloalkyl
  • R 11 and R 15 are selected from amino and aminoalkyl
  • R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • e 0, 1, or 2;
  • k 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q 0, 1, or 2, or 3;
  • R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
  • each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • ring D is absent or present;
  • R 9 is hydrogen
  • R 10 is other than hydrogen
  • L, R 11 and R 12 are as defined in Formula (I); then:
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen and remaining two of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , are independently selected from hydrogen, alkyl, cycloalkyl, amino, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, and aminoalkyl; then Z is other than hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, —OR a (where R a is hydrogen or alkyl), —OC(O)NH 2 , —O-tetrahydrofuran-3-yl, —O-oxetan-3-yl, cyano, pyrazol-1-yl, —CH 2 OCH 3 ,
  • R 5 and R 6 are hydrogen and two of R 1 , R 2 , R 3 , and R 4 are hydrogen, and one of a) R 1 and R 2 and b) R 3 and R 4 , are hydrogen and the other of a) R 1 and R 2 , and b) R 3 and R 4 are attached to the same carbon and are combined together to form alkylidene, 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, then Z is other than hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, —OR a (where R a is hydrogen or alkyl), —NH 2 , and —Y-M (wherein Y is bond and M is alkyl substituted with —OR a or —NR p R q wherein each R a is hydrogen or alkyl and R p and R q are independently hydrogen, alkyl, hydroxyalkyl or
  • R 1 and R 2 when Z is hydrogen, one of a) R 1 and R 2 , and b) R 3 and R 4 are attached to the same carbon and are combined together to form 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, and three of the remaining R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen, then the remaining one of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is not hydrogen, alkyl, cycloalkyl, halo, haloalkyl, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, or amino.
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl, cycloalkyl, heterocycly
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 1 and R 2 and R 3 and R 4 when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R 5 and R 6 is optionally substituted heterocyclyl and the other of R 5 and R 6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 7 R 8 where R 7 and R 8 are independently hydrogen or alkyl;
  • Z 1 is a group of formula (a) or (b):
  • R 9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R 13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 14 is hydrogen, alkyl, or haloalkyl
  • R 11 and R 15 are selected from amino and aminoalkyl
  • R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • e 0, 1, or 2;
  • k 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q 0, 1, or 2, or 3;
  • R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
  • each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • ring D is absent or present;
  • R 9 is hydrogen
  • R 10 is other than hydrogen
  • L, R 11 and R 12 are as defined in Formula (IB); then
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen and remaining two of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, and aminoalkyl; then Z is other than hydrogen, halo, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —OR a , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR
  • R 5 and R 6 are each hydrogen and two of R 1 , R 2 , R 3 , and R 4 are each hydrogen, and one of a) R 1 and R 2 , and b) R 3 and R 4 are hydrogen and the other of a) R 1 and R 2 , and b) R 3 and R 4 are attached to the same carbon and are combined together to form alkylidene, 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, then Z is other than hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, —OR a (wherein R a is hydrogen or alkyl), —NH 2 , and —Y-M (wherein Y is bond and M is alkyl substituted with —OR a or —NR p R q wherein each R a is hydrogen or alkyl and R p and R q are independently hydrogen, alkyl, hydroxyalkyl or alkoxyal
  • R 1 and R 2 when Z is hydrogen, one of a) R 1 and R 2 , and b) R 3 and R 4 are attached to the same carbon and are combined together to form 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene and three of the remaining R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen, then the remaining one of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is not hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, or amino.
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 1 and R 2 , and R 3 and R 4 when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R 5 and R 6 is optionally substituted heterocyclyl and the other is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 7 R 8 where R 7 and R 8 are independently hydrogen or alkyl;
  • Z 1 is a group of formula (a) or (b):
  • R 9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R 13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 14 is hydrogen, alkyl, or haloalkyl
  • R 11 and R 15 are selected from amino and aminoalkyl
  • R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • e 0, 1, or 2;
  • k 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q 0, 1, or 2, or 3;
  • R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl, and haloalkyl;
  • each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • ring D is absent or present;
  • a pharmaceutical composition comprising a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
  • a method of treating a disease treatable by inhibition of SHP2 in a patient comprises administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount thereof a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein), or comprises administering to the patient, preferably a patient in of such treatment, a pharmaceutical composition comprising a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein) and a pharmaceutically acceptable excipient.
  • the disease is cancer.
  • the disease is cancer selected from lung, stomach, liver, colon, kidney, breast, pancreatitis, juvenile myelomonocytic leukemias, neurolastoma, melanoma, and acute myeloid leukemia.
  • the disease is selected from Noonan syndrome and Leopard syndrome.
  • a compound of Formula (I), (IA), (IB), or (IC) (or any embodiments thereof described herein) or a pharmaceutically acceptable salt thereof for use as a medicament.
  • a compound of Formula (I), (IA), (IB), or (IC) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein) in the manufacture of a medicament for treating a disease in a patient in need of such treatment in which the activity of SHP2 contributes to the pathology and/or symptoms of the disease.
  • a ninth aspect provided is a method of inhibiting SHP2 which method comprises contacting SHP2 with a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof; or contacting SHP2 with a pharmaceutical composition comprising a compound of the present disclosure (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • Q is halo or SH
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 1 and R 2 , and R 3 and R 4 when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R 5 and R 6 is optionally substituted heterocyclyl and the other of R 5 and R 6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • Q is halo. In a subembodiment of the first embodiment, Q is chloro, bromo, or iodo.
  • Q is —S ⁇ M + where M + metal ion.
  • M + is sodium or potassium.
  • first, second, and third embodiments and subembodiments contained therein are as defined in the embodiment section herein below.
  • R 3 , R 4 , and Z substituents can replace any hydrogen on the 6-membered ring which comprises group A, including one or both of the hydrogens of the CH 2 group when A is CH 2 , and including the hydrogen of NH when A is NH.
  • R 3 , R 4 , and Z substituents can replace any hydrogen on the 6-membered ring which comprises group A, including one or both of the hydrogens of the CH 2 group when A is CH 2 , and including the hydrogen of NH when A is NH.
  • one or both of the hydrogens are optionally replaced by one or two R 19 groups.
  • Alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like. It will be recognized by a person skilled in the art that the term “alkyl” may include “alkylene” groups.
  • Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
  • Alkenyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing a double bond, e.g., propenyl, butenyl, and the like.
  • Alkyldienyl is alkenyl as defined above that is attached via the terminal divalent carbon.
  • alkenyl as defined above that is attached via the terminal divalent carbon.
  • the alkyldienyl group is enclosed by the box which is indicated by the arrow.
  • Alkylthio means a —SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.
  • Alkylsulfonyl means a —SO 2 R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
  • Alkylsulfoxide means a —SOR radical where R is alkyl as defined above, e.g., methylsulfoxide, ethylsulfoxide, and the like.
  • Amino means a —NH 2 .
  • Alkylamino means a —NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, propylamino, or 2-propylamino, and the like.
  • “Acylamino” means a —NHC(O)R radical where R is alkyl as defined above, e.g., acetylamino, propionoylamino, and the like.
  • Aminoalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with —NR′R′′ where R′ and R′′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, or R′ and R′′ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl, each as defined herein, e.g., aminomethyl, aminoethyl, methylaminomethyl, morpholinylethyl, piperazin-1-ylethyl, and the like.
  • Alkoxy means a —OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
  • Alkoxyalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, such as one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.
  • Alkoxycarbonyl means a —C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
  • Aryl means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.
  • “Aralkyl” means -(alkylene)-R where R is aryl as defined above e.g., benzyl or phenethyl.
  • Cycloalkyl means a monocyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
  • Cycloalkylalkyl means a -(alkylene)-R radical where R is cycloalkyl as defined above, e.g., cyclopropylmethyl, cyclohexylmethyl, and the like.
  • Cycloalkylene means, unless stated otherwise, a monocyclic saturated divalent hydrocarbon radical of three to six carbon atoms optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, each as defined herein. Examples include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, and the like.
  • Carboxy means —C(O)OH.
  • Dialkylamino means a —NRR′ radical where R and R′ are alkyl as defined above, e.g., dimethylamino, methylethylamino, and the like.
  • Aminosulfonyl means a —SO 2 NRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and the like.
  • Aminocarbonyl means a —CONRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, and the like.
  • Aminocarboxy means a —C(O)ONRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminocarbonyloxy, methylaminocarbonyloxy, dimethylaminocarbonyloxy, and the like.
  • Halo means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
  • Haloalkyl means alkyl radical as defined above, which is substituted with one or more halogen atoms, e.g., one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., —CH 2 Cl, —CF 3 , —CHF 2 , —CH 2 CF 3 , —CF 2 CF 3 , —CF(CH 3 ) 2 , and the like.
  • halogen atoms e.g., one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., —CH 2 Cl, —CF 3 , —CHF 2 , —CH 2 CF 3 , —CF 2 CF 3 , —CF(CH 3 ) 2 , and the like.
  • fluoroalkyl When the alkyl is substituted with only fluoro, it can be referred to in this Application
  • Haloalkoxy means a —OR radical where R is haloalkyl as defined above e.g., —OCF 3 , —OCHF 2 , and the like.
  • R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.
  • Hydroalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom.
  • Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
  • Heterocyclyl means a saturated or unsaturated monovalent monocyclic or bicyclic ring of 4 to 10 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a —CO— group.
  • heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydro-pyranyl, thiomorpholino, 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, 6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one, and the like.
  • the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic.
  • the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino and is a subset of the heterocyclyl group.
  • Heterocyclylene means, unless stated otherwise, a saturated or unsaturated divalent monocyclic or bicyclic ring of 4 to 6 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C. Heterocyclylene can be optionally substituted with one or two substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, cyano, or hydroxy, each as defined herein.
  • Heteroaryl means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms, unless otherwise stated, where one or more, (in one embodiment, one, two, or three), ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon.
  • Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like.
  • the terms “heteroaryl” and “aryl” are mutually exclusive. When the heteroaryl ring contains 5- or 6 ring atoms it is also referred to herein as 5- or 6-membered heteroaryl.
  • Heteroaralkyl means -(alkylene)-R where R is heteroaryl as defined above e.g., benzyl or phenethyl.
  • any definition herein may be used in combination with any other definition to describe a composite structural group.
  • the trailing element of any such definition is that which attaches to the parent moiety.
  • the composite group alkoxyalkyl means that an alkoxy group attached to the parent molecule through an alkyl group.
  • the present disclosure also includes protected derivatives of compounds of Formula (I), (IA), (IB), or (IC) or embodiments thereof.
  • compounds of Formula (I), (IA), (IB), or (IC) when compounds of Formula (I), (IA), (IB), or (IC) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups.
  • suitable protecting groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, 5 th Ed., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety.
  • the protected derivatives of compounds of Formula (I), (IA), (IB), or (IC) can be prepared by methods well known in the art.
  • the present disclosure also includes polymorphic forms and deuterated forms of the compounds of Formula (I), (IA), (IB), or (IC).
  • prodrug refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug.
  • prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • a “pharmaceutically acceptable salt” of a compound of Formula (I), (IA), (IB), or (IC) means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Such salts include:
  • acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulf
  • a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
  • organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • the compounds of Formula (I), (IA), (IB), or (IC) may have asymmetric centers.
  • Compounds of Formula (I), (IA), (IB), or (IC) containing an asymmetrically substituted atom may be isolated in optically active or racemic forms.
  • Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art.
  • Certain compounds of Formula (I), (IA), (IB), or (IC) can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure.
  • alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth.
  • the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all the positional isomers albeit only a few examples are set forth.
  • all hydrates of a compound of Formula (I), (IA), (IB), or (IC) are within the scope of this disclosure.
  • the compounds of Formula (I), (IA), (IB), or (IC) may also contain unnatural amounts of isotopes at one or more of the atoms that constitute such compounds.
  • Unnatural amounts of an isotope may be defined as ranging from the amount found in nature to an amount 100% of the atom in question. that differ only in the presence of one or more isotopically enriched atoms.
  • Exemplary isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • Isotopically labeled compounds e.g., those labeled with 3 H and 14 C
  • Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements).
  • substituents such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements).
  • one or more hydrogen atoms are replaced by 2 H or 3 H, or one or more carbon atoms are replaced by 13 C- or 14 C-enriched carbon.
  • Positron emitting isotopes such as 15 O, 13 N, 11 C, and 15 F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
  • Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • Optionally substituted aryl means aryl that is optionally substituted with one, two, or three substituents independently selected from alkyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfonyl, amino, alkylamino, dialkylamino, halo, haloalkyl, haloalkoxy, and cyano.
  • Optionally substituted aralkyl means -(alkylene)-R where R is optionally substituted aryl as defined above.
  • Optionally substituted heteroaryl means heteroaryl as defined above that is optionally substituted with one, two, or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, and cyano.
  • Optionally substituted heteroaralkyl means -(alkylene)-R where R is optionally substituted heteroaryl as defined above.
  • Optionally substituted heterocyclyl means heterocyclyl as defined above that is optionally substituted with one, two, or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy, and cyano.
  • Optionally substituted heterocyclylalkyl means -(alkylene)-R where R is optionally substituted heterocyclyl as defined above.
  • a “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the specification and claims includes both one and more than one such excipient.
  • disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • combination therapy means the administration of two or more therapeutic agents to treat a disease or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • patient is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
  • Treating” or “treatment” of a disease includes:
  • treating or treatment means (2) or (3) above.
  • a “therapeutically effective amount” means the amount of a compound of Formula (I), (IA), (IB), or (IC) or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment for the disease.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
  • inhibiting includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of SHP2 activity compared to normal.
  • the present disclosure includes:
  • the compound in a first subembodiment of embodiment 1, is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the compound in a second subembodiment of embodiment 1, is a compound of Formula (IA), or a pharmaceutically acceptable salt thereof.
  • the compound in a third subembodiment of embodiment 1, is a compound of Formula (IB), or a pharmaceutically acceptable salt thereof.
  • the compound in a fourth subembodiment of embodiment 1, the compound is a compound of Formula (IC), or a pharmaceutically acceptable salt thereof.
  • the compound of any one of embodiment 1 and subembodiments contained within embodiment 1, or a pharmaceutically acceptable salt thereof is wherein the has a structure of formula (II): (i.e., Z 1 is a group of formula (a))
  • the compound of any one of embodiments 1 and 2 and subembodiment contained therein, and or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIA):
  • the compound of any one of embodiment 1 and subembodiment contained within embodiment 1, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (III): (i.e., Z 1 is a group of formula (b))
  • the compound of any one of embodiment 1 and 4 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIIA):
  • the compound of any one of embodiments 1 to 5 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein E is O and A is CH 2 or bond.
  • the compound of any one of embodiments 1 to 5 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein E is O and A is bond.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O) 2 R d , —OC(O)NR i R j , —S(O) 2 NR n R o , —NR p R q , or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl,
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond or O and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)OR b , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , or —S(O) 2 NR n R o .
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O—R a where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)OR a where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —OR a where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —O(alk)OR b where R b is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethyloxy, methoxyethyloxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is methoxymethyloxy, methoxyethyloxy, methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxymethyl, or oxetan-3-ylmethyloxymethyl.
  • the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is fluoro.
  • the compound of any one of embodiments 1 to 19 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 9 and R 13 are hydrogen.
  • the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R 9 and R 13 are amino.
  • the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R 9 and R 13 are methyl.
  • the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R 9 and R 13 are independently hydrogen, alkyl, or amino.
  • the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S.
  • the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S(O) or S(O) 2 .
  • the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is bond.
  • the compound of any one of embodiments 1 to 24 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is CR 7 R 8 where R 5 and R 6 are independently hydrogen or alkyl.
  • L is CH 2 .
  • L is C(CH 3 ) 2 .
  • the compound of any one of embodiments 1 to 3, 6-8, and 10 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 10 is hydroxyalkyl. In a first sub-embodiment of embodiment 11, R 10 is hydroxymethyl.
  • the compound of any one of embodiments 1 to 3, 6-8, and 10 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 10 is alkylsulfonyl.
  • R 2 is methylsulfonyl or ethylsulfonyl.
  • the compound of any one of embodiments 11 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 14 is -alkyl. In a first subembodiment, R 14 is methyl.
  • R 1 and R 15 are selected from amino and aminoalkyl; and R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano.
  • R′′ and R 15 are aminomethyl, and R 12 and R 16 are methyl.
  • the compound of any one of embodiments 1 to 29 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein: R 11 and R 12 , and R 15 and R 16 together with the carbon atom to which they are attached form a ring of formula (c):
  • ring of formula (c) is:
  • the compound of any one of 1 to 29 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 11 and R 12 , and R 15 and R 16 together with the carbon atom to which they are attached form a ring of formula (c):
  • ring of formula (c) is:
  • the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, or hydroxy, amino.
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, or hydroxy, amino.
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, or hydroxy, amino.
  • R 1 , R 2 , R 3 , and R 4 are hydrogen and the remaining one or two of R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, or amino.
  • R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 5 is hydrogen, alkyl, halo, or amino and R 6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, or cyano.
  • the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 5 is hydrogen, chloro, methyl, or amino and R 6 is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy, or methoxy.
  • R 5 and R 6 are hydrogen.
  • embodiments set forth above include all combination of embodiments and subembodiments listed therein.
  • the ring of formula (c) listed in embodiment 31 and first and second sub-embodiments of embodiment 31 can independently be combined with one or more of the embodiments 1-30 and 32-36 and/or subembodiments contained therein.
  • Embodiments 37-63 Additional embodiments include Embodiments 37-63 below:
  • R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O) 2 R, —C(O)R, —OR′, —NR′C(O)R, —NR′SO 2 R, —OC(O)NR′R′′, —C(O)NR′R′′, —S(O) 2 NR′R′′, —NR′R′′, or —
  • t 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO 2 where the remaining atoms are carbon; and W is O, CH 2 , or N; substituted with R a , R b , and/or R c wherein R a and R b are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when R a and R c are attached to the same carbon atom, R a and R c together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene
  • Q 1 is N or CR 1 wherein R 1 is hydrogen or deuterium
  • Q 2 is N or CH, or CD
  • R 2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl;
  • n 0, 1; or 2;
  • n 0, 1, or 2 wherein when n is 2 then one of the CH 2 can be replaced with O, S, or SO 2 ; provided m+n is 1, 2, or 3;
  • k 0, 1 or 2;
  • z 0, 1, or 2;
  • each R d is independently hydrogen, alkyl, or halogen
  • R e and R e1 are independently hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
  • R e and R e1 when R e and R e1 are attached to the same carbon atom, then R e and R e1 together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • R f and R g are independently hydrogen, alkyl, or haloalkyl
  • each R h is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X 1 , contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X 1 are independently N or C provided only one of X and X 1 can be N;
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with R i and/or R j independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • R k and R m are independently hydrogen, alkyl, or haloalkyl
  • one of Y and Z is CH 2 , O, S, S(O), S(O) 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • R n and R o when R n and R o are attached to the same carbon atom, then R n and R o together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene; or
  • R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O) 2 R, —C(O)R, —NR′C(O)R, —NR′SO 2 R, —C(O)NR′R′′, —S(O) 2 NR′R′′, —NR′R′′, or —NR′C(O)C(O)R where R is alkyl, cycloalky
  • A has the structure (d):
  • t 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO 2 where the remaining atoms are carbon; and W is O, CH 2 , or N; optionally substituted with R a , R b , and/or R c wherein R a and R b are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when R a and R c are attached to the same carbon atom, R a and R c together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • Q 1 is N or CR 1 wherein R 1 is hydrogen or deuterium
  • Q 2 is N or CH, or CD
  • R 2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl;
  • n 0, 1; or 2;
  • n 0, 1, or 2; provided m+n is 1, 2, or 3;
  • k 0, 1 or 2
  • z 0, 1, or 2
  • each R d is independently hydrogen, alkyl, or halogen
  • R e is hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
  • R f and R g are independently hydrogen, alkyl, or haloalkyl
  • each R h is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X 1 , contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X 1 are independently N or C provided only one of X and X 1 can be N;
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with R i and/or R j independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • R k and R m are independently hydrogen, alkyl, or haloalkyl
  • one of Y and Z is CH 2 , O, S, S(O), S(O) 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O) 2 R, —C(O)R, —NR′C(O)R, —NR′SO 2 R, —C(O)NR′R′′, —S(O) 2 NR′R′′, —NR′R′′, or —NR′C(O)C(O)R where R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optional
  • Q 1 is N or CR 1 wherein R 1 is hydrogen or deuterium
  • Q 2 is N or CH, or CD
  • R 2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl;
  • n 0, 1; or 2;
  • k 0, 1 or 2
  • z 0, 1, or 2
  • each R d is independently hydrogen, alkyl, or halogen
  • R e is hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
  • R f and R g are independently hydrogen, alkyl, or haloalkyl
  • each R h is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X 1 , contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X 1 are independently N or C provided only one of X and X 1 can be N;
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with R i and/or R i independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • R k and R m are independently hydrogen, alkyl, or haloalkyl
  • one of Y and Z is CH 2 , O, S, S(O), S(O) 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —NHCOR, or —NR′R′′ where R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R′′ are independently hydrogen or alkyl or R′ and R′′ together with the nitrogen atom to which they are attached form optionally substituted
  • A has the structure (d):
  • t 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO 2 where the remaining atoms are carbon; and W is O, CH 2 , or N; optionally substituted with R a , R b , and/or R c wherein R a and R b are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when R a and R c are attached to the same carbon atom, R a and R c together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • Q 1 is N or CR 1 wherein R 1 is hydrogen or deuterium
  • Q 2 is N, CH, or CD
  • R 2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, SO, SO 2 , or CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl;
  • n 0, 1; or 2;
  • n 0, 1, or 2; provided m+n is 1, 2, or 3;
  • R d is hydrogen or alkyl
  • R e is hydrogen, alkyl, halogen, or oxo
  • R h is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X 1 , contains one to three heteroatoms independently selected from N, O, or S and ring D can optionally be substituted with alkyl;
  • X and X 1 are independently N or C provided only one of X and X 1 can be N;
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with R i and/or R j independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl; or
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • one of Y and Z is CH 2 , O, S, SO, SO 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, or oxo; or
  • R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —NHCOR, or —NR′R′′ where R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R′′ are independently hydrogen or alkyl or R′ and R′′ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • Q 1 is N or CR 1 wherein R 1 is hydrogen or deuterium
  • Q 2 is N, CH, or CD
  • R 2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, SO, SO 2 , or CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl;
  • n 0, 1; or 2;
  • n 0, 1, or 2; provided m+n is 1, 2, or 3;
  • R d is hydrogen or alkyl
  • R e is hydrogen, alkyl, halogen, or oxo
  • R h is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X 1 , contains one to three heteroatoms independently selected from N, O, or S and ring D can optionally be substituted with alkyl;
  • X and X 1 are independently N or C provided only one of X and X 1 can be N;
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with R′ and/or R i independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl; or
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • one of Y and Z is CH 2 , O, S, SO, SO 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, or oxo; or
  • the compound of any one of embodiments 37 to 41, or a pharmaceutically acceptable salt thereof has the structure of formula (III′):
  • the compound of any one of embodiments 37 to 41, or a pharmaceutically acceptable salt thereof has the structure of formula (V′) or (VI′):
  • the compound or a pharmaceutically acceptable salt thereof has structure (V). In another sub-embodiment of embodiment 4, the compound or a pharmaceutically acceptable salt thereof has structure (VI).
  • the compound of any one of embodiments 37 to 43 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 1 is hydrogen.
  • the compound of any one of embodiments 37 to 43 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R 1 is deuterium.
  • the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S.
  • the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S(O) or S(O) 2 .
  • the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is bond.
  • the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is CR 5 R 6 where R 5 and R 6 are independently hydrogen or alkyl.
  • L is CH 2 .
  • L is C(CH 3 ) 2 .
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is hydroxyalkyl. In a first sub-embodiment of embodiment 51, R 2 is hydroxymethyl.
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is alkylsulfonyl.
  • R 2 is methylsulfonyl or ethylsulfonyl.
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is alkylsulfoxide.
  • R 2 is methylsulfoxide, ethylsulfoxide, or isopropylsulfoxide.
  • R 2 is methylsulfoxide.
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is —CD 2 OH.
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is alkoxycarbonyl, aminosulfonyl or aminocarbonyl.
  • R 2 is —S(O) 2 NH 2 .
  • R 2 is —CONH 2 .
  • R 2 is —C(O)CH 3 .
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is hydroxy.
  • the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R 2 is halo. In a sub-embodiment of embodiment 17, R 2 is chloro.
  • n 0, 1; or 2;
  • n 0, 1, or 2 wherein when n is 2 then one of the CH 2 can be replaced with O, S, or SO 2 ; provided m+n is 1, 2, or 3;
  • k 0, 1 or 2
  • z 0, 1, or 2
  • each R d is independently hydrogen, alkyl, or halogen
  • R e and R e1 are independently hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
  • R e and R e1 when R e and R e1 are attached to the same carbon atom, then R e and R e1 together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • R 3 is amino or aminoalkyl
  • R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with R i and/or R j independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl.
  • z is 0, R 3 is aminomethyl, and R 4 is methyl.
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • R k and R m are independently hydrogen, alkyl, or haloalkyl
  • one of Y and Z is CH 2 , O, S, S(O), S(O) 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or when R n and R o are attached to the same carbon atom, then R n and R o together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • n1 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • R k and R m are independently hydrogen, alkyl, or haloalkyl
  • one of Y and Z is CH 2 , O, S, S(O), S(O) 2 , or NH; and the other of X and Y is CH 2 ; and wherein ring of formula (c) is substituted with R n and/or R o independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl.
  • R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O) 2 R, —C(O)R, —NR′C(O)R, —NR′SO 2 R, —C(O)NR′R′′, —S(O) 2 NR′R′′, —NR′R′′, or —NR′C(O)
  • R c and R a when R c and R a are attached to the same carbon of cycloalkyl or fused heteroaryl ring, then R c and R a together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and R c is hydrogen or —NR′R′′ where R′ and R′′ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and R c is hydrogen or —NR′R′′ where R′ and R′′ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and R c is hydrogen or —NR′R′′ where R′ and R′′ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • R a and R b are independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, hydroxy, or cyano, and R c is hydrogen.
  • ring A has the structure (d):
  • t 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO 2 where the remaining atoms are carbon; and W is O, CH 2 , or N; substituted with R a , R b , and/or R c wherein R a and R b are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and R c is hydrogen, alkyl, halo, hydroxy, or alkoxy; or
  • R a and R c when R a and R c are attached to the same carbon atom, R a and R c together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • ring A is
  • ring A is:
  • ring A is:
  • ring A is:
  • embodiments 37 to 63 set forth above include all combination of embodiments and subembodiments listed therein.
  • the ring A listed in fifth sub-embodiment of embodiment 63 can independently be combined with one or more of the embodiments 35 to 62 and/or subembodiments contained therein.
  • Embodiments include embodiments 66 to 112 below:
  • a and E are independently selected from a bond, CH 2 , O, NH, S, and S(O) 2 ;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk) y R a , —O(alk)OR b , —S(O)R c , —S(O) 2 R d , —NR e C(O)R f , —NR g SO 2 R h , —OC(O)NR i R j , —C(O)NR k R m , —S(O) 2 NR n R o , —NR p R q , —NR r C(O)C(O)R s or —Y-M (wherein Y is bond, O, or SO 2 and M is alkyl, haloalkyl
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • R 1 and R 2 and R 3 and R 4 when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R 5 and R 6 is optionally substituted heterocyclyl and the other R 5 and R 6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O) 2 , or CR 7 R 8 where R 7 and R 8 are independently hydrogen or alkyl;
  • Z 1 is a group of formula (a) or (b):
  • R 9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD 2 OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R 13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl
  • R 14 is hydrogen, alkyl, or haloalkyl
  • R 11 and R 15 are selected from amino and aminoalkyl
  • R 12 and R 16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • e 0, 1; or 2;
  • k 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q 0, 1, or 2, or 3;
  • R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
  • each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • ring D is absent or present;
  • the compound of embodiment 66, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (III):
  • R 11 and R 15 are selected from amino and aminoalkyl; and R 12 and R 16 are independently selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano.
  • a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 and a pharmaceutically acceptable excipient.
  • a method of treating a disease treatable by inhibition of SHP2 in a patient which method comprises administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 or which method comprises administering to the patient, preferably a patient in need of such treatment, a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 and a pharmaceutically acceptable excipient.
  • the method of embodiment 110 wherein the cancer is selected from lung, stomach, liver, colon, kidney, breast, pancreatitis, juvenile myelomonocytic leukemias, neurolastoma, melanoma, and acute myeloid leukemia.
  • the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
  • the reactions described herein take place at atmospheric pressure over a temperature range from about ⁇ 78° C. to about 150° C., such as from about 0° C. to about 125° C. and further such as at about room (or ambient) temperature, e.g., about 20° C.
  • compounds of Formula (I), (IA), (IB), or (IC) can be prepared by reacting compound of formula 1-a with 3-mercaptopropanoate ester in the presence of transition metal catalyst such as Pd 2 (dba) 3 and xantphos under standard coupling condition to provide a compound of formula 1-b where R′ is an alkyl group such as 3-methylheptane.
  • transition metal catalyst such as Pd 2 (dba) 3
  • xantphos under standard coupling condition
  • R′ is an alkyl group such as 3-methylheptane.
  • Treatment of a compound of formula 1-b with a base such as potassium t-butoxide, sodium t-butoxide, sodium methoxide, and the like, provides a compound of formula 1-c as a thiosalt, where M + is a metal ion such as potassium or sodium.
  • Coupling of 1-c with a compound of formula 1-e or formula 1-f where X 2 or X 3 is halo provides a compound of Formula (I), (IA), (IB), or (IC) where Z1 is a group of formula (a) or (b), respectively.
  • tert-butyl (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate tert-butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate tert-butyl (2S,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • tert-butyl (S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate tert-butyl (2S,4R)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate
  • tert-butyl (2S,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate tert-butyl (S)-6-(hydroxymethyl)-5-azaspiro[2.4]heptan
  • Boc group can be cleaved under acidic condition such HCl in dioxane.
  • Cyclization of compound 2-d with a base such as K 2 CO 3 , sodium carbonate, and the like provides a compound of formula 2-e.
  • Lithiation of compound 2-e using alkyl lithium such n-BuLi, followed by trapping with iodine provides a compound of formula 1-a.
  • the Src Homolgy-2 phosphatase (SHP2) is a protein tyrosine phosphatase encoded by the PTPN1 1 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3-kinase-AKT pathways. SHP2 mediates activation of Erk1 and Erk2 (Erk1/2, Erk) MAP kinases by receptor tyrosine kinases such as ErbB1, ErbB2 and c-Met.
  • SHP2 has two N-terminal Src homology 2 domains (N—SH2 and C—SH2), a catalytic domain (PTP), and a C-terminal tail.
  • the two SH2 domains control the subcellular localization and functional regulation of SHP2.
  • the molecule exists in an inactive conformation, inhibiting its own activity via a binding network involving residues from both the N—SH2 and PTP domains.
  • SHP2 binds to specific tyrosine-phosphorylated sites on docking proteins such as Gab1 and Gab2 via its SH2 domains. This induces a conformational change that results in SHP2 activation.
  • SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
  • PDGF-R platelet-derived growth factor
  • FGF-R fibroblast growth factor
  • EGF-R epidermal growth factor
  • SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer.
  • MAP mitogen activated protein
  • SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers.
  • SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
  • PTPN1 1 The gene most commonly mutated in NS and LS is PTPN1 1.
  • SHP2 Germline mutations in PTPN1 1 (SHP2) are found in ⁇ 50% of the cases with NS and nearly all patients with LS that shares certain features with NS.
  • Y62D and Y63C substitutions in the protein are largely invariant and are among the most common mutations. Both these mutations affect the catalytically inactive conformation of SHP2 without perturbing the binding of the phosphatase to its phosphorylated signaling partners.
  • JMML Juvenile Myelomonocytic Leukemias
  • Acute Myeloid Leukemia PTPN1 1 mutations have been identified in: ⁇ 10% of pediatric acute leukemias, such as myelodysplastic syndrome (MDS); ⁇ 7% of B cell acute lymphoblastic leukemia (B-ALL); and ⁇ 4% of acute myeloid leukemia (AML).
  • MDS myelodysplastic syndrome
  • B-ALL B cell acute lymphoblastic leukemia
  • AML acute myeloid leukemia
  • NS and leukemia mutations cause changes in amino acids located at the interface formed by the N—SH2 and PTP domains in the self-inhibited SHP2 conformation, disrupting the inhibitory intramolecular interaction, leading to hyperactivity of the catalytic domain.
  • SHP2 acts as a positive regulator in receptor tyrosine kinase (RTK) signaling.
  • RTK receptor tyrosine kinase
  • Cancers containing RTK alterations include Esophageal, Breast, Lung, Colon, Gastric, Glioma, Head and Neck cancers.
  • Esophageal cancer (or oesophageal cancer) is a malignancy of the esophagus.
  • Esophageal cancer is a malignancy of the esophagus.
  • squamous cell cancer ⁇ 50%)
  • adenocarcinoma There is a high rate of RTK expression in esophageal adenocarcinoma and squamous cell cancer.
  • a SHP2 inhibitor of the invention can, therefore, be employed for innovative treatment strategies.
  • Breast cancer is a major type of cancer and a leading cause of death in women, where patients develop resistance to current drugs.
  • breast cancers There are four major subtypes of breast cancers including luminal A, luminal B, Her2 like, and triple negative/Basal-like.
  • Triple negative breast cancer (TNBC) is an aggressive breast cancer lacking specific targeted therapy.
  • Epidermal growth factor receptor I (EGFR) has emerged as a promising target in TNBC. Inhibition of Her2 as well as EGFR via SHP2 may be a promising therapy in breast cancer.
  • NSCLC Lung Cancer
  • Colon Cancer Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS, and BRAF mutations occur in 10 to 15% of colorectal cancers. For a subset of patients whose colorectal tumors have been demonstrated to over express EGFR, these patients exhibit a favorable clinical response to anti-EGFR therapy.
  • Gastic Cancer is one of the most prevalent cancer types. Aberrant expression of tyrosine kinases, as reflected by the aberrant tyrosine phosphorylation in gastric cancer cells, is known in the art. Three receptor-tyrosine kinases, c-met (HGF receptor), FGF receptor 2, and erbB2/neu are frequently amplified in gastric carcinomas. Thus, subversion of different signal pathways may contribute to the progression of different types of gastric cancers.
  • Neuroblastoma is a pediatric tumor of the developing sympathetic nervous system, accounting for about 8% of childhood cancers. Genomic alterations of the anaplastic lymphoma kinase (ALK) gene have been postulated to contribute to neuroblastoma pathogenesis.
  • ALK anaplastic lymphoma kinase
  • Squamous-cell carcinoma of the head and neck Squamous-cell carcinoma of the head and neck (SCCHN).
  • High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN).
  • Blocking of the EGFR signaling results in inhibition of the stimulation of the receptor, cell proliferation, and reduced invasiveness and metastases.
  • the EGFR is, therefore, a prime target for new anticancer therapy in SCCHN.
  • the present invention relates to compounds capable of inhibiting the activity of SHP2.
  • the invention further provides a process for the preparation of compounds of the invention and pharmaceutical preparations comprising such compounds.
  • Another aspect of the present invention relates to a method of treating SHP2-mediated disorders comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined in the Summary.
  • the present invention relates to the aforementioned method, wherein said SHP2-mediated disorders are cancers selected from, but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; Gastric cancer, Head and Neck cancer.
  • SHP2-mediated disorders are cancers selected from, but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; Gastric cancer, Head and Neck cancer.
  • the compounds of the present invention may also be useful in the treatment of other diseases or conditions related to the aberrant activity of SHP2.
  • the invention relates to a method of treatment of a disorder selected from: NS; LS; JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; gastric cancer; head and neck cancer.
  • a SHP2 inhibitor of the present invention may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of cancer.
  • a compound of the current invention or a pharmaceutically acceptable salt thereof, as defined above may be administered simultaneously, sequentially or separately in combination with one or more agents selected from chemotherapy agents, for example, mitotic inhibitors such as a taxane, a vinca alkaloid, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine, and other anticancer agents, e.g. cisplatin, 5-fluorouracil or 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU), flutamide or gemcitabine.
  • chemotherapy agents for example, mitotic inhibitors such as a taxane, a vinca alkaloid, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine
  • the present invention relates to the aforementioned method, wherein said compound is administered parenterally.
  • the present invention relates to the aforementioned method, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally.
  • the present invention relates to the aforementioned method, wherein said compound is administered systemically.
  • the present invention relates to the aforementioned method, wherein said patient is a mammal.
  • the present invention relates to the aforementioned method, wherein said patient is a primate.
  • the present invention relates to the aforementioned method, wherein said patient is a human.
  • the present invention relates to a method of treating an SHP2-mediated disorder, comprising the step of: administering to a patient in need thereof a therapeutically effective amount of a chemotherapeutic agent in combination with a therapeutically effective amount of a compound of formula I as defined in the Summary.
  • a chemotherapeutic agent in combination with a therapeutically effective amount of a compound of formula I as defined in the Summary.
  • inhibition of SHP2 also has the therapeutic potential for treatment of systemic lupus erythematosus, rheumatoid arthritis and fibrosis.
  • SHP2 inhibitory activity of the compounds of Formula (I), (IA), (IB), and (IC) can be tested using the in vitro assay described in Biological Examples 1 below.
  • the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • Therapeutically effective amounts of compounds this disclosure may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses.
  • a suitable dosage level may be from about 0.1 to about 250 mg/kg per day; about 0.5 to about 100 mg/kg per day.
  • a suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day.
  • compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient.
  • the actual amount of the compound of this disclosure, i.e., the active ingredient will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound being utilized, the route and form of administration, and other factors.
  • compositions will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • routes e.g., oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • parenteral e.g., intramuscular, intravenous or subcutaneous
  • compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • formulations in the form of tablets, pills or capsules, including enteric coated or delayed release tablets, pills or capsules are preferred.
  • compositions are comprised of in general, a compound of this disclosure in combination with at least one pharmaceutically acceptable excipient.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of this disclosure.
  • excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
  • sterile liquid carrier for example, saline or sterile pyrogen-free water
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
  • Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
  • Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
  • compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the disclosure may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
  • the level of the compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation will contain, on a weight percent (wt. %) basis, from about 0.01-99.99 wt. % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compound is present at a level of about 1-80 wt. %.
  • the compounds of this disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of this disclosure or the other drugs may have utility.
  • Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I).
  • a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula (I) is preferred.
  • the combination therapy may also include therapies in which the compound of this disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of Formula (I) and the other active ingredients may be used in lower doses than when each is used singly.
  • compositions of Formula (I) also include those that contain one or more other drugs, in addition to a compound of Formula (I).
  • the above combinations include combinations of a compound of this disclosure not only with one other drug, but also with two or more other active drugs.
  • a compound of this disclosure may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which a compound of this disclosure is useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I).
  • a pharmaceutical composition containing such other drugs in addition to the compound of this disclosure can be used.
  • the pharmaceutical compositions of Formula (I) also include those that also contain one or more other active ingredients, in addition to a compound of this disclosure.
  • the weight ratio of the compound of this disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
  • the subject in need is suffering from or at risk of suffering from cancer
  • the subject can be treated with a compound of this disclosure in any combination with one or more other anti-cancer agents including but not limited to:
  • MAP kinase pathway inhibitors including but not limited to: Vemurafanib (PLX4032), Dabrafenib, Encorafenib (LGX818), TQ-B3233, XL-518 (Cas No.
  • CSF1R inhibitors PLX3397, LY3022855, etc.
  • CSF1R antibodies IMC-054, RG7155
  • TGF beta receptor kinase inhibitor such as LY2157299.
  • BTK inhibitor such as ibrutinib; BCR-ABL inhibitors: Imatinib (Gleevec®); Inilotinib hydrochloride; Nilotinib (Tasigna®); Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and A/-[2-[(15,4R)-6-[[4-(Cyclobutylarmno)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3).
  • ALK inhibitors PF-2341066 (XALKOPJ®; crizotinib); 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; GSK1838705 A; CH5424802; Ceritinib (ZYKADIA); TQ-B3139, TQ-B3101 PI3K inhibitors: 4-[2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]mo ⁇ holine (also known as GDC 0941 and described in PCT Publication Nos.
  • VEGF receptor inhibitors Bevacizumab (sold under the trademark Avastin® by Genentech/Roche), axitinib, (N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No.
  • Brivanib Alaninate ((S)—((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2 -aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No.
  • pasireotide also known as SOM230, and described in PCT Publication No. WO 02/010192
  • sorafenib sold under the tradename Nexavar®
  • AL-2846 MET inhibitor such as foretinib, carbozantinib, or crizotinib.
  • FLT3 inhibitors subunitinib malate (sold under the tradename Sutent® by Pfizer); PKC412 (midostaurin); tanutinib, sorafenib, lestaurtinib, KW-2449, quizartinib (AC220) and crenolanib.
  • Epidermal growth factor receptor (EGFR) inhibitors Gefitnib (sold under the tradename Iressa®), N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3′′S′′)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide, sold under the tradename Tovok® by Boehringer Ingelheim), cetuximab (sold under the tradename Erbitux® by Bristol-Myers Squibb), panitumumab (sold under the tradename Vectibix® by Amgen).
  • EGFR Epidermal growth factor receptor
  • HER2 receptor inhibitors Trastuzumab (sold under the trademark Herceptin® by Genentech/Roche), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(d imethylamino)but-2-enamide, and described PCT Publication No.
  • lapatinib or lapatinib ditosylate sold under the trademark Tykerb® by GlaxoSmithKline
  • Trastuzumab emtansine in the United States, ado-trastuzumab emtansine, trade name Kadcyla
  • an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1);
  • HER dimerization inhibitors Pertuzumab (sold under the trademark Omnitarg®, by Genentech).
  • CD20 antibodies Rituximab (sold under the trademarks Riuxan® and MabThera® by Genentech/Roche), tositumomab (sold under the trademarks Bexxar® by GlaxoSmithKline), ofatumumab (sold under the trademark Arzerra® by GlaxoSmithKline).
  • Tyrosine kinase inhibitors Erlotinib hydrochloride (sold under the trademark Tarceva® by Genentech/Roche), Linifanib (N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold under the tradename Sutent® by Pfizer), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-car bonitrile, also known as SKI-606, and described in U.S.
  • dasatinib (sold under the tradename Sprycel® by Bristol-Myers Squibb), armala (also known as pazopanib, sold under the tradename Votrient® by GlaxoSmithKline), imatinib and imatinib mesylate (sold under the tradenames Gilvec® and Gleevec® by Novartis).
  • DNA Synthesis inhibitors Capecitabine (sold under the trademark Xeloda® by Roche), gemcitabine hydrochloride (sold under the trademark Gemzar® by Eli Lilly and Company), nelarabine ((2R3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymet hyl)oxolane-3,4-diol, sold under the tradenames Arranon® and Atriance® by GlaxoSmithKline).
  • Antineoplastic agents oxaliplatin (sold under the tradename Eloxatin® ay Sanofi-Aventis and described in U.S. Pat. No. 4,169,846).
  • G-CSF modulators Filgrastim (sold under the tradename Neupogen® by Amgen).
  • Immunomodulators Afutuzumab (available from Roche®), pegfilgrastim (sold under the tradename Neulasta® by Amgen), lenalidomide (also known as CC-5013, sold under the tradename Revlimid®), thalidomide (sold under the tradename Thalomid®);
  • CD40 inhibitors Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc); Pro-apoptotic receptor agonists (PARAs): Dulanermin (also known as AMG-951, available from Amgen/Genentech).
  • PARAs Pro-apoptotic receptor agonists
  • Dulanermin also known as AMG-951, available from Amgen/Genentech.
  • Hedgehog antagonists 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfony 1)-benzamide (also known as GDC-0449, and described in PCT Publication No. WO 06/028958);
  • Phospholipase A2 inhibitors Anagrelide (sold under the tradename Agrylin®);
  • BCL-2 inhibitors 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]met hyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09/155386);
  • MC1-1 inhibitors MIK665, S64315, AMG 397, and AZD5991;
  • Aromatase inhibitors Exemestane (sold under the trademark Aromasin® by Pfizer), letrozole (sold under the tradename Femara® by Novartis), anastrozole (sold under the tradename Arimidex®);
  • Topoisomerase I inhibitors Irinotecan (sold under the trademark Camptosar® by Pfizer), topotecan hydrochloride (sold under the tradename Hycamtin® by GlaxoSmithKline);
  • Topoisomerase II inhibitors etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), teniposide (also known as VM-26, sold under the tradename Vumon®);
  • etoposide also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®
  • teniposide also known as VM-26, sold under the tradename Vumon®
  • mTOR inhibitors Temsirolimus (sold under the tradename Torisel® by Pfizer), ridaforolimus (formally known as deferolimus, (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0 4′9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyc lohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03/064383
  • Proteasome inhibitor such as carfilzomib, MLN9708, delanzomib, or bortezomib
  • BET inhibitors such as INCB054329, OTX015, CPI-0610; LSD1 inhibitors such as GSK2979552, INCB059872; HIF-2 ⁇ inhibitors such as PT2977 and PT2385;
  • Osteoclastic bone resorption inhibitors 1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate (sold under the tradename Zometa® by Novartis); CD33 Antibody Drug Conjugates: Gemtuzumab ozogamicin (sold under the tradename Mylotarg® by Pfizer/Wyeth);
  • CD22 Antibody Drug Conjugates Inotuzumab ozogamicin (also referred to as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);
  • CD20 Antibody Drug Conjugates Ibritumomab tiuxetan (sold under the tradename Zevalin®);
  • octreotide also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®
  • Sandostatin® also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®
  • IL-11 Synthetic Interleukin-11: oprelvekin (sold under the tradename Neumega® by Pfizer/Wyeth);
  • RANK Nuclear Factor ⁇ B
  • Thrombopoietin mimetic peptibodies Romiplostim (sold under the tradename Nplate® by Amgen;
  • IGF-1R Anti-Insulin-like Growth Factor-1 receptor antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);
  • Anti-CSI antibodies Elotuzumab (HuLuc63, CAS No. 915296-00-3);
  • CD52 antibodies Alemtuzumab (sold under the tradename Campath®);
  • Histone deacetylase inhibitors Voninostat (sold under the tradename Zolinza® by Merck);
  • Alkylating agents Temozolomide (sold under the tradenames Temodar® and Temodal® by Schering-Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexalen®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol
  • Anti-tumor antibiotics doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename Lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename EllenceTM), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®), mitomycin C (sold under the tradename Mutamycin®);
  • Anti-microtubule agents Estramustine (sold under the tradename Emcyl®);
  • Cathepsin K inhibitors Odanacatib (also know as MK-0822, N-(1-cyanocyclopropyl)-4-fluoro-N 2- ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethyl ⁇ -L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, and described in PCT Publication no. WO 03/075836); Epothilone B analogs: Ixabepilone (sold under the tradename Lxempra® by Bristol-Myers Squibb);
  • HSP Heat Shock Protein
  • TpoR agonists Eltrombopag (sold under the tradenames Promacta® and Revolade® by GlaxoSmithKline);
  • Anti-mitotic agents Docetaxel (sold under the tradename Taxotere® by Sanofi-Aventis); Adrenal steroid inhibitors: aminoglutethimide (sold under the tradename Cytadren®);
  • Nilutamide sold under the tradenames Nilandron® and Anandron®
  • bicalutamide sold under tradename Casodex®
  • flutamide sold under the tradename FulexinTM
  • CDK (CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, or CDK9) inhibitors including but not limited to Alvocidib (pan-CDK inhibitor, also known as flovopirdol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone, and described in U.S. Pat. No. 5,621,002);
  • CDK4/6 inhibitors pabociclib, ribociclib, abemaciclib, and Trilaciclib; CDK9 inhibtiors AZD 4573, P276-00, AT7519M, TP-1287;
  • GnRH Gonadotropin-releasing hormone receptor agonists: Leuprolide or leuprolide acetate (sold under the tradenames Viadure® by Bayer AG, Eligard® by Sanofi-Aventis and Lupron® by Abbott Lab);
  • Taxane anti-neoplastic agents Cabazitaxel (1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3- ⁇ [(tert-butoxy)carbonyl]amino ⁇ -2-hydroxy-3-phenylpropanoate), larotaxel ((2 ⁇ ,3 ⁇ ,4 ⁇ ,5 ⁇ ,7 ⁇ ,10 ⁇ ,13 ⁇ )-4,10-bis(acetyloxy)-13-( ⁇ (2R,3S)-3-[(tert-butoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl ⁇ oxy)-1-hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-11-en-2-yl benzoate);
  • 5HTla receptor agonists Xaliproden (also known as SR57746, 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine, and described in U.S. Pat. No. 5,266,573); HPC vaccines: Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck; Iron Chelating agents: Deferasinox (sold under the tradename Exjade® by Novartis);
  • Claribine (2-chlorodeoxyadenosine, sold under the tradename Leustatin®), 5-fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCytTM), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, DroxiaTM and MylocelTM), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine, sold under
  • Bisphosphonates Pamidronate (sold under the tradename Aredia®), zoledronic acid (sold under the tradename Zometa®); Demethylating agents: 5-azacitidine (sold under the tradename Vidaza®), decitabine (sold under the tradename Dacogen®);
  • Plant Alkaloids Paclitaxel protein-bound (sold under the tradename Abraxane®), vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, sold under the tradenames Alkaban-AQ® and Velban®), vincristine (also known as vincristine sulfate, LCR, and VCR, sold under the tradenames Oncovin® and Vincasar Pfs®), vinorelbine (sold under the tradename Navelbine®), paclitaxel (sold under the tradenames Taxol and OnxalTM);
  • Retinoids Ali tretinoin (sold under the tradename Panretin®), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid®), Isotretinoin (13-cis-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Clarus®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), bexarotene (sold under the tradename Targretin®);
  • Glucocorticosteroids Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, Hydrocortisone Phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), dexamethazone ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one), prednisolone (sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid
  • Cytokines interleukin-2 (also known as aldesleukin and IL-2, sold under the tradename Proleukin®), interleukin-11 (also known as oprevelkin, sold under the tradename Neumega®), alpha interferon alfa (also known as IFN-alpha, sold under the tradenames Intron® A, and Roferon-A®); [00209] Estrogen receptor downregulators: Fulvestrant (sold under the tradename Faslodex®);
  • Anti-estrogens tamoxifen (sold under the tradename Novaldex®); Toremifene (sold under the tradename Fareston®);
  • SERMs selective estrogen receptor modulators: Raloxifene (sold under the tradename Evista®);
  • LHRH Leutinizing hormone releasing hormone
  • Goserelin sold under the tradename Zoladex®
  • Progesterones megestrol (also known as megestrol acetate, sold under the tradename Megace®);
  • Miscellaneous cytotoxic agents Arsenic trioxide (sold under the tradename Trisenox®), asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the tradenames Elspar® and Kidrolase®);
  • immune checkpoint inhibitors can be used in combination with a compound as described herein for treatment of SHP2-associated diseases, disorders or conditions.
  • exemplary immune checkpoint inhibitors include inhibitors (smack molecules or biologics) against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM kinase, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2 ⁇ , B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2.
  • the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, CD137 and STING.
  • the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, Arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA.
  • the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody.
  • the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224.
  • the anti-PD-1 monoclonal antibody is nivolumab, or pembrolizumab or PDR001.
  • the anti-PD1 antibody is pembrolizumab.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody.
  • the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
  • the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
  • the anti-CTLA-4 antibody is ipilimumab or tremelimumab.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
  • the anti-LAG3 antibody is BMS-986016 or LAG525.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody.
  • the anti-GITR antibody is TRX518 or, MK-4166, INCAGN01876 or MK-1248.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein.
  • the anti-OX40 antibody is MEDI0562 or, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600 or LAG525.
  • the OX40L fusion protein is MEDI6383
  • Compounds of the invention can also be used to increase or enhance an immune response, including increasing the immune response to an antigen; to improve immunization, including increasing vaccine efficacy; and to increase inflammation.
  • the compounds of the invention can be sued to enhance the immune response to vaccines including, but not limited, Listeria vaccines, oncolytic viarl vaccines, and cancer vaccines such as GVAX® (granulocyte-macrophage colony-stimulating factor (GM-CF) gene-transfected tumor cell vaccine).
  • GVAX® granulocyte-macrophage colony-stimulating factor (GM-CF) gene-transfected tumor cell vaccine.
  • Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
  • Other immune-modulatory agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4; Sting agonists and Toll receptor agonists.
  • anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
  • Compounds of this application may be effective in combination with CAR (Chimeric antigen receptor) T cell treatment as a booster for T cell activation
  • a compound of the invention can also be used in combination with the following adjunct therapies:
  • NK-1 receptor antagonists Casopitant (sold under the tradenames Rezonic® and Zunrisa® by GlaxoSmithKline); and
  • Cytoprotective agents Amifostine (sold under the tradename Ethyol®), leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).
  • Step 2 1-tert-butyl 4-methyl 4-[1-(trifluoromethanesulfonyloxy)ethyl]piperidine-1,4-dicarboxylate
  • Step 5 tert-butyl 4-ethenyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate
  • Step 6 tert-butyl 4-acetyl-4-ethenylpiperidine-1-carboxylate
  • Step 7 tert-butyl 4-[(2Z)-3-(dimethylamino)prop-2-enoyl]-4-ethenylpiperidine-1-carboxylate
  • Step 8 tert-butyl 4-ethenyl-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
  • Step 9 tert-butyl 4-(oxiran-2-yl)-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
  • Step 10 tert-butyl 5-hydroxy-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Step 11 tert-butyl 5-oxo-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Step 12 tert-butyl (S)-5-[(R)-2-methylpropane-2-sulfinyl)amino]-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Step 1 tert-butyl (2S)-2-[[(2-fluoropyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Step 4 (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Step 5 2-ethylhexyl 3-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
  • Step 6 potassium (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiolate
  • Step 7 methyl 6-bromo-3-[(3S,4S)-4-[[(tert-butoxy)carbonyl]amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazine-2-carboxylate
  • Step 8 tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate
  • Step 9 tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Step 10 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
  • Step 1 tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • Step 2 tert-butyl (2S,4S)-4-fluoro-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Step 3 2-fluoro-3-(((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy)-4-iodopyridine hydrochloride
  • Step 4 (6aS,8S)-8-fluoro-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Step 5 2-ethylhexyl 3-([5-[(3S,4S)-4-[(tert-butoxycarbonyl)amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2-yl]sulfanyl)propanoate
  • Step 6 sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]-decan-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate
  • Step 7 tert-butyl ((3S,4S)-8-(5-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Step 8 (3-((S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Step 1 1-tert-butyl 2-methyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]pyrrolidine-1,2-dicarboxylate
  • Step 2 tert-butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • Step 3 tert-butyl (2S, 4S)-4-[(tert-butyldimethylsilyl)oxy]-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Step 5 (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,22-d][1,4]oxazin-8-ol
  • Step 6 (6aS,8S)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Step 7 tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Step 8 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
  • Step 1 (6aS,8R)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Step 2 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Step 1 (6aS,8S)-4-iodo-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Step 2 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol

Abstract

The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is an International Application claiming the benefit of U.S. Provisional Application No. 62/733,061 filed Sep. 18, 2018, U.S. Provisional Application No. 62/749,655 filed Oct. 23, 2018, U.S. Provisional Application No. 62/810,911 filed Feb. 26, 2019, U.S. Provisional Application No. 62/883,120 filed Aug. 6, 2019, and U.S. Provisional Application No. 62/883,121 filed Aug. 6, 2019; the entireties of which are herein incorporated by reference.
    • FIELD OF THE DISCLOSURE
  • The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    • BACKGROUND
  • SHP2 is a non-receptor protein phosphatase ubiquitously expressed in various tissues and cell types (see reviews: Tajan M et al., Eur J Med Genet 2016 58(10):509-25; Grossmann K S et al., Adv Cancer Res 2010 106:53-89). SHP2 is composed of two Src homology 2 (N—SH2 and C—SH2) domains in its NH2-terminus, a catalytic PTP (protein-tyrosine phosphatase) domain, and a C-terminal tail with regulatory properties. At the basal state, the intermolecular interactions between the SH2 domains and the PTP domain prevent the access of substrates to the catalytic pocket, keeping SHP2 into a closed, auto-inhibited conformation. In response to stimulation, SHP2 activating proteins bearing phosphor-tyrosine motifs bind to the SH2 domains, leading to exposure of active site and enzymatic activation of SHP2.
  • SHP2 plays important roles in fundamental cellular functions including proliferation, differentiation, cell cycle maintenance and motility. By dephosphorylating its associated signaling molecules, SHP2 regulates multiple intracellular signaling pathways in response to a wide range of growth factors, cytokines, and hormones. Cell signaling processes in which SHP2 participates include the RAS-MAPK (mitogen-activated protein kinase), the PI3K (phosphoinositol 3-kinase)-AKT, and the JAK-STAT pathways.
  • The RAS-MAPK signaling pathway is crucial for tumor formation and maintenance. Genes encoding various components of this pathway, including RTKs (receptor tyrosine kinases), SHP2, NF1, RAS, or RAF are mutated in cancers, leading to upregulation of MAPK signaling. SHP2 also plays a signal-enhancing role on this pathway, acting downstream of RTKs and upstream of RAS. RTK-driven cancer cells were demonstrated to depend on SHP2 for survival. Thus, SHP2 inhibitor has been proposed as a valid treatment for RTK-driven cancers (see Prahallad, A. et al. Cell Reports 12, 1978-1985 (2015); Chen Y N, Nature 535, 148-152(2016)).
  • A lot of efforts have been made to develop pharmacological agents targeting various nodes along the RAS-MAPK pathway, such as RTK inhibitors, BRAF inhibitors, and MEK inhibitors for the treatment of cancer. Although these agents demonstrate good initial efficacy, resistance occurs frequently to these agents. One common mechanism of resistance involves activation of RTKs that fuel reactivation of the MAPK signaling. Since SHP2 is required downstream of multiple RTKs for signal transduction, SHP2 inhibition may provide a general strategy for preventing resistance to MAPK pathway targeted cancer drugs. Recent studies in preclinical models have shown that SHP2 inhibition overcomes resistance and offers synergistic therapeutic effects when combined with an ALK inhibitor (see Dardaei L et al. Nat Med. 24, 512-17 (2018)), MEK inhibitor (see Mainardi, S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0023-9 (2018); Ruess, D. A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0024-8 (2018); Wong, G. S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0022-x (2018); Fedele C et al. Cancer Discov pii: CD-18-0444. doi: 10.1158/2159-8290.CD-18-0444 (2018)), or BRAF inhibitor (see Prahallad, A. et al. Cell Reports 12, 1978-1985 (2015)). Especially, the combined inhibition of MEK/SHP2 has been identified to have potential to treat cancers driven by KRAS, the most frequently mutated oncogene. Despite years of efforts, inhibitors directly targeting KRAS has not yet been successfully developed for clinical use. Inhibiting MEK, the downstream effector of KRAS, only transiently suppressed MAPK signaling. The discovery of MEK/SHP2 dual inhibition makes important strides in the long-time effort to better understand and to therapeutically target KRAS-driven cancers.
  • Given the essential physiological functions SHP2 plays, targeting deregulation of SHP2 is expected to have broad therapeutic applications. Gain of function mutations in PTPN11, the gene that encodes SHP2, have been causally linked to several human diseases, including Noonan Syndrome, juvenile myelomonocytic leukemias, acute myeloid leukemia, myelodysplastic syndrome, and acute B lymphoblastic leukemia. SHP2 functions as an oncogene, and its overexpression and/or activating mutations are reported in various solid tumors, such as neuroblastoma, breast cancer, colon cancer, lung cancer, melanoma, and hepatocellular carcinoma.
  • Furthermore, SHP-2 is believed to mediate inhibitory immune checkpoint signaling of multiple receptors (e.g. PD-1) by dephosphorylating CD28. To support this notion, a dominant negative SHP-2 abrogates PD-1 signaling pathways and restores function of cytotoxic CAR T cells. Therefore, SHP-2 inhibitors have potential for use in combination therapy with existing targeted and Immune-Oncolocy (IO) agents.
  • In addition to human tumors, increases in expression or activity of SHP2 have been implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (Wang J et al. J Clin Invest. 2016 Jun. 1; 126(6):2077-92) and rheumatoid arthritis (see Stanford S. M et al. Arthritis Rheum. 2013 May; 65(5):1171-80; Maeshima K et al. JCI Insight. 2016 May 19; 1(7)). Recently, SHP2 has also been characterized as a molecular checkpoint for TGFβ-induced JAK2/STAT3 signaling, suggesting that SHP2 inhibition may offer therapeutic benefit for the treatment of fibrosis (see Zehender A et al. Nat Commun. 2018 Aug. 14; 9(1):3259). Accordingly, SHP2 represents a highly attractive target for the development of novel therapies to treat various diseases.
    • SUMMARY
  • In a first aspect, provided is a compound of Formula (I):
  • Figure US20200115389A1-20200416-C00001
  • wherein:
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2, and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or one of R5 and R6 is optionally substituted heterocyclyl and the other of R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
  • Z1 is a group of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00002
  • wherein:
  • R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R14 is hydrogen, alkyl, or haloalkyl;
  • R11 and R15 are selected from amino and aminoalkyl;
  • R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00003
  • wherein:
  • e is 0, 1, or 2;
  • k is 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q is 0, 1, or 2, or 3;
  • R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl, and haloalkyl;
  • each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • ring D is absent or present; wherein:
      • (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
      • (ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • In a second aspect, provided is a compound of Formula (IA):
  • Figure US20200115389A1-20200416-C00004
  • wherein:
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2, and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and the other of R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
  • Z1 is a group of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00005
  • wherein:
  • R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R14 is hydrogen, alkyl, or haloalkyl;
  • R11 and R15 are selected from amino and aminoalkyl;
  • R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00006
  • wherein:
  • e is 0, 1, or 2;
  • k is 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q is 0, 1, or 2, or 3;
  • R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
  • each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • ring D is absent or present; wherein:
      • (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
      • (ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl;
  • or a pharmaceutically acceptable salt thereof; provided that when the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is a compound of formula
  • Figure US20200115389A1-20200416-C00007
  • or a pharmaceutically acceptable salt thereof, where R9 is hydrogen, R10 is other than hydrogen, amino, and aminoalkyl, and L, R11 and R12 are as defined in Formula (I); then:
  • (i) when four of R1, R2, R3, R4, R5, and R6 are hydrogen and remaining two of R1, R2, R3, R4, R5, and R6, are independently selected from hydrogen, alkyl, cycloalkyl, amino, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, and aminoalkyl; then Z is other than hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, —ORa (where Ra is hydrogen or alkyl), —OC(O)NH2, —O-tetrahydrofuran-3-yl, —O-oxetan-3-yl, cyano, pyrazol-1-yl, —CH2OCH3,
  • —OCH2OCH3, —OCH2cyclopropyl, —O—CH2CH2OCH3, and —SO2CH3,
  • (ii) when R5 and R6 are hydrogen and two of R1, R2, R3, and R4 are hydrogen, and one of a) R1 and R2 and b) R3 and R4, are hydrogen and the other of a) R1 and R2, and b) R3 and R4 are attached to the same carbon and are combined together to form alkylidene, 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, then Z is other than hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, —ORa (where Ra is hydrogen or alkyl), —NH2, and —Y-M (wherein Y is bond and M is alkyl substituted with —ORa or —NRpRq wherein each Ra is hydrogen or alkyl and Rp and Rq are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl or Rp and Rq together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl); and
  • (iii) when Z is hydrogen, one of a) R1 and R2, and b) R3 and R4 are attached to the same carbon and are combined together to form 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, and three of the remaining R1, R2, R3, R4, R5, and R6 are hydrogen, then the remaining one of R1, R2, R3, R4, R5, and R6 is not hydrogen, alkyl, cycloalkyl, halo, haloalkyl, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, or amino.
  • In a third aspect provided is a compound of Formula (IB):
  • Figure US20200115389A1-20200416-C00008
  • wherein:
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2 and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and the other of R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
  • Z1 is a group of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00009
  • wherein:
  • R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R14 is hydrogen, alkyl, or haloalkyl;
  • R11 and R15 are selected from amino and aminoalkyl;
  • R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00010
  • wherein:
  • e is 0, 1, or 2;
  • k is 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q is 0, 1, or 2, or 3;
  • R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
  • each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • ring D is absent or present; wherein:
      • (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
      • (ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally be substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl;
  • or a pharmaceutically acceptable salt thereof; provided that when the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is a compound of formula
  • Figure US20200115389A1-20200416-C00011
  • or a pharmaceutically acceptable salt thereof, where R9 is hydrogen, R10 is other than hydrogen, amino, and aminoalkyl, and L, R11 and R12 are as defined in Formula (IB); then
  • (i) when four of R1, R2, R3, R4, R5, and R6 are hydrogen and remaining two of R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, and aminoalkyl; then Z is other than hydrogen, halo, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —ORa, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs (wherein Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and Ra, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, and Rr are independently hydrogen, alkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl) and Y-M (wherein (a) Y is bond or O and M is alkyl substituted with —ORa or —NRpRq wherein Ra is hydrogen or alkyl and Rp and Rq are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl or Rp and Rq together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl and (b) Y is SO2 and M is cycloalkyl (substituted with —ORa), heteroaryl or heterocyclyl wherein heteroaryl or heterocyclyl are independently substituted with —ORa, —S(O)2Rd, or —NRpRq; where Ra is hydrogen or alkyl, Rd is alkyl, and Rp and Rq are independently hydrogen or alkyl and cycloalkyl is optionally further substituted with one halo and heterocyclyl, and heteroaryl are optionally further substituted with 1 or 2 halo);
  • (ii) when R5 and R6 are each hydrogen and two of R1, R2, R3, and R4 are each hydrogen, and one of a) R1 and R2, and b) R3 and R4 are hydrogen and the other of a) R1 and R2, and b) R3 and R4 are attached to the same carbon and are combined together to form alkylidene, 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene, then Z is other than hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, —ORa (wherein Ra is hydrogen or alkyl), —NH2, and —Y-M (wherein Y is bond and M is alkyl substituted with —ORa or —NRpRq wherein each Ra is hydrogen or alkyl and Rp and Rq are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl or Rp and Rq together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl); and
  • (iii) when Z is hydrogen, one of a) R1 and R2, and b) R3 and R4 are attached to the same carbon and are combined together to form 3 to 6 membered cycloalkylene or 4 to 6 membered heterocyclylene and three of the remaining R1, R2, R3, R4, R5, and R6 are hydrogen, then the remaining one of R1, R2, R3, R4, R5, and R6 is not hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, or amino.
  • In a fourth aspect, provided is a compound of Formula (IC):
  • Figure US20200115389A1-20200416-C00012
  • wherein:
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2, and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and the other is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
  • Z1 is a group of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00013
  • wherein:
  • R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R14 is hydrogen, alkyl, or haloalkyl;
  • R11 and R15 are selected from amino and aminoalkyl;
  • R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00014
  • wherein:
  • e is 0, 1, or 2;
  • k is 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q is 0, 1, or 2, or 3;
  • R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl, and haloalkyl;
  • each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene. ring D is absent or present; wherein:
      • (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
      • (ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl; or a pharmaceutically acceptable salt thereof; provided that the compound of Formula (IC) is not a compound of any one of embodiments 37 to 42 and 45 to 63 disclosed herein below and embodiments contained therein, or a pharmaceutically acceptable salt thereof.
  • In a fifth aspect, provided a pharmaceutical composition comprising a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
  • In a sixth aspect, provided is a method of treating a disease treatable by inhibition of SHP2 in a patient which method comprises administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount thereof a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein), or comprises administering to the patient, preferably a patient in of such treatment, a pharmaceutical composition comprising a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein) and a pharmaceutically acceptable excipient. In one embodiment, the disease is cancer. In another embodiment, the disease is cancer selected from lung, stomach, liver, colon, kidney, breast, pancreatitis, juvenile myelomonocytic leukemias, neurolastoma, melanoma, and acute myeloid leukemia. In one embodiment, the disease is selected from Noonan syndrome and Leopard syndrome.
  • In a seventh aspect, provided is a compound of Formula (I), (IA), (IB), or (IC) (or any embodiments thereof described herein) or a pharmaceutically acceptable salt thereof for use as a medicament.
  • In a eighth aspect provided is the use of a compound of Formula (I), (IA), (IB), or (IC) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein) in the manufacture of a medicament for treating a disease in a patient in need of such treatment in which the activity of SHP2 contributes to the pathology and/or symptoms of the disease.
  • In a ninth aspect provided is a method of inhibiting SHP2 which method comprises contacting SHP2 with a compound of Formula (I), (IA), (IB), or (IC) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof; or contacting SHP2 with a pharmaceutical composition comprising a compound of the present disclosure (or any of the embodiments thereof described herein) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • In a tenth aspect, provided is an intermediate of Formula (V):
  • Figure US20200115389A1-20200416-C00015
  • wherein:
  • Q is halo or SH;
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)yORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2, and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and the other of R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • or an acceptable salt thereof.
  • In a first embodiment of the tenth aspect, Q is halo. In a subembodiment of the first embodiment, Q is chloro, bromo, or iodo.
  • In a second embodiment of the tenth aspect, Q is —S−M+ where M+ metal ion. In a subembodiment of the second embodiment, M+ is sodium or potassium.
  • In a third embodiment of any one of tenth aspect, first and second embodiments and subembodiments contained therein,
  • Figure US20200115389A1-20200416-C00016
  • In a fourth embodiment of any one of tenth aspect, first, second, and third embodiments and subembodiments contained therein, A, E, Z, R1, R2, R3, R4 R5, and R6 are as defined in the embodiment section herein below.
    • DETAILED DESCRIPTION
  • Certain structures provided herein are drawn with one or more floating substituents. Unless provided otherwise or otherwise clear from the context, the substituent(s) may be present on any atom of the ring to which it is attached, where chemically feasible and valency rules permitting. For example, in the structure:
  • Figure US20200115389A1-20200416-C00017
  • the R3, R4, and Z substituents can replace any hydrogen on the 6-membered ring which comprises group A, including one or both of the hydrogens of the CH2 group when A is CH2, and including the hydrogen of NH when A is NH. In another example, in the ring of formula (c):
  • Figure US20200115389A1-20200416-C00018
  • when ring D is absent and Q and/or W is CH2, one or both of the hydrogens are optionally replaced by one or two R19 groups.
    • Definitions
  • Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:
  • “Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like. It will be recognized by a person skilled in the art that the term “alkyl” may include “alkylene” groups.
  • “Alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
  • “Alkenyl” means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing a double bond, e.g., propenyl, butenyl, and the like.
  • “Alkyldienyl” is alkenyl as defined above that is attached via the terminal divalent carbon. For example, in the compound below:
  • Figure US20200115389A1-20200416-C00019
  • the alkyldienyl group is enclosed by the box which is indicated by the arrow.
  • “Alkylthio” means a —SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.
  • “Alkylsulfonyl” means a —SO2R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
  • “Alkylsulfoxide” means a —SOR radical where R is alkyl as defined above, e.g., methylsulfoxide, ethylsulfoxide, and the like.
  • “Amino” means a —NH2.
  • “Alkylamino” means a —NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, propylamino, or 2-propylamino, and the like.
  • “Acylamino” means a —NHC(O)R radical where R is alkyl as defined above, e.g., acetylamino, propionoylamino, and the like.
  • “Aminoalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with —NR′R″ where R′ and R″ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl, each as defined herein, e.g., aminomethyl, aminoethyl, methylaminomethyl, morpholinylethyl, piperazin-1-ylethyl, and the like.
  • “Alkoxy” means a —OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
  • “Alkoxyalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, such as one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.
  • “Alkoxycarbonyl” means a —C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
  • “Aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.
  • “Aralkyl” means -(alkylene)-R where R is aryl as defined above e.g., benzyl or phenethyl.
  • “Cycloalkyl” means a monocyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
  • “Cycloalkylalkyl” means a -(alkylene)-R radical where R is cycloalkyl as defined above, e.g., cyclopropylmethyl, cyclohexylmethyl, and the like.
  • “Cycloalkylene” means, unless stated otherwise, a monocyclic saturated divalent hydrocarbon radical of three to six carbon atoms optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, each as defined herein. Examples include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, and the like.
  • “Carboxy” means —C(O)OH.
  • “Dialkylamino” means a —NRR′ radical where R and R′ are alkyl as defined above, e.g., dimethylamino, methylethylamino, and the like.
  • “Aminosulfonyl” means a —SO2NRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and the like.
  • “Aminocarbonyl” means a —CONRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, and the like.
  • “Aminocarboxy” means a —C(O)ONRR′ radical where R and R′ are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl, each as defined herein, e.g., aminocarbonyloxy, methylaminocarbonyloxy, dimethylaminocarbonyloxy, and the like.
  • “Halo” means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
  • “Haloalkyl” means alkyl radical as defined above, which is substituted with one or more halogen atoms, e.g., one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., —CH2Cl, —CF3, —CHF2, —CH2CF3, —CF2CF3, —CF(CH3)2, and the like. When the alkyl is substituted with only fluoro, it can be referred to in this Application as fluoroalkyl.
  • “Haloalkoxy” means a —OR radical where R is haloalkyl as defined above e.g., —OCF3, —OCHF2, and the like. When R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.
  • “Hydroxyalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
  • “Heterocyclyl” means a saturated or unsaturated monovalent monocyclic or bicyclic ring of 4 to 10 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a —CO— group. More specifically the term heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydro-pyranyl, thiomorpholino, 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, 6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one, and the like. When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic. When the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino and is a subset of the heterocyclyl group.
  • “Heterocyclylene” means, unless stated otherwise, a saturated or unsaturated divalent monocyclic or bicyclic ring of 4 to 6 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, O, and S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. Heterocyclylene can be optionally substituted with one or two substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, cyano, or hydroxy, each as defined herein.
  • “Heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms, unless otherwise stated, where one or more, (in one embodiment, one, two, or three), ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. As defined herein, the terms “heteroaryl” and “aryl” are mutually exclusive. When the heteroaryl ring contains 5- or 6 ring atoms it is also referred to herein as 5- or 6-membered heteroaryl.
  • “Heteroaralkyl” means -(alkylene)-R where R is heteroaryl as defined above e.g., benzyl or phenethyl.
  • The term “oxo,” as used herein, alone or in combination, refers to ═(O).
  • When needed, any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkoxyalkyl means that an alkoxy group attached to the parent molecule through an alkyl group.
  • The present disclosure also includes protected derivatives of compounds of Formula (I), (IA), (IB), or (IC) or embodiments thereof. For example, when compounds of Formula (I), (IA), (IB), or (IC) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups. A comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, 5th Ed., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula (I), (IA), (IB), or (IC) can be prepared by methods well known in the art.
  • The present disclosure also includes polymorphic forms and deuterated forms of the compounds of Formula (I), (IA), (IB), or (IC). The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • A “pharmaceutically acceptable salt” of a compound of Formula (I), (IA), (IB), or (IC) means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include:
  • acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or
  • salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference in its entirety.
  • The compounds of Formula (I), (IA), (IB), or (IC) may have asymmetric centers. Compounds of Formula (I), (IA), (IB), or (IC) containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. All chiral, diastereomeric, all mixtures of chiral or diasteromeric forms, and racemic forms are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated. It will also be understood by a person of ordinary skill in the art that when a compound is denoted as (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity and vice versa.
  • Certain compounds of Formula (I), (IA), (IB), or (IC) can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. Additionally, as used herein the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all the positional isomers albeit only a few examples are set forth. Furthermore, all hydrates of a compound of Formula (I), (IA), (IB), or (IC) are within the scope of this disclosure.
  • The compounds of Formula (I), (IA), (IB), or (IC) may also contain unnatural amounts of isotopes at one or more of the atoms that constitute such compounds. Unnatural amounts of an isotope may be defined as ranging from the amount found in nature to an amount 100% of the atom in question. that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present invention, such as a compound of Formula (I), (IA), (IB), or (IC) (and any embodiment thereof disclosed herein including specific compounds) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36Cl, 123I, and 125I, respectively. Isotopically labeled compounds (e.g., those labeled with 3H and 14C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in compounds disclosed herein, including in Table 1 below one or more hydrogen atoms are replaced by 2H or 3H, or one or more carbon atoms are replaced by 13C- or 14C-enriched carbon. Positron emitting isotopes such as 15O, 13N, 11C, and 15F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • “Optionally substituted aryl” means aryl that is optionally substituted with one, two, or three substituents independently selected from alkyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfonyl, amino, alkylamino, dialkylamino, halo, haloalkyl, haloalkoxy, and cyano.
  • “Optionally substituted aralkyl” means -(alkylene)-R where R is optionally substituted aryl as defined above.
  • “Optionally substituted heteroaryl” means heteroaryl as defined above that is optionally substituted with one, two, or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, and cyano.
  • “Optionally substituted heteroaralkyl” means -(alkylene)-R where R is optionally substituted heteroaryl as defined above.
  • “Optionally substituted heterocyclyl” means heterocyclyl as defined above that is optionally substituted with one, two, or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy, and cyano.
  • “Optionally substituted heterocyclylalkyl” means -(alkylene)-R where R is optionally substituted heterocyclyl as defined above.
  • A “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the specification and claims includes both one and more than one such excipient.
  • The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass ±10%, preferably ±5%, the recited value and the range is included.
  • The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • The term “combination therapy” means the administration of two or more therapeutic agents to treat a disease or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
  • “Treating” or “treatment” of a disease includes:
  • (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;
  • (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
  • (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms. In one embodiment, treating or treatment means (2) or (3) above.
  • A “therapeutically effective amount” means the amount of a compound of Formula (I), (IA), (IB), or (IC) or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
  • The terms “inhibiting” and “reducing,” or any variation of these terms in relation of SHP2, includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of SHP2 activity compared to normal.
  • Representative compounds of Formula (I) are disclosed in Table (I) below
  • TABLE 1
    Com-
    pound
    # Structure Name
    1
    Figure US20200115389A1-20200416-C00020
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((S)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-4-yl)thio)pyrazin-2-yl) methanol
    2
    Figure US20200115389A1-20200416-C00021
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((R)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-4-yl)thio)pyrazin-2-yl) methanol
    3
    Figure US20200115389A1-20200416-C00022
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-fluoro-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    4
    Figure US20200115389A1-20200416-C00023
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8R)-8-fluoro-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    5
    Figure US20200115389A1-20200416-C00024
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-methoxy-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    6
    Figure US20200115389A1-20200416-C00025
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8R)-8-methoxy-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    7
    Figure US20200115389A1-20200416-C00026
         		(6aS,8S)-4-((5-((3S,4S)- 4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-8- ol
    8
    Figure US20200115389A1-20200416-C00027
         		(6aS,8R)-4-((5-((3S,4S)-4- amino-3-methyl-2-oxa- 8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-8- ol
    9
    Figure US20200115389A1-20200416-C00028
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aR,8R)-8-methoxy-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    10
    Figure US20200115389A1-20200416-C00029
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aR,8S)-8-methoxy-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)methanol
    11
    Figure US20200115389A1-20200416-C00030
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(((S)-tetrahydrofuran- 3-yl)oxy)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    12
    Figure US20200115389A1-20200416-C00031
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(((R)-tetrahydrofuran- 3-yl)oxy)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    13
    Figure US20200115389A1-20200416-C00032
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(oxetan-3-yloxy)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    14
    Figure US20200115389A1-20200416-C00033
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(methoxymethoxy)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pvrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    15
    Figure US20200115389A1-20200416-C00034
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(2-methoxyethoxy)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    16
    Figure US20200115389A1-20200416-C00035
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(cyclopropylmethoxy)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    17
    Figure US20200115389A1-20200416-C00036
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((S)-6a′,7′-dihydro-6′H,9′H-spiro [cyclopropane-1,8′-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin]-4′- yl)thio)pyrazin-2-yl)methanol
    18
    Figure US20200115389A1-20200416-C00037
         		(6aS,8S)-4-((5-((3S,4S)-4- amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)-8- methyl-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-8-ol
    19
    Figure US20200115389A1-20200416-C00038
         		(6aS,8R)-4-((5-((3S,4S)- 4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)-8- methyl-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-8-ol
    20
    Figure US20200115389A1-20200416-C00039
         		(6aS,8S)-4-((5-((3S,4S)- 4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazine- 8-carbonitrile
    21
    Figure US20200115389A1-20200416-C00040
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(methylsulfonyl)- 6a,7,8.9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    22
    Figure US20200115389A1-20200416-C00041
         		(6aS,8S)-4-((5-((3S,4S)- 4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)- 6a,7,8,9-tetrahydro-6H-pyrido [3,2-b]pyrrolo[1,2-d][1,4]oxazin-8- yl carbamate
    23
    Figure US20200115389A1-20200416-C00042
         		(6aS,8R)-4-((5-((3S,4S)- 4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)-6- (hydroxymethyl)pyrazin-2-yl)thio)- 6a,7,8,9-tetrahydro-6H-pyrido [3,2-b]pyrrolo[1,2-d][1,4]oxazin-8- yl carbamate
    24
    Figure US20200115389A1-20200416-C00043
         		(6-(((6aS,8S)-8-(1H-pyrazol-1- yl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)-3-((3S,4S)-4- amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl)pyrazin-2- yl)methanol
    25
    Figure US20200115389A1-20200416-C00044
         		(6-(((6aS,8R)-8-(1H-pyrazol-1- yl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)-3-((3S,4S)-4- amino-3-methyl-2-oxa-8-azaspiro [4.5]decan-8-yl)pyrazin-2- yl)methanol
    26
    Figure US20200115389A1-20200416-C00045
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((R)-6a,7,9,10-tetrahydro-6H- [1,4]oxazino[4,3-d]pyrido[3,2- b][1,4]oxazin-4-yl)thio)pyrazin-2-yl) methanol
    27
    Figure US20200115389A1-20200416-C00046
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((S)-6a,7,9,10-tetrahydro-6H- [1,4]oxazino[4,3-d]pyrido[3,2- b][1,4]oxazin-4-yl)thio)pyrazin-2-yl) methanol
    28
    Figure US20200115389A1-20200416-C00047
         		4-((5-((3S,4S)-4-amino-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8- yl)-6-(hydroxymethyl)pyrazin-2-yl) thio)-6a,7,9,10-tetrahydro-6H- pyrido[3,2-b][1,4]thiazino[4,3-d][1,4] oxazine 8,8-dioxide
    29
    Figure US20200115389A1-20200416-C00048
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    30
    Figure US20200115389A1-20200416-C00049
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8R)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    31
    Figure US20200115389A1-20200416-C00050
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    32
    Figure US20200115389A1-20200416-C00051
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-((2-methoxyethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    33
    Figure US20200115389A1-20200416-C00052
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-((cyclopropylmethoxy) methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    34
    Figure US20200115389A1-20200416-C00053
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-((oxetan-3-ylmethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    35
    Figure US20200115389A1-20200416-C00054
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((S)-2-amino-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-4-yl)thio)pyrazin-2-yl) methanol formate
    36
    Figure US20200115389A1-20200416-C00055
         		(3-((S)-5-amino-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-6-(((6aS,8S)- 8-(methoxymethyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    37
    Figure US20200115389A1-20200416-C00056
         		(3-((S)-5-amino-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-6-(((6aS,8R)- 8-(methoxymethyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    38
    Figure US20200115389A1-20200416-C00057
         		(3-((S)-5-amino-13-oxa-9-azadispiro [3.1.56.24]tridecan-9-yl)-6- (((6aS,8S)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    39
    Figure US20200115389A1-20200416-C00058
         		(3-((S)-5-amino-13-oxa-9-azadispiro [3.1.56.24]tridecan-9-yl)-6- (((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    40
    Figure US20200115389A1-20200416-C00059
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(((methoxymethoxy) methoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    41
    Figure US20200115389A1-20200416-C00060
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(hydroxymethyl)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    42
    Figure US20200115389A1-20200416-C00061
         		(3S,4S)-8-(5-(((6aS.8S)-8- ((methoxymethoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4- amine
    43
    Figure US20200115389A1-20200416-C00062
         		(3S,4S)-8-(5-(((6aS,8S)-8- (methoxymethyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)thio)pyrazin-2- yl)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine
    44
    Figure US20200115389A1-20200416-C00063
         		(3S,4S)-8-(6-amino-5-(((6aS,8S)- 8-((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4- amine
    45
    Figure US20200115389A1-20200416-C00064
         		(3S,4S)-8-(6-amino-5-(((6aS,8S)- 8-(methoxymethyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-3-methyl- 2-oxa-8-azaspiro[4.5]decan-4- amine
    46
    Figure US20200115389A1-20200416-C00065
         		(S)-1′-(5-(((6aS,8S)-8- ((methoxymethoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-5-amine
    47
    Figure US20200115389A1-20200416-C00066
         		(S)-1′-(6-amino-5-(((6aS,8S)- 8-((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-5-amine
    48
    Figure US20200115389A1-20200416-C00067
         		(3-((S)-5-amino-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-6-(((6aS,8S)- 8-((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido [3,2-b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)methanol
    49
    Figure US20200115389A1-20200416-C00068
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)thio)-5- methylpyrazin-2-yl)methanol
    50
    Figure US20200115389A1-20200416-C00069
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8R)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)thio)pyrazin-2- yl)methanol
    51
    Figure US20200115389A1-20200416-C00070
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aR,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)thio)pyrazin-2- yl)methanol
    52
    Figure US20200115389A1-20200416-C00071
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aR,8R)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)thio)pyrazin-2- yl)methanol
    53
    Figure US20200115389A1-20200416-C00072
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-((6aS,8S)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H- pyndo[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)pyrazin-2- yl)methanol
    54
    Figure US20200115389A1-20200416-C00073
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d] [1,4]oxazin-4-yl)pyrazin-2- yl)methanol

    Contemplated compounds of Formula (I) are disclosed in Table 2 below
  • II-1
    Figure US20200115389A1-20200416-C00074
         		6-amino-2-((3S,4S)-4-amino-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8-yl)-5- (((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)-3-methylpyrimidin- 4(3H)-one
    II-2
    Figure US20200115389A1-20200416-C00075
         		2-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)-5- (((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)-3-methyl- pyrimidin-4(3H)-one
    II-3
    Figure US20200115389A1-20200416-C00076
         		6-amino-2-((3S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5] decan-8-yl)-5-(((6aS,8S)-8- (methoxymethyl)-6a,7,8,9-tetra- hydro-6H-pyrido[3,2-b]pyrrolo [1,2-d][1,4]oxazin-4-yl)thio)- 3-methylpyrimidin-4(3H)-one
    II-4
    Figure US20200115389A1-20200416-C00077
         		2-((3S,4S)-4-amino-3-methyl-2-oxa- 8-azaspiro[4.5]decan-8-yl)-5- (((6aS,8S)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)-3-methylpyrimidin-4(3H)- one
    II-5
    Figure US20200115389A1-20200416-C00078
         		(3-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)- 6-(((6aS,8S)-8-(methoxymethyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)-5-methylpyrazin-2- yl)methanol
    II-6
    Figure US20200115389A1-20200416-C00079
         		(S)-1′-(5-(((6aS,8S)-8-(methoxy- methyl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2-yl)- 5,7-dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-5-amine
    II-7
    Figure US20200115389A1-20200416-C00080
         		(S)-1′-(6-amino-5-(((6aS,8S)-8- (methoxymethyl)-6a,7,8,9-tetrahydro- 6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2-yl)-5,7- dihydrospiro[cyclopenta[b]pyridine- 6,4′-piperidin]-5-amine
    II-8
    Figure US20200115389A1-20200416-C00081
         		(3S,4S)-8-(5-(((6aS,8S)-8-((cyclo- propylmethoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-amine
    II-9
    Figure US20200115389A1-20200416-C00082
         		(3S,4S)-8-(6-amino-5-(((6aS,8S)-8- ((cyclopropylmethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2- b]pyrrolol[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-amine
    II-10
    Figure US20200115389A1-20200416-C00083
         		6-amino-2-((3S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan- 8-yl)-5-(((6aS,8S)-8-((cyclopropyl- methoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b]pyrrolo [1,2-d][1,4]oxazin-4-yl)thio)-3- methylpyrimidin-4(3H)-one
    II-11
    Figure US20200115389A1-20200416-C00084
         		2-((3S,4S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl)-5- (((6aS,8S)-8-((cyclopropyl- methoxy)methyl)-6a,7,8,9-tetra- hydro-6H-pyrido[3,2-b]pyrrolo [1,2-d][1,4]oxazin-4-yl)thio)-3- methylpyrimidin-4(3H)-one
    II-12
    Figure US20200115389A1-20200416-C00085
         		(3-((S)-5-amino-5,7-dihydro- spiro[cyclopenta[b]pyridine- 6,4′-piperidin]-1′-yl)-6- (((6aS,8R)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    II-13
    Figure US20200115389A1-20200416-C00086
         		(3-((S)-5-amino-5,7-dihydro- spiro[cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-6-(((6aR,8R)-8- ((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2-d][1,4] oxazin-4-yl)thio)pyrazin-2- yl)methanol
    II-14
    Figure US20200115389A1-20200416-C00087
         		(3-((S)-5-amino-5,7-dihydro- spiro[cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-6-(((6aR,8S)-8- ((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H- pyrido[3,2-b]pyrrolo[1,2- d][1,4]oxazin-4-yl)thio)pyrazin- 2-yl)methanol
    II-15
    Figure US20200115389A1-20200416-C00088
         		(S)-1′-(5-(((6aS,8R)-8-((methoxy- methoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)-5,7-dihydro- spiro[cyclopenta[b]pyridine- 6,4′-piperidin]-5-amine
    II-16
    Figure US20200115389A1-20200416-C00089
         		(S)-1′-(5-(((6aR,8R)-8-((methoxy- methoxy)methyl)-6a,7,8,9-tetra- hydro-6H-pyrido[3,2-b]pyrrolo [1,2-d][1,4]oxazin-4-yl)thio)pyrazin- 2-yl)-5,7-dihydrospiro[cyclo- penta[b]pyridine-6,4′-piperidin]- 5-amine
    II-17
    Figure US20200115389A1-20200416-C00090
         		(S)-1′-(5-(((6aR,8S)-8-((methoxy- methoxy)methyl)-6a,7,8,9- tetrahydro-6H-pyrido[3,2-b] pyrrolo[1,2-d][1,4]oxazin-4-yl) thio)pyrazin-2-yl)-5,7-dihydro- spiro[cyclopenta[b]pyridine-6,4′- piperidin]-5-amine
    II-18
    Figure US20200115389A1-20200416-C00091
         		(S)-1′-(6-amino-5-(((6aS,8R)-8- ((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido[3,2- b]pyrrolo[1,2-d][1,4]oxazin-4- yl)thio)pyrazin-2-yl)-5,7-dihydro- spiro[cyclopenta[b]pyridine-6,4′- piperidin]-5-amine
    II-19
    Figure US20200115389A1-20200416-C00092
         		(S)-1′-(6-amino-5-(((6aR,8R)-8- ((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido [3,2-b]pyrrolo[1,2-d][1,4]oxazin- 4-yl)thio)pyrazin-2-yl)-5,7- dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-5-amine
    II-20
    Figure US20200115389A1-20200416-C00093
         		(S)-1′-(6-amino-5-(((6aR,8S)-8- ((methoxymethoxy)methyl)- 6a,7,8,9-tetrahydro-6H-pyrido [3,2-b]pyrrolo[1,2-d][1,4]oxazin- 4-yl)thio)pyrazin-2-yl)-5,7- dihydrospiro[cyclopenta[b]pyridine- 6,4′-piperidin]-5-amine
    • EMBODIMENTS
  • In further embodiments 1-36 below, the present disclosure includes:
  • 1. In embodiment 1, provided is a compound of Formula (I), (IA), (IB), or (IC) as described in the Summary above, or a pharmaceutically acceptable salt thereof.
  • In a first subembodiment of embodiment 1, the compound is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In a second subembodiment of embodiment 1, the compound is a compound of Formula (IA), or a pharmaceutically acceptable salt thereof. In a third subembodiment of embodiment 1, the compound is a compound of Formula (IB), or a pharmaceutically acceptable salt thereof. In a fourth subembodiment of embodiment 1, the compound is a compound of Formula (IC), or a pharmaceutically acceptable salt thereof.
  • 2. In embodiment 2, the compound of any one of embodiment 1 and subembodiments contained within embodiment 1, or a pharmaceutically acceptable salt thereof is wherein the has a structure of formula (II): (i.e., Z1 is a group of formula (a))
  • Figure US20200115389A1-20200416-C00094
  • 3. In embodiment 3, the compound of any one of embodiments 1 and 2 and subembodiment contained therein, and or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIA):
  • Figure US20200115389A1-20200416-C00095
  • 4. In embodiment 5, the compound of any one of embodiment 1 and subembodiment contained within embodiment 1, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (III): (i.e., Z1 is a group of formula (b))
  • Figure US20200115389A1-20200416-C00096
  • 5. In embodiment 5, the compound of any one of embodiment 1 and 4 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIIA):
  • Figure US20200115389A1-20200416-C00097
  • 6. In embodiment 6, the compound of any one of embodiments 1 to 5 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein E is O and A is CH2 or bond.
  • 7. In embodiment 7, the compound of any one of embodiments 1 to 5 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein E is O and A is bond.
  • 8. In embodiment 8, the compound of embodiment 3 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof has a structure of formula (IIB):
  • Figure US20200115389A1-20200416-C00098
  • 9. In embodiment 9, the compound of embodiment 5 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof has the structure of formula (IIIB):
  • Figure US20200115389A1-20200416-C00099
  • 10. In embodiment 10, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, —OC(O)NRiRj, —S(O)2NRnRo, —NRpRq, or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, or —NRpRq and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo).
  • 11. In embodiment 11, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond or O and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)ORb, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, or —S(O)2NRnRo.
  • 12. In embodiment 12, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O—Ra where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 13. In embodiment 13, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)ORa where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 14. In embodiment 14, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —ORa where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 15. In embodiment 15, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is —O(alk)ORb where Rb is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 16. In embodiment 16, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethyloxy, methoxyethyloxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • 17. In embodiment 17, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is methoxymethyloxy, methoxyethyloxy, methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • 18. In embodiment 18, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxymethyl, or oxetan-3-ylmethyloxymethyl.
  • 19. In embodiment 18, the compound of any one of embodiments 1 to 9 and subembodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein Z is fluoro.
  • 20. In embodiment 20, the compound of any one of embodiments 1 to 19 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R9 and R13 are hydrogen.
  • 21. In embodiment 21, the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R9 and R13 are amino.
  • 21A. In embodiment 21A, the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R9 and R13 are methyl.
  • 21B. In embodiment 21B, the compound of any one of embodiments 1 to 19 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R9 and R13 are independently hydrogen, alkyl, or amino.
  • 22. In embodiment 22, the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S.
  • 23. In embodiment 23, the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S(O) or S(O)2.
  • 24. In embodiment 24, the compound of any one of embodiments 1 to 21B and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is bond.
  • 25. In embodiment 25, the compound of any one of embodiments 1 to 24 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is CR7R8 where R5 and R6 are independently hydrogen or alkyl. In one sub-embodiment, of embodiment 10, L is CH2. In another sub-embodiment of embodiment 10, L is C(CH3)2.
  • 26. In embodiment 26, the compound of any one of embodiments 1 to 3, 6-8, and 10 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R10 is hydroxyalkyl. In a first sub-embodiment of embodiment 11, R10 is hydroxymethyl.
  • 27. In embodiment 27, the compound of any one of embodiments 1 to 3, 6-8, and 10 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R10 is alkylsulfonyl. In a first sub-embodiment of embodiment 27, R2 is methylsulfonyl or ethylsulfonyl.
  • 27A. In embodiment 27A, the compound of any one of embodiments 1 to 3, 6-8, and 10 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R10 is hydrogen.
  • 28. In embodiment 28, the compound of any one of embodiments 11 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R14 is hydrogen.
  • 29. In embodiment 29, the compound of any one of embodiments 11 to 25 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R14 is -alkyl. In a first subembodiment, R14 is methyl.
  • 30. In embodiment 30, the compound of any one of embodiments 1 to 29 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein:
  • R1 and R15 are selected from amino and aminoalkyl; and R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano. In a sub-embodiment of embodiment 30, R″ and R15 are aminomethyl, and R12 and R16 are methyl.
  • 31. In embodiment 31, the compound of any one of embodiments 1 to 29 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein: R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00100
  • In a first subembodiment of embodiment 31, ring of formula (c) is:
  • Figure US20200115389A1-20200416-C00101
  • In a second subembodiment of embodiment 31, ring of formula (c) is
  • Figure US20200115389A1-20200416-C00102
  • 32. In embodiment 32, the compound of any one of 1 to 29 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00103
  • In a first embodiment of embodiment 32, ring of formula (c) is:
  • Figure US20200115389A1-20200416-C00104
    Figure US20200115389A1-20200416-C00105
  • 33. In embodiment 33, the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, or hydroxy, amino. In a first subembodiment 33, one of R1, R2, R3, and R4 is hydrogen and the remaining three of R1, R2, R3, and R4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, or amino. In a second subembodiment 33, two or three of R1, R2, R3, and R4 are hydrogen and the remaining one or two of R1, R2, R3, and R4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, or amino. In a third subembodiment 33, R1, R2, R3, and R4 are hydrogen.
  • 34. In embodiment 34, the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R5 is hydrogen, alkyl, halo, or amino and R6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, or cyano.
  • 35. In embodiment 35, the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R5 is hydrogen, chloro, methyl, or amino and R6 is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy, or methoxy.
  • 36. In embodiment 34, the compound of any one of embodiments 1 to 32 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is R5 and R6 are hydrogen.
  • It is understood that the embodiments set forth above include all combination of embodiments and subembodiments listed therein. For example, the ring of formula (c) listed in embodiment 31 and first and second sub-embodiments of embodiment 31, can independently be combined with one or more of the embodiments 1-30 and 32-36 and/or subembodiments contained therein.
  • Additional embodiments include Embodiments 37-63 below:
  • 37. A compound of Formula (I′):
  • Figure US20200115389A1-20200416-C00106
  • wherein:
  • A is
  • Figure US20200115389A1-20200416-C00107
  • substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O)2R, —C(O)R, —OR′, —NR′C(O)R, —NR′SO2R, —OC(O)NR′R″, —C(O)NR′R″, —S(O)2NR′R″, —NR′R″, or —NR′C(O)C(O)R where R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl; or when Rc and Ra are attached to the same carbon of cycloalkyl or fused heteroaryl ring, then Rc and Ra together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • or A is has the structure (d):
  • Figure US20200115389A1-20200416-C00108
  • where:
  • t is 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO2 where the remaining atoms are carbon; and W is O, CH2, or N; substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when Ra and Rc are attached to the same carbon atom, Ra and Rc together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene
  • Q1 is N or CR1 wherein R1 is hydrogen or deuterium;
  • Q2 is N or CH, or CD;
  • R2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O)2, or CR5R6 where R5 and R6 are independently hydrogen or alkyl;
  • and
  • Figure US20200115389A1-20200416-C00109
  • is a ring of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00110
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2 wherein when n is 2 then one of the CH2 can be replaced with O, S, or SO2; provided m+n is 1, 2, or 3;
  • k is 0, 1 or 2;
  • z is 0, 1, or 2;
  • each Rd is independently hydrogen, alkyl, or halogen;
  • Re and Re1 are independently hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
  • when Re and Re1 are attached to the same carbon atom, then Re and Re1 together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • Rf and Rg are independently hydrogen, alkyl, or haloalkyl;
  • each Rh is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • when one Rh is connected to carbon 2 or 3 of the piperidine (b) ring and the second Rh is attached to carbon 5 or 6 of the piperidine (b) ring, the nitrogen atom being position 1, then the first and second Rh combine to form alkylene chain;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X1, contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X1 are independently N or C provided only one of X and X1 can be N;
  • R3 is amino or aminoalkyl;
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with Ri and/or Rj independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00111
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • Rk and Rm are independently hydrogen, alkyl, or haloalkyl;
  • one of Y and Z is CH2, O, S, S(O), S(O)2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • when Rn and Ro are attached to the same carbon atom, then Rn and Ro together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene; or
  • a pharmaceutically acceptable salt thereof.
  • 38. The compound of embodiment 37 having a structure of Formula (I′A):
  • Figure US20200115389A1-20200416-C00112
  • wherein:
  • A is
  • Figure US20200115389A1-20200416-C00113
  • substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O)2R, —C(O)R, —NR′C(O)R, —NR′SO2R, —C(O)NR′R″, —S(O)2NR′R″, —NR′R″, or —NR′C(O)C(O)R where R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl; or when Rc and Ra are attached to the same carbon of cycloalkyl or fused heteroaryl ring, then Rc and Ra together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • A has the structure (d):
  • Figure US20200115389A1-20200416-C00114
  • where:
  • t is 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO2 where the remaining atoms are carbon; and W is O, CH2, or N; optionally substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when Ra and Rc are attached to the same carbon atom, Ra and Rc together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • Q1 is N or CR1 wherein R1 is hydrogen or deuterium;
  • Q2 is N or CH, or CD;
  • R2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O)2, or CR5R6 where R5 and R6 are independently hydrogen or alkyl;
  • and
  • Figure US20200115389A1-20200416-C00115
  • is a ring of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00116
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2; provided m+n is 1, 2, or 3;
  • k is 0, 1 or 2
  • z is 0, 1, or 2
  • each Rd is independently hydrogen, alkyl, or halogen;
  • Re is hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
  • Rf and Rg are independently hydrogen, alkyl, or haloalkyl;
  • each Rh is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • when one Rh is connected to carbon 2 or 3 of the piperidine (b) ring and the second Rh is attached to carbon 5 or 6 of the piperidine (b) ring, the nitrogen atom being position 1, then the first and second Rh combine to form alkylene chain;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X1, contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X1 are independently N or C provided only one of X and X1 can be N;
  • R3 is amino or aminoalkyl;
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with Ri and/or Rj independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00117
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • Rk and Rm are independently hydrogen, alkyl, or haloalkyl;
  • one of Y and Z is CH2, O, S, S(O), S(O)2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • a pharmaceutically acceptable salt thereof.
  • 39. A compound of Formula (I′B):
  • Figure US20200115389A1-20200416-C00118
  • wherein:
  • A is
  • Figure US20200115389A1-20200416-C00119
  • substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O)2R, —C(O)R, —NR′C(O)R, —NR′SO2R, —C(O)NR′R″, —S(O)2NR′R″, —NR′R″, or —NR′C(O)C(O)R where R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • Q1 is N or CR1 wherein R1 is hydrogen or deuterium;
  • Q2 is N or CH, or CD;
  • R2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, S(O), S(O)2, or CR5R6 where R5 and R6 are independently hydrogen or alkyl;
  • and
  • Figure US20200115389A1-20200416-C00120
  • is a ring of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00121
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2; provided m+n is 1, 2, or 3;
  • k is 0, 1 or 2
  • z is 0, 1, or 2
  • each Rd is independently hydrogen, alkyl, or halogen;
  • Re is hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
  • Rf and Rg are independently hydrogen, alkyl, or haloalkyl;
  • each Rh is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo; or
  • when one Rh is connected to carbon 2 or 3 of the piperidine (b) ring and the second Rh is attached to carbon 5 or 6 of the piperidine (b) ring, the nitrogen atom being position 1, then the first and second Rh combine to form alkylene chain;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X1, contains one to three heteroatoms independently selected from N, O, and S and ring D can optionally be substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, cycloalkyl, heterocyclyl, heteroaryl, and acylamino;
  • X and X1 are independently N or C provided only one of X and X1 can be N;
  • R3 is amino or aminoalkyl;
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclalkyl, cycloalkylalkyl, heterocyclalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl by itself or as part of aralkyl or heteroaralkyl is substituted with Ri and/or Ri independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide, or alkylsulfonyl; or
  • R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00122
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • Rk and Rm are independently hydrogen, alkyl, or haloalkyl;
  • one of Y and Z is CH2, O, S, S(O), S(O)2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
  • a pharmaceutically acceptable salt thereof.
  • 40. A compound of Formula (I′C):
  • Figure US20200115389A1-20200416-C00123
  • wherein:
  • A is
  • Figure US20200115389A1-20200416-C00124
  • substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —NHCOR, or —NR′R″ where R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen or alkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl; or when Rc and Ra are attached to the same carbon of cycloalkyl or fused heteroaryl ring, then Rc and Ra together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • A has the structure (d):
  • Figure US20200115389A1-20200416-C00125
  • where:
  • t is 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO2 where the remaining atoms are carbon; and W is O, CH2, or N; optionally substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, or alkoxy; or when Ra and Rc are attached to the same carbon atom, Ra and Rc together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • Q1 is N or CR1 wherein R1 is hydrogen or deuterium;
  • Q2 is N, CH, or CD;
  • R2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, SO, SO2, or CR5R6 where R5 and R6 are independently hydrogen or alkyl;
  • and
  • Figure US20200115389A1-20200416-C00126
  • is a ring of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00127
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2; provided m+n is 1, 2, or 3;
  • Rd is hydrogen or alkyl;
  • Re is hydrogen, alkyl, halogen, or oxo;
  • Rh is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X1, contains one to three heteroatoms independently selected from N, O, or S and ring D can optionally be substituted with alkyl;
  • X and X1 are independently N or C provided only one of X and X1 can be N;
  • R3 is amino or aminoalkyl;
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with Ri and/or Rj independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl; or
  • R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00128
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • one of Y and Z is CH2, O, S, SO, SO2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, or oxo; or
  • a pharmaceutically acceptable salt thereof.
  • 41. A compound of Formula (I′D):
  • Figure US20200115389A1-20200416-C00129
  • wherein:
  • A is
  • Figure US20200115389A1-20200416-C00130
  • substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —NHCOR, or —NR′R″ where R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen or alkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • Q1 is N or CR1 wherein R1 is hydrogen or deuterium;
  • Q2 is N, CH, or CD;
  • R2 is alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • L is bond, O, S, SO, SO2, or CR5R6 where R5 and R6 are independently hydrogen or alkyl;
  • and
  • Figure US20200115389A1-20200416-C00131
  • is a ring of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00132
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2; provided m+n is 1, 2, or 3;
  • Rd is hydrogen or alkyl;
  • Re is hydrogen, alkyl, halogen, or oxo;
  • Rh is independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano, or oxo;
  • ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including X and X1, contains one to three heteroatoms independently selected from N, O, or S and ring D can optionally be substituted with alkyl;
  • X and X1 are independently N or C provided only one of X and X1 can be N;
  • R3 is amino or aminoalkyl;
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with R′ and/or Ri independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl; or
  • R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00133
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • one of Y and Z is CH2, O, S, SO, SO2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, or oxo; or
  • a pharmaceutically acceptable salt thereof.
  • 42. In embodiment 42, the compound of any one of embodiments 37 to 41, or a pharmaceutically acceptable salt thereof has the structure of formula (III′):
  • Figure US20200115389A1-20200416-C00134
  • 43. In embodiment 43, the compound of any one of embodiments 37 to 41, or a pharmaceutically acceptable salt thereof has the structure of formula (IV′):
  • Figure US20200115389A1-20200416-C00135
  • 44. In embodiment 44, the compound of any one of embodiments 37 to 41, or a pharmaceutically acceptable salt thereof has the structure of formula (V′) or (VI′):
  • Figure US20200115389A1-20200416-C00136
  • In one sub-embodiment of embodiment 4, the compound or a pharmaceutically acceptable salt thereof has structure (V). In another sub-embodiment of embodiment 4, the compound or a pharmaceutically acceptable salt thereof has structure (VI).
  • 45. In embodiment 45, the compound of any one of embodiments 37 to 43 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R1 is hydrogen.
  • 46. In embodiment 46, the compound of any one of embodiments 37 to 43 and sub-embodiment contained therein, or a pharmaceutically acceptable salt thereof is wherein R1 is deuterium.
  • 47. In embodiment 7, the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S.
  • 48. In embodiment 8, the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is S(O) or S(O)2.
  • 49. In embodiment 49, the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is bond.
  • 50. In embodiment 50, the compound of any one of embodiments 37 to 46 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein L is CR5R6 where R5 and R6 are independently hydrogen or alkyl. In one sub-embodiment, of embodiment 50, L is CH2. In another sub-embodiment of embodiment 50, L is C(CH3)2.
  • 51. In embodiment 11, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is hydroxyalkyl. In a first sub-embodiment of embodiment 51, R2 is hydroxymethyl.
  • 52. In embodiment 52, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is alkylsulfonyl. In a first sub-embodiment of embodiment 52, R2 is methylsulfonyl or ethylsulfonyl.
  • 53. In embodiment 53, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is alkylsulfoxide. In a first sub-embodiment of embodiment 53, R2 is methylsulfoxide, ethylsulfoxide, or isopropylsulfoxide. In a second sub-embodiment of embodiment 53, R2 is methylsulfoxide.
  • 54. In embodiment 54, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is —CD2OH.
  • 55. In embodiment 55, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is alkoxycarbonyl, aminosulfonyl or aminocarbonyl. In a first sub-embodiment of embodiment 55, R2 is —S(O)2NH2. In a second sub-embodiment of embodiment 55, R2 is —CONH2. In a third sub-embodiment of embodiment 55, R2 is —C(O)CH3.
  • 56. In embodiment 16, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is hydroxy.
  • 57. In embodiment 57, the compound of any one of embodiments 37 to 50 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein R2 is halo. In a sub-embodiment of embodiment 17, R2 is chloro.
  • 58. In embodiment 58, the compound of any one of embodiments 37 to 57 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein:
  • Figure US20200115389A1-20200416-C00137
  • is a ring of formula (a):
  • Figure US20200115389A1-20200416-C00138
  • wherein:
  • m is 0, 1; or 2;
  • n is 0, 1, or 2 wherein when n is 2 then one of the CH2 can be replaced with O, S, or SO2; provided m+n is 1, 2, or 3;
  • k is 0, 1 or 2
  • z is 0, 1, or 2
  • each Rd is independently hydrogen, alkyl, or halogen;
  • Re and Re1 are independently hydrogen, alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
  • when Re and Re1 are attached to the same carbon atom, then Re and Re1 together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • In a first embodiment of embodiment 58,
  • Figure US20200115389A1-20200416-C00139
  • is a ring of formula:
  • Figure US20200115389A1-20200416-C00140
  • 59. In embodiment 59, the compound of any one of embodiments 37 to 57 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein:
  • Figure US20200115389A1-20200416-C00141
  • is a ring of formula (a):
  • Figure US20200115389A1-20200416-C00142
  • In a first sub-embodiment of embodiment 59,
  • Figure US20200115389A1-20200416-C00143
  • is:
  • Figure US20200115389A1-20200416-C00144
    Figure US20200115389A1-20200416-C00145
  • In a second sub-embodiment of embodiment 59,
  • Figure US20200115389A1-20200416-C00146
  • is:
  • Figure US20200115389A1-20200416-C00147
    Figure US20200115389A1-20200416-C00148
  • In a third sub-embodiment of embodiment 59,
  • Figure US20200115389A1-20200416-C00149
  • 60. In embodiment 60, the compound of any one of embodiments 37 to 57 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein
  • Figure US20200115389A1-20200416-C00150
  • preferably where z is 1, and
  • where R3 is amino or aminoalkyl; and
  • R4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5 or 6 membered heteroaryl, or 4 to 6 membered heterocyclyl wherein heteroaryl or heterocyclyl is substituted with Ri and/or Rj independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, or alkylsulfonyl. In a sub-embodiment of embodiment 20, z is 0, R3 is aminomethyl, and R4 is methyl.
  • 61. In embodiment 61, the compound of any one of embodiments 37 to 57 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein
  • Figure US20200115389A1-20200416-C00151
  • preferably where z is 1, and
  • where R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00152
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • Rk and Rm are independently hydrogen, alkyl, or haloalkyl;
  • one of Y and Z is CH2, O, S, S(O), S(O)2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or when Rn and Ro are attached to the same carbon atom, then Rn and Ro together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
  • In a first subembodiment of embodiment 61,
  • Figure US20200115389A1-20200416-C00153
    Figure US20200115389A1-20200416-C00154
  • 62. In embodiment 62, the compound of any one of embodiments 37 to 57 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof is wherein
  • Figure US20200115389A1-20200416-C00155
  • preferably where z is 1, and
  • where R3 and R4 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00156
  • wherein:
  • m1 is 0, 1; or 2;
  • n1 is 0, 1, or 2; provided m1+n1 is 1, 2, or 3;
  • Rk and Rm are independently hydrogen, alkyl, or haloalkyl;
  • one of Y and Z is CH2, O, S, S(O), S(O)2, or NH; and the other of X and Y is CH2; and wherein ring of formula (c) is substituted with Rn and/or Ro independently selected from hydrogen, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl.
  • In a first sub-embodiment of embodiment 62,
  • Figure US20200115389A1-20200416-C00157
  • is:
  • Figure US20200115389A1-20200416-C00158
    Figure US20200115389A1-20200416-C00159
  • In a second subembodiment of embodiment 62,
  • Figure US20200115389A1-20200416-C00160
  • is:
  • Figure US20200115389A1-20200416-C00161
  • In a third sub-embodiment of embodiment 62,
  • Figure US20200115389A1-20200416-C00162
  • is:
  • Figure US20200115389A1-20200416-C00163
  • In a fourth sub-embodiment of embodiment 62,
  • Figure US20200115389A1-20200416-C00164
  • 63. In embodiment 63, the compound of any one of embodiments 37 to 60 and sub-embodiments contained therein, or a pharmaceutically acceptable salt thereof Ra and Rb are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —S(O)R, S(O)2R, —C(O)R, —NR′C(O)R, —NR′SO2R, —C(O)NR′R″, —S(O)2NR′R″, —NR′R″, or —NR′C(O)C(O)R where R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl or R′ and R″ together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl; or
  • when Rc and Ra are attached to the same carbon of cycloalkyl or fused heteroaryl ring, then Rc and Ra together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • In a first sub-embodiment of embodiment 63, Ra and Rb are independently selected from hydrogen, alkyl, amino, cycloalkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and Rc is hydrogen or —NR′R″ where R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • In a second sub-embodiment of embodiment 63, Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and Rc is hydrogen or —NR′R″ where R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • In a third sub-embodiment of embodiment 63, Ra and Rb are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, and cyano and Rc is hydrogen or —NR′R″ where R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or optionally substituted heterocyclyl.
  • In a fourth sub-embodiment of embodiment 63, Ra and Rb are independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, hydroxy, or cyano, and Rc is hydrogen.
  • In a fifth sub-embodiment of embodiment 63, and first subembodiment therein, ring A has the structure (d):
  • Figure US20200115389A1-20200416-C00165
  • where:
  • t is 0, 1 or 2;
  • ring E is 4 to 7 membered heterocycle containing 1 or 2 heteroatoms independently selected from O, N, S, and SO2 where the remaining atoms are carbon; and W is O, CH2, or N; substituted with Ra, Rb, and/or Rc wherein Ra and Rb are independently selected from hydrogen, amino, alkyl, alkyldienyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxy, and alkoxycarbonyl and Rc is hydrogen, alkyl, halo, hydroxy, or alkoxy; or
  • when Ra and Rc are attached to the same carbon atom, Ra and Rc together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • In a first embodiment, of the fifth sub-embodiment, ring A is
  • Figure US20200115389A1-20200416-C00166
  • In a second embodiment, of the fourth sub-embodiment, ring A is:
  • Figure US20200115389A1-20200416-C00167
  • In an second embodiment of the fifth sub-embodiment, ring A is:
  • Figure US20200115389A1-20200416-C00168
  • In an sixth subembodiment of embodiment 63, ring A is:
  • Figure US20200115389A1-20200416-C00169
    Figure US20200115389A1-20200416-C00170
    Figure US20200115389A1-20200416-C00171
  • It is understood that the embodiments 37 to 63 set forth above include all combination of embodiments and subembodiments listed therein. For example, the ring A listed in fifth sub-embodiment of embodiment 63, can independently be combined with one or more of the embodiments 35 to 62 and/or subembodiments contained therein.
  • Additional Embodiments include embodiments 66 to 112 below:
  • 66. A compound of Formula (I):
  • Figure US20200115389A1-20200416-C00172
  • wherein:
  • A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
  • Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, Rr, and Rs are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
  • R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
  • or one of R1 and R2 and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
  • R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and the other R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
  • L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
  • Z1 is a group of formula (a) or (b):
  • Figure US20200115389A1-20200416-C00173
  • wherein:
  • R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
  • R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
  • R14 is hydrogen, alkyl, or haloalkyl;
  • R11 and R15 are selected from amino and aminoalkyl;
  • R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
  • or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00174
  • wherein:
  • e is 0, 1; or 2;
  • k is 0, 1, or 2 provided e+k is 1, 2, or 3;
  • q is 0, 1, or 2, or 3;
  • R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
  • each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
  • when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene.
  • ring D is absent or present; wherein:
      • (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
      • (ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally be substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl; or a pharmaceutically acceptable salt thereof.
  • 67. The compound of embodiment 66, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (II):
  • Figure US20200115389A1-20200416-C00175
  • 68. The compound of embodiment 67 or 68, and or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIA):
  • Figure US20200115389A1-20200416-C00176
  • 69. The compound of embodiment 66, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (III):
  • Figure US20200115389A1-20200416-C00177
  • 70. The compound of embodiment 66 or 69, or a pharmaceutically acceptable salt thereof is wherein the compound has structure of Formula (IIIA):
  • Figure US20200115389A1-20200416-C00178
  • 71. The compound of claim any one of embodiments 66 to 70, or a pharmaceutically acceptable salt thereof wherein E is O and A is CH2 or bond.
  • 72. The compound of claim any one of embodiments 66 to 70, or a pharmaceutically acceptable salt thereof wherein E is O and A is bond.
  • 73. The compound of claim 68, or a pharmaceutically acceptable salt thereof has a structure of formula (IIB):
  • Figure US20200115389A1-20200416-C00179
  • 74. The compound of claim 70, or a pharmaceutically acceptable salt thereof has the structure of formula (IIIB):
  • Figure US20200115389A1-20200416-C00180
  • 75. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, —OC(O)NRiRj, —S(O)2NRnRo, —NRpRq, or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, or —NRpRq and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo).
  • 76. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is —Y-M (wherein Y is bond or O and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)ORb, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, or —S(O)2NRnRo.
  • 77. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O—Ra where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 78. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)ORa where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 79. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is —ORa where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 80. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is —O(alk)ORb where Rb is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • 81. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethyloxy, methoxyethyloxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • 82. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is methoxymethyloxy, methoxyethyloxy, methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
  • 83. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is methoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxymethyl, or oxetan-3-ylmethyloxymethyl.
  • 84. The compound of claim any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof wherein Z is fluoro.
  • 85. The compound of claim any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof wherein R9 and R13 are hydrogen.
  • 86. The compound of claim any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof wherein R9 and R13 are amino.
  • 87. The compound of claim any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof wherein R9 and R13 are amino.
  • 88. The compound of claim any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof wherein R9 and R13 are methyl.
  • 89. The compound of claim any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof wherein R9 and R13 are independently hydrogen, alkyl, or amino.
  • 90. The compound of claim any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof wherein L is S.
  • 91. The compound of claim any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof wherein L is S(O) or S(O)2.
  • 92. The compound of claim any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof wherein L is bond.
  • 93. The compound of claim any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof wherein L is CR7R8 where R5 and R6 are independently hydrogen or alkyl.
  • 94. The compound of claim any one of embodiments 66 to 68, 71 to 73 and 75 to 93, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxyalkyl.
  • 95. The compound of claim any one of embodiments 66 to 68, 71 to 73 and 75 to 93, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxymethyl.
  • 96. The compound of claim any one of embodiments 66, 69 to 72, and 74 to 93, or a pharmaceutically acceptable salt thereof is wherein R14 is hydrogen or methyl.
  • 97. The compound of claim any one of embodiments 66 to 96, or a pharmaceutically acceptable salt thereof wherein:
  • R11 and R15 are selected from amino and aminoalkyl; and R12 and R16 are independently selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano.
  • 98. The compound of embodiments 97, or a pharmaceutically acceptable salt thereof wherein R11 and R15 are aminomethyl and R12 and R16 are methyl.
  • 99. The compound of claim any one of embodiments 66 to 96, or a pharmaceutically acceptable salt thereof wherein R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00181
  • 100. The compound of embodiment 99, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
  • Figure US20200115389A1-20200416-C00182
  • 101. The compound of claim any one of embodiments 66 to 96, or a pharmaceutically acceptable salt thereof wherein R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
  • Figure US20200115389A1-20200416-C00183
  • 102. The compound of embodiment 101, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
  • Figure US20200115389A1-20200416-C00184
    Figure US20200115389A1-20200416-C00185
  • 103. The compound of any one of embodiments 66 to 102, or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, and hydroxy, amino.
  • 104. The compound of embodiment 103, or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, and R4 is hydrogen and the remaining three of R1, R2, R3, and R4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, and amino.
  • 105. The compound of embodiment 103, or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, and R4 are hydrogen.
  • 106. The compound of any one of embodiments 66 to 105, or a pharmaceutically acceptable salt wherein R5 is hydrogen, alkyl, halo, or amino and R6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, or cyano.
  • 107. The compound of embodiment 106, or a pharmaceutically acceptable salt thereof wherein R5 and R6 are hydrogen.
  • 108. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 and a pharmaceutically acceptable excipient.
  • 109. A method of treating a disease treatable by inhibition of SHP2 in a patient which method comprises administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 or which method comprises administering to the patient, preferably a patient in need of such treatment, a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 66 to 107 and a pharmaceutically acceptable excipient.
  • 110. The method of embodiment 109 wherein the disease is cancer.
  • 111. The method of embodiment 110 wherein the cancer is selected from lung, stomach, liver, colon, kidney, breast, pancreatitis, juvenile myelomonocytic leukemias, neurolastoma, melanoma, and acute myeloid leukemia.
  • 112. The method of embodiment 109 wherein the disease is selected from Noonan syndrome and Leopard syndrome.
    • General Synthetic Scheme
  • Compounds of this disclosure can be made by the methods depicted in the reaction schemes shown below.
  • The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this disclosure can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art reading this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
  • Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about −78° C. to about 150° C., such as from about 0° C. to about 125° C. and further such as at about room (or ambient) temperature, e.g., about 20° C.
    • General Synthetic Scheme
  • Compounds of Formula (I), (IA), (IB), or (IC) in which, L is Sand other groups are as defined in Summary can be prepared as illustrated and described in Scheme 1 below.
  • Figure US20200115389A1-20200416-C00186
  • Coupling of a compound of formula 1-a, where X1 is halogen, where Z, R1, R2, R3, R4, R5, and R6 are as defined in the Summary or a precursor group thereof and E and A are as defined in the Summary, with a compound of formula 1-d where M1 is metal such as sodium or potassium, in the presence of transition metal catalyst such as Pd2(dba)3 and xantphos under standard coupling condition provides compounds of Formula (I). If a compound of formula 1-a is substituted with an amino group, then the amino group can be protected with a suitable protecting group such as t-butyl carbamate prior to the coupling reaction. Removal of the amino protecting group by methods well known in the art then provides a compound of Formula (I), (IA), (IB), or (IC)
  • Alternatively, compounds of Formula (I), (IA), (IB), or (IC) can be prepared by reacting compound of formula 1-a with 3-mercaptopropanoate ester in the presence of transition metal catalyst such as Pd2(dba)3 and xantphos under standard coupling condition to provide a compound of formula 1-b where R′ is an alkyl group such as 3-methylheptane. Treatment of a compound of formula 1-b with a base such as potassium t-butoxide, sodium t-butoxide, sodium methoxide, and the like, provides a compound of formula 1-c as a thiosalt, where M+ is a metal ion such as potassium or sodium. Coupling of 1-c with a compound of formula 1-e or formula 1-f where X2 or X3 is halo provides a compound of Formula (I), (IA), (IB), or (IC) where Z1 is a group of formula (a) or (b), respectively.
  • Compounds of formula 1-a where X1 is halogen, E is O, and A, E, Z, R1, R2, R3, R4, R5, R6, are as defined in Summary or a precursor group thereof, can be prepared as illustrated and described in Methods 1 and 2 below.
    • Method (1):
  • Figure US20200115389A1-20200416-C00187
  • Coupling a compound of formula 2-b in which R5 and R6 are as defined in Summary or a precursor group thereof with an alcohol of formula 2-a where PG is a suitable amino protecting group such as Boc, under Mitsunobu condition, for example, using diethyl azodicarboxylate and triphenyl phosphine provides a compound of formula 2-c. Compounds of formula 2-b are commercially available or they can be prepared by methods well known in the art. For example, 2-fluoropyridin-3-ol is commercially available. Compounds of formula 2-a are commercially available or they can be prepared by methods well known in the art. For example, tert-butyl (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate, tert-butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate, tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylate, tert-butyl (2S,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate, tert-butyl (S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate, tert-butyl (2S,4R)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate, tert-butyl (2S,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate, tert-butyl (S)-6-(hydroxymethyl)-5-azaspiro[2.4]heptane-5-carboxylate, tert-butyl (R)-3-(hydroxymethyl)morpholine-4-carboxylate, tert-butyl (S)-3-(hydroxymethyl)morpholine-4-carboxylate, tert-butyl (R)-2-(hydroxymethyl)azetidine-1-carboxylate, tert-butyl (S)-2-(hydroxymethyl)azetidine-1-carboxylate are commercially available.
  • Removal of the amino protecting group provides a compound of formula 2-d. For example, Boc group can be cleaved under acidic condition such HCl in dioxane. Cyclization of compound 2-d with a base such as K2CO3, sodium carbonate, and the like, provides a compound of formula 2-e. Lithiation of compound 2-e using alkyl lithium such n-BuLi, followed by trapping with iodine provides a compound of formula 1-a.
    • Method (2)
  • Figure US20200115389A1-20200416-C00188
  • Alternatively, coupling a compound of formula 3-a where X1 is halogen, R5 and R6 are as defined in summary and an alcohol of formula 2-a where PG is an amino protecting group such as Boc, under Mitsunobu condition, for example, using diethyl azodicarboxylate and triphenyl phosphine provides a compound of formula 3-b. Compounds of formula 3-a are commercially available or they can be prepared by methods well known in the art. For example, 2-fluoro-4-iodopyridin-3-ol is commercially available. Compound 3-c is converted to a compound of formula 1-a as described in Scheme 1 above.
    • Utility
  • The Src Homolgy-2 phosphatase (SHP2) is a protein tyrosine phosphatase encoded by the PTPN1 1 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3-kinase-AKT pathways. SHP2 mediates activation of Erk1 and Erk2 (Erk1/2, Erk) MAP kinases by receptor tyrosine kinases such as ErbB1, ErbB2 and c-Met.
  • SHP2 has two N-terminal Src homology 2 domains (N—SH2 and C—SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive conformation, inhibiting its own activity via a binding network involving residues from both the N—SH2 and PTP domains. In response to growth factor stimulation, SHP2 binds to specific tyrosine-phosphorylated sites on docking proteins such as Gab1 and Gab2 via its SH2 domains. This induces a conformational change that results in SHP2 activation.
  • Mutations in PTPN11 have been identified in several human diseases, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
  • Noonan Syndrome (NS) and Leopard Syndrome (LS): PTPN11 mutations cause LS (multiple lentigenes, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, sensorineural deafness) and NS (congenital anomalies including cardiac defects, craniofacial abnormalities and short stature). Both disorders are part of a family of autosomal dominant syndromes caused by germline mutations in components of the RAS/RAF/MEK/ERK mitogen activating protein kinase pathway, required for normal cell growth and differentiation. Aberrant regulation of this pathway has profound effects, particularly on cardiac development, resulting in various abnormalities, including valvuloseptal defects and/or hypertrophic cardiomyopathy (HCM). Perturbations of the MAPK signaling pathway have been established as central to these disorders and several candidate genes along this pathway have been identified in humans, including mutations in KRAS, NRAS, SOS1, RAF1, BRAF, MEK1, MEK2, SHOC2, and CBL. The gene most commonly mutated in NS and LS is PTPN1 1. Germline mutations in PTPN1 1 (SHP2) are found in −50% of the cases with NS and nearly all patients with LS that shares certain features with NS. For NS, Y62D and Y63C substitutions in the protein are largely invariant and are among the most common mutations. Both these mutations affect the catalytically inactive conformation of SHP2 without perturbing the binding of the phosphatase to its phosphorylated signaling partners.
  • Juvenile Myelomonocytic Leukemias (JMML): Somatic mutations in PTPN1 1(SHP2) occur in about 35% of the patients with JMML, a childhood myeloproliferative disorder (MPD). These gain-of-function mutations are typically point mutations in the N—SH2 domain or in the phosphatase domain, which prevent self-inhibition between the catalytic domain and the N—SH2 domain, resulting in SHP2 activity.
  • Acute Myeloid Leukemia: PTPN1 1 mutations have been identified in: −10% of pediatric acute leukemias, such as myelodysplastic syndrome (MDS); −7% of B cell acute lymphoblastic leukemia (B-ALL); and −4% of acute myeloid leukemia (AML).
  • NS and leukemia mutations cause changes in amino acids located at the interface formed by the N—SH2 and PTP domains in the self-inhibited SHP2 conformation, disrupting the inhibitory intramolecular interaction, leading to hyperactivity of the catalytic domain.
  • SHP2 acts as a positive regulator in receptor tyrosine kinase (RTK) signaling. Cancers containing RTK alterations (EGFR amp, Her2 amp, FGFR amp, Met 31″15, translocated/activated RTK, i.e. ALK, BCR/ABL) include Esophageal, Breast, Lung, Colon, Gastric, Glioma, Head and Neck cancers.
  • Esophageal cancer (or oesophageal cancer) is a malignancy of the esophagus. There are various subtypes, primarily squamous cell cancer (<50%) and adenocarcinoma. There is a high rate of RTK expression in esophageal adenocarcinoma and squamous cell cancer. A SHP2 inhibitor of the invention can, therefore, be employed for innovative treatment strategies.
  • Breast cancer is a major type of cancer and a leading cause of death in women, where patients develop resistance to current drugs. There are four major subtypes of breast cancers including luminal A, luminal B, Her2 like, and triple negative/Basal-like. Triple negative breast cancer (TNBC) is an aggressive breast cancer lacking specific targeted therapy. Epidermal growth factor receptor I (EGFR) has emerged as a promising target in TNBC. Inhibition of Her2 as well as EGFR via SHP2 may be a promising therapy in breast cancer.
  • Lung Cancer—NSCLC is currently a major cause of cancer-related mortality, accounting for about 85% of lung cancers (predominantly adenocarcinomas and squamous cell carcinomas). Although cytotoxic chemotherapy remains an important part of treatment, targeted therapies based on genetic alterations such as EGFR and ALK in the tumor are more likely to benefit from a targeted therapy.
  • Colon Cancer—Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS, and BRAF mutations occur in 10 to 15% of colorectal cancers. For a subset of patients whose colorectal tumors have been demonstrated to over express EGFR, these patients exhibit a favorable clinical response to anti-EGFR therapy.
  • Gastic Cancer is one of the most prevalent cancer types. Aberrant expression of tyrosine kinases, as reflected by the aberrant tyrosine phosphorylation in gastric cancer cells, is known in the art. Three receptor-tyrosine kinases, c-met (HGF receptor), FGF receptor 2, and erbB2/neu are frequently amplified in gastric carcinomas. Thus, subversion of different signal pathways may contribute to the progression of different types of gastric cancers.
  • Neuroblastoma is a pediatric tumor of the developing sympathetic nervous system, accounting for about 8% of childhood cancers. Genomic alterations of the anaplastic lymphoma kinase (ALK) gene have been postulated to contribute to neuroblastoma pathogenesis.
  • Squamous-cell carcinoma of the head and neck (SCCHN). High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking of the EGFR signaling results in inhibition of the stimulation of the receptor, cell proliferation, and reduced invasiveness and metastases. The EGFR is, therefore, a prime target for new anticancer therapy in SCCHN.
  • The present invention relates to compounds capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention and pharmaceutical preparations comprising such compounds. Another aspect of the present invention relates to a method of treating SHP2-mediated disorders comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined in the Summary.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said SHP2-mediated disorders are cancers selected from, but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; Gastric cancer, Head and Neck cancer.
  • The compounds of the present invention may also be useful in the treatment of other diseases or conditions related to the aberrant activity of SHP2. Thus, as a further aspect, the invention relates to a method of treatment of a disorder selected from: NS; LS; JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; gastric cancer; head and neck cancer.
  • A SHP2 inhibitor of the present invention may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of cancer. For example, a compound of the current invention or a pharmaceutically acceptable salt thereof, as defined above, may be administered simultaneously, sequentially or separately in combination with one or more agents selected from chemotherapy agents, for example, mitotic inhibitors such as a taxane, a vinca alkaloid, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine, and other anticancer agents, e.g. cisplatin, 5-fluorouracil or 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU), flutamide or gemcitabine. Such combinations may offer significant advantages, including synergistic activity, in therapy.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered parenterally.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered systemically.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said patient is a mammal.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said patient is a primate.
  • In certain embodiments, the present invention relates to the aforementioned method, wherein said patient is a human.
  • In another aspect, the present invention relates to a method of treating an SHP2-mediated disorder, comprising the step of: administering to a patient in need thereof a therapeutically effective amount of a chemotherapeutic agent in combination with a therapeutically effective amount of a compound of formula I as defined in the Summary. In addition to human cancer, inhibition of SHP2 also has the therapeutic potential for treatment of systemic lupus erythematosus, rheumatoid arthritis and fibrosis.
    • Testing
  • The SHP2 inhibitory activity of the compounds of Formula (I), (IA), (IB), and (IC) can be tested using the in vitro assay described in Biological Examples 1 below.
    • Pharmaceutical Compositions
  • In general, the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds this disclosure may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. A suitable dosage level may be from about 0.1 to about 250 mg/kg per day; about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of this disclosure, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound being utilized, the route and form of administration, and other factors.
  • In general, compounds of this disclosure will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules, including enteric coated or delayed release tablets, pills or capsules are preferred) and the bioavailability of the drug substance.
  • The compositions are comprised of in general, a compound of this disclosure in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of this disclosure. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
  • The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
  • The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
  • Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
  • For administration by inhalation, compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the disclosure may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
  • The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt. %) basis, from about 0.01-99.99 wt. % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1-80 wt. %.
    • Combinations and Combination Therapies
  • The compounds of this disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of this disclosure or the other drugs may have utility. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I). When a compound of this disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula (I) is preferred. However, the combination therapy may also include therapies in which the compound of this disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of Formula (I) and the other active ingredients may be used in lower doses than when each is used singly.
  • Accordingly, the pharmaceutical compositions of Formula (I) also include those that contain one or more other drugs, in addition to a compound of Formula (I).
  • The above combinations include combinations of a compound of this disclosure not only with one other drug, but also with two or more other active drugs. Likewise, a compound of this disclosure may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which a compound of this disclosure is useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I). When a compound of this disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of this disclosure can be used. Accordingly, the pharmaceutical compositions of Formula (I) also include those that also contain one or more other active ingredients, in addition to a compound of this disclosure. The weight ratio of the compound of this disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
  • Where the subject in need is suffering from or at risk of suffering from cancer, the subject can be treated with a compound of this disclosure in any combination with one or more other anti-cancer agents including but not limited to:
  • MAP kinase pathway (RAS/RAF/MEK/ERK) inhibitors including but not limited to: Vemurafanib (PLX4032), Dabrafenib, Encorafenib (LGX818), TQ-B3233, XL-518 (Cas No. 1029872-29-4, available from ACC Corp); trametinib, selumetinib (AZD6244), TQ-B3234, PD184352, PD325901, TAK-733, pimasertinib, binimetinib, refametinib, cobimetinib (GDC-0973), AZD8330, BVD-523, LTT462, Ulixertinib, AMG510, ARS853, and any RAS inhibitors disclosed in patents WO2016049565, WO2016164675,WO2016168540, WO2017015562, WO2017058728, WO2017058768, WO2017058792, WO2017058805,WO2017058807, WO2017058902, WO2017058915, WO2017070256, WO2017087528, WO2017100546, WO2017172979, WO2017201161, WO2018064510,WO2018068017, WO2018119183.
  • CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155)TGF beta receptor kinase inhibitor such as LY2157299.
  • BTK inhibitor such as ibrutinib; BCR-ABL inhibitors: Imatinib (Gleevec®); Inilotinib hydrochloride; Nilotinib (Tasigna®); Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and A/-[2-[(15,4R)-6-[[4-(Cyclobutylarmno)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3).
  • ALK inhibitors: PF-2341066 (XALKOPJ®; crizotinib); 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; GSK1838705 A; CH5424802; Ceritinib (ZYKADIA); TQ-B3139, TQ-B3101 PI3K inhibitors: 4-[2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]moφholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09/036082 and WO 09/055730), 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]pheny l]propionitrile (also known as BEZ 235 or NVP-BEZ 235, and described in PCT Publication No. WO 06/122806).
  • Vascular Endothelial Growth Factor (VEGF) receptor inhibitors: Bevacizumab (sold under the trademark Avastin® by Genentech/Roche), axitinib, (N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No. WO 01/002369), Brivanib Alaninate ((S)—((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No. WO 02/066470), pasireotide (also known as SOM230, and described in PCT Publication No. WO 02/010192), sorafenib (sold under the tradename Nexavar®); AL-2846 MET inhibitor such as foretinib, carbozantinib, or crizotinib.
  • FLT3 inhibitors—sunitinib malate (sold under the tradename Sutent® by Pfizer); PKC412 (midostaurin); tanutinib, sorafenib, lestaurtinib, KW-2449, quizartinib (AC220) and crenolanib.
  • Epidermal growth factor receptor (EGFR) inhibitors: Gefitnib (sold under the tradename Iressa®), N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3″S″)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide, sold under the tradename Tovok® by Boehringer Ingelheim), cetuximab (sold under the tradename Erbitux® by Bristol-Myers Squibb), panitumumab (sold under the tradename Vectibix® by Amgen).
  • HER2 receptor inhibitors: Trastuzumab (sold under the trademark Herceptin® by Genentech/Roche), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(d imethylamino)but-2-enamide, and described PCT Publication No. WO 05/028443), lapatinib or lapatinib ditosylate (sold under the trademark Tykerb® by GlaxoSmithKline); Trastuzumab emtansine (in the United States, ado-trastuzumab emtansine, trade name Kadcyla)—an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1);
  • HER dimerization inhibitors: Pertuzumab (sold under the trademark Omnitarg®, by Genentech).
  • CD20 antibodies: Rituximab (sold under the trademarks Riuxan® and MabThera® by Genentech/Roche), tositumomab (sold under the trademarks Bexxar® by GlaxoSmithKline), ofatumumab (sold under the trademark Arzerra® by GlaxoSmithKline).
  • Tyrosine kinase inhibitors: Erlotinib hydrochloride (sold under the trademark Tarceva® by Genentech/Roche), Linifanib (N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold under the tradename Sutent® by Pfizer), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-car bonitrile, also known as SKI-606, and described in U.S. Pat. No. 6,780,996), dasatinib (sold under the tradename Sprycel® by Bristol-Myers Squibb), armala (also known as pazopanib, sold under the tradename Votrient® by GlaxoSmithKline), imatinib and imatinib mesylate (sold under the tradenames Gilvec® and Gleevec® by Novartis).
  • DNA Synthesis inhibitors: Capecitabine (sold under the trademark Xeloda® by Roche), gemcitabine hydrochloride (sold under the trademark Gemzar® by Eli Lilly and Company), nelarabine ((2R3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymet hyl)oxolane-3,4-diol, sold under the tradenames Arranon® and Atriance® by GlaxoSmithKline).
  • Antineoplastic agents: oxaliplatin (sold under the tradename Eloxatin® ay Sanofi-Aventis and described in U.S. Pat. No. 4,169,846).
  • Human Granulocyte colony-stimulating factor (G-CSF) modulators: Filgrastim (sold under the tradename Neupogen® by Amgen).
  • Immunomodulators: Afutuzumab (available from Roche®), pegfilgrastim (sold under the tradename Neulasta® by Amgen), lenalidomide (also known as CC-5013, sold under the tradename Revlimid®), thalidomide (sold under the tradename Thalomid®);
  • CD40 inhibitors: Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc); Pro-apoptotic receptor agonists (PARAs): Dulanermin (also known as AMG-951, available from Amgen/Genentech).
  • Hedgehog antagonists: 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfony 1)-benzamide (also known as GDC-0449, and described in PCT Publication No. WO 06/028958);
  • Phospholipase A2 inhibitors: Anagrelide (sold under the tradename Agrylin®);
  • BCL-2 inhibitors: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]met hyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09/155386);
  • MC1-1 inhibitors: MIK665, S64315, AMG 397, and AZD5991;
  • Aromatase inhibitors: Exemestane (sold under the trademark Aromasin® by Pfizer), letrozole (sold under the tradename Femara® by Novartis), anastrozole (sold under the tradename Arimidex®);
  • Topoisomerase I inhibitors: Irinotecan (sold under the trademark Camptosar® by Pfizer), topotecan hydrochloride (sold under the tradename Hycamtin® by GlaxoSmithKline);
  • Topoisomerase II inhibitors: etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), teniposide (also known as VM-26, sold under the tradename Vumon®);
  • mTOR inhibitors: Temsirolimus (sold under the tradename Torisel® by Pfizer), ridaforolimus (formally known as deferolimus, (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0 4′9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyc lohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03/064383), everolimus (sold under the tradename Afinitor® by Novartis);
  • Proteasome inhibitor such as carfilzomib, MLN9708, delanzomib, or bortezomib
  • BET inhibitors such as INCB054329, OTX015, CPI-0610; LSD1 inhibitors such as GSK2979552, INCB059872; HIF-2α inhibitors such as PT2977 and PT2385;
  • Osteoclastic bone resorption inhibitors: 1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate (sold under the tradename Zometa® by Novartis); CD33 Antibody Drug Conjugates: Gemtuzumab ozogamicin (sold under the tradename Mylotarg® by Pfizer/Wyeth);
  • CD22 Antibody Drug Conjugates: Inotuzumab ozogamicin (also referred to as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);
  • CD20 Antibody Drug Conjugates: Ibritumomab tiuxetan (sold under the tradename Zevalin®);
  • Somatostain analogs: octreotide (also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®);
  • Synthetic Interleukin-11 (IL-11): oprelvekin (sold under the tradename Neumega® by Pfizer/Wyeth);
  • Synthetic erythropoietin: Darbepoetin alfa (sold under the tradename Aranesp® by Amgen);
  • Receptor Activator for Nuclear Factor κ B (RANK) inhibitors: Denosumab (sold under the tradename Prolia® by Amgen);
  • Thrombopoietin mimetic peptibodies: Romiplostim (sold under the tradename Nplate® by Amgen;
  • Cell growth stimulators: Palifermin (sold under the tradename Kepivance® by Amgen);
  • Anti-Insulin-like Growth Factor-1 receptor (IGF-1R) antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);
  • Anti-CSI antibodies: Elotuzumab (HuLuc63, CAS No. 915296-00-3);
  • CD52 antibodies: Alemtuzumab (sold under the tradename Campath®);
  • Histone deacetylase inhibitors (HDI): Voninostat (sold under the tradename Zolinza® by Merck);
  • Alkylating agents: Temozolomide (sold under the tradenames Temodar® and Temodal® by Schering-Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexalen®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol®-AQ), chlorambucil (sold under the tradename Leukeran®), cyclophosphamide (sold under the tradenames Cytoxan® and Neosar®), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-Dome®), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename Hexalen®), ifosfamide (sold under the tradename Ifex®), procarbazine (sold under the tradename Matulane®), mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, sold under the tradename Mustargen®), streptozocin (sold under the tradename Zanosar®), thiotepa (also known as thiophosphoamide, TESPA and TSPA, sold under the tradename Thioplex®; Biologic response modifiers: bacillus calmette-guerin (sold under the tradenames theraCys® and TICE® BCG), denileukin diftitox (sold under the tradename Ontak®);
  • Anti-tumor antibiotics: doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename Lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename Ellence™), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®), mitomycin C (sold under the tradename Mutamycin®);
  • Anti-microtubule agents: Estramustine (sold under the tradename Emcyl®);
  • Cathepsin K inhibitors: Odanacatib (also know as MK-0822, N-(1-cyanocyclopropyl)-4-fluoro-N 2-{(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, and described in PCT Publication no. WO 03/075836); Epothilone B analogs: Ixabepilone (sold under the tradename Lxempra® by Bristol-Myers Squibb);
  • Heat Shock Protein (HSP) inhibitors: Tanespimycin (17-allylamino-17-demethoxygeldanamycin, also known as KOS-953 and 17-AAG, available from SIGMA, and described in U.S. Pat. No. 4,261,989), NVP-HSP990, AUY922, AT13387, STA-9090, Debio 0932, KW-2478, XL888, CNF2024, TAS-116
  • TpoR agonists: Eltrombopag (sold under the tradenames Promacta® and Revolade® by GlaxoSmithKline);
  • Anti-mitotic agents: Docetaxel (sold under the tradename Taxotere® by Sanofi-Aventis); Adrenal steroid inhibitors: aminoglutethimide (sold under the tradename Cytadren®);
  • Anti-androgens: Nilutamide (sold under the tradenames Nilandron® and Anandron®), bicalutamide (sold under tradename Casodex®), flutamide (sold under the tradename Fulexin™);
  • Androgens: Fluoxymesterone (sold under the tradename Halotestin®);
  • Proteasome inhibitors: Bortezomib (sold under the tradename Velcade®);
  • CDK (CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, or CDK9) inhibitors including but not limited to Alvocidib (pan-CDK inhibitor, also known as flovopirdol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone, and described in U.S. Pat. No. 5,621,002);
  • CDK4/6 inhibitors pabociclib, ribociclib, abemaciclib, and Trilaciclib; CDK9 inhibtiors AZD 4573, P276-00, AT7519M, TP-1287;
  • Gonadotropin-releasing hormone (GnRH) receptor agonists: Leuprolide or leuprolide acetate (sold under the tradenames Viadure® by Bayer AG, Eligard® by Sanofi-Aventis and Lupron® by Abbott Lab);
  • Taxane anti-neoplastic agents: Cabazitaxel (1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate), larotaxel ((2α,3ξ,4α,5β,7α,10β,13α)-4,10-bis(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-11-en-2-yl benzoate);
  • 5HTla receptor agonists: Xaliproden (also known as SR57746, 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine, and described in U.S. Pat. No. 5,266,573); HPC vaccines: Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck; Iron Chelating agents: Deferasinox (sold under the tradename Exjade® by Novartis);
  • Anti-metabolites: Claribine (2-chlorodeoxyadenosine, sold under the tradename Leustatin®), 5-fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt™), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, Droxia™ and Mylocel™), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename Leustatin™), methotrexate (also known as amethopterin, methotrexate sodim (MTX), sold under the tradenames Rheumatrex® and Trexall™), pentostatin (sold under the tradename Nipent®);
  • Bisphosphonates: Pamidronate (sold under the tradename Aredia®), zoledronic acid (sold under the tradename Zometa®); Demethylating agents: 5-azacitidine (sold under the tradename Vidaza®), decitabine (sold under the tradename Dacogen®);
  • Plant Alkaloids: Paclitaxel protein-bound (sold under the tradename Abraxane®), vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, sold under the tradenames Alkaban-AQ® and Velban®), vincristine (also known as vincristine sulfate, LCR, and VCR, sold under the tradenames Oncovin® and Vincasar Pfs®), vinorelbine (sold under the tradename Navelbine®), paclitaxel (sold under the tradenames Taxol and Onxal™);
  • Retinoids: Ali tretinoin (sold under the tradename Panretin®), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid®), Isotretinoin (13-cis-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Clarus®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), bexarotene (sold under the tradename Targretin®);
  • Glucocorticosteroids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, Hydrocortisone Phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), dexamethazone ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one), prednisolone (sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid Red®, Meticorten® and Orasone®), methylprednisolone (also known as 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, sold under the tradenames Duralone®, Medralone®, Medrol®, M-Prednisol® and Solu-Medrol®);
  • Cytokines: interleukin-2 (also known as aldesleukin and IL-2, sold under the tradename Proleukin®), interleukin-11 (also known as oprevelkin, sold under the tradename Neumega®), alpha interferon alfa (also known as IFN-alpha, sold under the tradenames Intron® A, and Roferon-A®); [00209] Estrogen receptor downregulators: Fulvestrant (sold under the tradename Faslodex®);
  • Anti-estrogens: tamoxifen (sold under the tradename Novaldex®); Toremifene (sold under the tradename Fareston®);
  • Selective estrogen receptor modulators (SERMs): Raloxifene (sold under the tradename Evista®);
  • Leutinizing hormone releasing hormone (LHRH) agonists: Goserelin (sold under the tradename Zoladex®); Progesterones: megestrol (also known as megestrol acetate, sold under the tradename Megace®);
  • Miscellaneous cytotoxic agents: Arsenic trioxide (sold under the tradename Trisenox®), asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the tradenames Elspar® and Kidrolase®);
  • One or more additional immune checkpoint inhibitors can be used in combination with a compound as described herein for treatment of SHP2-associated diseases, disorders or conditions. Exemplary immune checkpoint inhibitors include inhibitors (smack molecules or biologics) against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM kinase, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2α, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, CD137 and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, Arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
  • In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, or pembrolizumab or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.
  • In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).
  • In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or, MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600 or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383
  • Compounds of the invention can also be used to increase or enhance an immune response, including increasing the immune response to an antigen; to improve immunization, including increasing vaccine efficacy; and to increase inflammation. In some embodiments, the compounds of the invention can be sued to enhance the immune response to vaccines including, but not limited, Listeria vaccines, oncolytic viarl vaccines, and cancer vaccines such as GVAX® (granulocyte-macrophage colony-stimulating factor (GM-CF) gene-transfected tumor cell vaccine). Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. Other immune-modulatory agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4; Sting agonists and Toll receptor agonists.
  • Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer. Compounds of this application may be effective in combination with CAR (Chimeric antigen receptor) T cell treatment as a booster for T cell activation
  • A compound of the invention can also be used in combination with the following adjunct therapies:
  • Anti-nausea drugs: NK-1 receptor antagonists: Casopitant (sold under the tradenames Rezonic® and Zunrisa® by GlaxoSmithKline); and
  • Cytoprotective agents: Amifostine (sold under the tradename Ethyol®), leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).
    • EXAMPLES
  • The following preparations of intermediates (References) compounds of Formula (I) are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.
    • Reference 1 Synthesis of (5S)-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazol]-5-amine dihydrochloride
  • Figure US20200115389A1-20200416-C00189
    • Step 1: 1-[1-[(tert-butoxy)(hydroxy)methyl]-4-[hydroxy(methoxy)methyl]piperidin-4-yl]ethan-1-ol
  • Figure US20200115389A1-20200416-C00190
  • To a solution of [1-[(tert-butoxy)(hydroxy)methyl]piperidin-4-yl](methoxy)methanol (20 g, 80.86 mmol, 1.0 equiv) in THF (200 mL) at −78° C. was added LDA (48.52 mL, 97.03 mmol, 1.2 equiv) dropwise under nitrogen atmosphere. After stirring for 1.5 h at −78° C.˜−60° C., to the above mixture was added acetaldehyde (5.34 g, 121.29 mmol, 1.5 equiv) dropwise over 5 minutes at −78° C. and the resulting mixture was stirred for additional 2 h at −78° C.˜−40° C. The reaction mixture was then poured into sat. NH4Cl aq. solution and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc/PE, 0-50%) to afford 12 g (50.9% yield) of the title compound as light yellow oil.
    • Step 2: 1-tert-butyl 4-methyl 4-[1-(trifluoromethanesulfonyloxy)ethyl]piperidine-1,4-dicarboxylate
  • Figure US20200115389A1-20200416-C00191
  • To a solution of 1-tert-butyl 4-methyl 4-(1-hydroxyethyl)piperidine-1,4-dicarboxylate (9.5 g, 33.06 mmol, 1 equiv) in DCM (100 mL) were added pyridine (10.4 g, 131.48 mmol, 4.0 equiv) and (trifluoromethane)sulfonyl trifluoromethanesulfonate (18.7 g, 66.27 mmol, 2.0 equiv) dropwise at 0° C. under nitrogen atmosphere. After stirring for 2 h at 0° C., the reaction mixture was quenched with water at 0° C. The resulting mixture was extracted with CH2Cl2. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 20 g (crude) of the title compound. This crude product was used directly in next step without further purification.
    • Step 3: 1-tert-butyl 4-methyl 4-ethenylpiperidine-1,4-dicarboxylate
  • Figure US20200115389A1-20200416-C00192
  • To a stirred solution of 1-tert-butyl 4-methyl 4-[1-(trifluoromethanesulfonyloxy)-ethyl]piperidine-1,4-dicarboxylate (20 g, crude) in DCM (300 mL) was added DBU (28.50 mL, 187.18 mmol) at rt under nitrogen atmosphere. After stirring for 4 h at rt, the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc/PE, 6%) to afford the title compound (4.5 g, 55.2% yield for two steps) as light yellow oil.
    • Step 4: 1-[(tert-butoxy)carbonyl]-4-ethenylpiperidine-4-carboxylic acid
  • Figure US20200115389A1-20200416-C00193
  • To a solution of 1-tert-butyl 4-methyl 4-ethenylpiperidine-1,4-dicarboxylate (4.8 g, 17.82 mmol, 1.0 equiv) in MeOH (40 mL) were added water (10 mL) and LiOH (2.35 g, 98.01 mmol, 5.5 equiv) at room temperature. After stirring for 16 h at rt, the mixture was acidified to pH=5 with 0.5 M HCl aq. solution. The reaction mixture was then extracted with CH2C12. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound (4.5 g, 98.9% yield) as a light yellow oil which was used for next step without further purification.
    • Step 5: tert-butyl 4-ethenyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00194
  • To a solution of 1-[(tert-butoxy)carbonyl]-4-ethenylpiperidine-4-carboxylic acid (4.5 g, 17.62 mmol, 1.0 equiv) and methoxy(methyl)amine (1.61 g, 26.43 mmol, 1.5 equiv) in DCM (70 mL) were added HATU (13.40 g, 35.25 mmol, 2.0 equiv) and Et3N (5.35 g, 52.86 mmol, 3.0 equiv) at rt under nitrogen atmosphere. After stirring for 12 h at rt, the reaction mixture was quenched with water at room temperature and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc/PE, 5%) to afford the title compound (5 g, 95% yield) as a white solid.
    • Step 6: tert-butyl 4-acetyl-4-ethenylpiperidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00195
  • To a solution of tert-butyl 4-ethenyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate (5 g, 16.75 mmol, 1.0 equiv) in THF (60 mL) was added 2.5 M CH3MgBr (16.76 mL, 41.89 mmol, 2.50 equiv) dropwise at 0° C. under nitrogen atmosphere. After stirring for 12 h at rt, the reaction was quenched with sat. NH4Cl aq. solution at 0° C. and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc/PE, 1/3) to afford the title compound (3.5 g, 82.4% yield) as light yellow oil.
    • Step 7: tert-butyl 4-[(2Z)-3-(dimethylamino)prop-2-enoyl]-4-ethenylpiperidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00196
  • A solution of tert-butyl 4-acetyl-4-ethenylpiperidine-1-carboxylate (2.2 g, 8.68 mmol, 1.0 equiv) in [(tert-butoxy)(dimethylamino)methyl]dimethylamine (2 mL, 9.69 mmol, 1.1 equiv.) was stirred for 4 h at 100° C. under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1) to afford the title compound (1.6 g, 59.7% yield) as light yellow oil.
    • Step 8: tert-butyl 4-ethenyl-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00197
  • To a stirred solution of tert-butyl 4-[(2Z)-3-(dimethylamino)prop-2-enoyl]-4-ethenylpiperidine-1-carboxylate (2.2 g, 7.13 mmol, 1.0 equiv.) in EtOH (50 mL) was added hydrazine monohydrate (0.54 g, 10.78 mmol, 1.5 equiv) at 25° C. under nitrogen atmosphere. After stirring for 16 h at 25° C., the reaction was quenched with water and the resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (30%-60%) to afford the title compound (1.6 g, 80.8% yield) as a white solid.
    • Step 9: tert-butyl 4-(oxiran-2-yl)-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00198
  • To a stirred mixture of tert-butyl 4-ethenyl-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate (2 g, 7.2 mmol, 1.0 equiv) and methyltrioxorhenium(VII) (179.72 mg, 0.72 mmol, 0.1 equiv) in DCM (30 mL) were added pyridine (228.14 mg, 2.88 mmol, 0.4 equiv) and H2O2(30%) (1.23 g, 10.85 mmol, 1.5 equiv) at rt. After stirring for 16 h at rt, the reaction was quenched with water and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (30%-60%) to afford the tittle compound (0.8 g, 37.82%) as a white solid.
    • Step 10: tert-butyl 5-hydroxy-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Figure US20200115389A1-20200416-C00199
  • To a stirred solution of tert-butyl 4-(oxiran-2-yl)-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate (0.7 g, 2.38 mmol, 1.0 equiv) in THF (10 mL) were added LiBr (0.62 g, 7.15 mmol, 3.0 equiv) and CH3COOH (0.43 g, 7.15 mmol, 3.0 equiv) at room temperature. After stirring for 16 h at rt, the reaction mixture was stirred at 45° C. for 8 h. After cooling to rt, the reaction mixture was quenched with sat. NaHCO3 aq. solution and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (30%-100%) to afford the title compound (0.4 g, 57.1% yield) as a white solid.
    • Step 11: tert-butyl 5-oxo-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Figure US20200115389A1-20200416-C00200
  • To a solution of tert-butyl 5-hydroxy-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (0.4 g, 1.36 mmol, 1.0 equiv) in DCM (8 mL) was added Dess-Martin (0.87 g, 2.04 mmol, 1.5 equiv) at rt. After stirring for 4 h at room temperature, the reaction mixture was quenched with sat. NaHCO3 aq. solution at room temperature and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc/PE, 20%-60%) to afford the title compound (0.36 g, 90.62%) as a white solid.
    • Step 12: tert-butyl (S)-5-[(R)-2-methylpropane-2-sulfinyl)amino]-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
  • Figure US20200115389A1-20200416-C00201
  • To a solution of tert-butyl 5-oxo-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (0.36 g, 1.23 mmol, 1.0 equiv.) in THF (6 mL) was added (R)-2-methylpropane-2-sulfinamide (0.30 g, 2.47 mmol, 2.0 equiv.) and Ti(OEt)4 (1.13 g, 4.94 mmol, 4.0 equiv.) at rt under nitrogen atmosphere. After stirring for 4 hrs at 75° C., the reaction mixture was cooled to −20° C. To the above mixture was added MeOH (1 mL) and LiBH4 (40.38 mg, 1.85 mmol, 1.50 equiv) at −20° C. After stirring for additional 6 h at 0° C., the reaction mixture was quenched with sat. NH4Cl aq. solution at 0° C. The mixture was then filtered and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was dissolved in MeOH (3 mL). To the above mixture was added LiBH4 (80.75 mg, 3.71 mmol, 3.0 equiv) at room temperature. The resulting mixture was stirred for additional 8 h at 45° C. The reaction mixture was quenched with sat. NH4Cl aq. solution at 0° C. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (30%-70%) to afford the title compound (200 mg, 40.8% yield) as a white solid.
    • Step 13: (5S)-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazol]-5-amine dihydrochloride
  • Figure US20200115389A1-20200416-C00202
  • To a stirred solution of tert-butyl (S)-5-[(R)-2-methylpropane-2-sulfinyl)amino]-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (100 mg, 0.252 mmol, 1.0 equiv) in 1,4-dioxane (0.5 mL) was added the solution of HCl in dioxane (4 M, 0.50 mL) dropwise at room temperature. After stirring for 30 mins at rt, the reaction mixture was concentrated under reduced pressure. To the residue was added Et2O (1 mL) and the precipitate was collected by filtration to afford the title compound (60 mg, 89.7% yield) as a white solid.
    • Example 1 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00203
    • Step 1: tert-butyl (2S)-2-[[(2-fluoropyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00204
  • To a stirred mixture of 2-fluoropyridin-3-ol (1 g, 8.84 mmol, 1.00 equiv.) and tert-butyl (2S)-2-(hydroxylmethyl)prrolidine-1-carboxylate (2.14 g, 10.61 mmol, 1.2 equiv.) in THF (15 mL) were added PPh3 (3.48 g, 13.26 mmol, 1.50 equiv) and DEAD (2.31 g, 13.26 mmol, 1.5 equiv.) at room temperature under nitrogen atmosphere. After stirring for 16 h at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (15:1) to afford the title compound (2.5 g, 95.4% yield) as a light yellow oil.
    • Step 2: 2-fluoro-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine dihydrochloride
  • Figure US20200115389A1-20200416-C00205
  • To a stirred solution of tert-butyl (2S)-2-[[(2-fluoropyridin-3-yl)oxy]methyl]-pyrrolidine-1-carboxylate (2500 mg, 8.43 mmol, 1.00 equiv) in DCM (15 mL) was added hydrogen chloride (4 M in dioxane) (15 mL) at room temperature. After stirring at rt for 4 h, the reaction mixture was concentrated under vacuum to afford the title compound (2.20 g, 96.8% yield) as a white solid.
    • Step 3: (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00206
  • To a stirred solution of 2-fluoro-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine dihydrochloride (2.20 g, 8.17 mmol, 1.00 equiv) in ethanol (50 mL) was added K2CO3 (5.64 g, 40.87 mmol, 5.00 equiv) at room temperature and the resulting mixture was stirred for 12 h at 65° C. The mixture was then filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (3:1) to afford the title compound (1.34 g, 93% yield) as colorless oil.
    • Step 4: (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00207
  • To a stirred solution of (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (600 mg, 3.41 mmol, 1.00 equiv) in THF (15 mL) was added dropwise n-butyllithium solution (2.5 M in hexane, 3.4 mL, 8.5 mmol, 2.50 equiv) at −78° C. under N2 atmosphere. The reaction mixture was allowed to warm to 0° C. and stirred for 1.5 h. To the above mixture was added to a solution of 12 (950.60 mg, 3.74 mmol, 1.10 equiv) in THF (2 mL) dropwise at −78° C. The resulting mixture was allowed to warm to room temperature and stirred for 2 h at room temperature. The reaction mixture was quenched with sat. NH4Cl aq. solution and diluted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (3:1) to afford the title compound (700 mg, 68% yield) as a yellow solid.
    • Step 5: 2-ethylhexyl 3-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
  • Figure US20200115389A1-20200416-C00208
  • To a stirred mixture of (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (150.00 mg, 0.496 mmol, 1.00 equiv), 2-ethylhexyl 3-sulfanylpropanoate (162.62 mg, 0.745 mmol, 1.50 equiv), Pd2(dba)3 (22.73 mg, 0.025 mmol, 0.05 equiv) and Xantphos (14.36 mg, 0.025 mmol, 0.05 equiv) in 1,4-dioxane (2 mL) was added DIEA (192.51 mg, 1.489 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere. After stirring for 1 h at 90° C., the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-30%) to afford the title compound (160 mg, 82% yield) as a light yellow solid.
    • Step 6: potassium (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiolate
  • Figure US20200115389A1-20200416-C00209
  • To a stirred solution of 2-ethylhexyl 3-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (140.00 mg, 0.357 mmol, 1.0 equiv) in THF (2 mL) was added 1.0 M t-BuOK (0.43 mL, 0.43 mmol, 1.20 equiv) at −10° C. After stirring for 0.5 h at 0° C., the reaction mixture was diluted with petroleum ether. The precipitated solids were collected by filtration and washed with ethyl acetate to afford the title compound (75 mg, 85% yield) as a light yellow solid.
    • Step 7: methyl 6-bromo-3-[(3S,4S)-4-[[(tert-butoxy)carbonyl]amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazine-2-carboxylate
  • Figure US20200115389A1-20200416-C00210
  • A solution of methyl 3,6-dibromopyrazine-2-carboxylate (500 mg, 1.690 mmol, 1 equiv), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (493.05 mg, 2.028 mmol, 1.2 equiv) and DIEA (1091.88 mg, 8.448 mmol, 5.0 equiv) in DMA (10 mL) was stirred for 2 h at 55° C. Di-tert-butyl dicarbonate (552.33 mg, 2.531 mmol, 1.5 equiv) was then added and the resulting mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc=1:1 to afford the title compound (615 mg, 2 steps yield 75%) as yellow oil.
    • Step 8: tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate
  • Figure US20200115389A1-20200416-C00211
  • To a stirred solution of methyl 6-bromo-3-[(3S,4S)-4-[[(tert-butoxy)carbonyl]-amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazine-2-carboxylate (150 mg, 0.309 mmol, 1 equiv) in DCM (3.75 mL) was added DIBAL-H (1.0 M in DCM, 1.24 mL, 1.240 mmol, 4.01 equiv) dropwise at −78° C. under nitrogen atmosphere. The resulting mixture was stirred for 30 min at −78° C. under nitrogen atmosphere, warmed to rt then quenched by adding sat. Rochelle's salt aq. solution. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%) to afford the title compound (65 mg, 46%) as a yellow solid.
    • Step 9: tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00212
  • To a stirred mixture of tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (25.00 mg, 0.055 mmol, 1.00 equiv), potassium (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiolate (20.20 mg, 0.082 mmol, 1.50 equiv), Pd2(dba)3 (15.02 mg, 0.0164 mmol, 0.30 equiv) and Xantphos (9.49 mg, 0.0164 mmol, 0.30 equiv) in 1,4-dioxane (1 mL) was added DIEA (21.19 mg, 0.164 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere. After stirring for 1.5 h at 100° C., the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (50%-100%) to afford the title compound (25 mg, 78% yield) as a light yellow solid.
    • Step 10: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
  • Figure US20200115389A1-20200416-C00213
  • To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (20.00 mg, 0.034 mmol, 1.0 equiv) in DCM (1.5 mL) was added TFA (0.3 mL) at room temperature. After stirring for 5 h at room temperature, the reaction mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC to afford the title compound (7 mg, 39% yield) as a light yellow solid. MS (ES, m/z): [M+1]+=485.2.
    • Example 2 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((R)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00214
  • Compound 2 was synthesized by the method described in Example 1 using tert-butyl (2R)-2-(hydroxylmethyl)prrolidine-1-carboxylate instead of tert-butyl (2S)-2-(hydroxylmethyl)-prrolidine-1-carboxylate in Step 1. MS (ES, m/z): [M+1]+=485.3.
    • Example 3 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00215
    • Step 1: tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00216
  • To a stirred solution of (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (2.33 g, 9.99 mmol, 1.0 equiv) in THF (25 mL) was added BH3-Me2S (2.8 mL, 29.5 mmol, 3.0 equiv) dropwise at 0-5° C. under nitrogen atmosphere and the resulting mixture was stirred overnight at room temperature. The mixture was cooled to 0° C. and quenched with MeOH. The resulting mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (1/1) to give the title compound (2.0 g, 91.3%).
    • Step 2: tert-butyl (2S,4S)-4-fluoro-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00217
  • To a stirred solution of 2-fluoro-4-iodopyridin-3-ol (436 mg, 1.82 mmol, 1.0 equiv), tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate (400 mg, 1.82 mmol, 1.0 equiv) and PPh3 (717 mg, 2.73 mmol, 1.5 equiv) in THF (4.00 mL) was added DEAD (476 mg, 2.73 mmol, 1.5 equiv) dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under nitrogen atmosphere. The reaction mixture was quenched with water and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%), to afford the title compound (610 mg, 75.5%).
    • Step 3: 2-fluoro-3-(((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy)-4-iodopyridine hydrochloride
  • Figure US20200115389A1-20200416-C00218
  • To a stirred solution of tert-butyl (2S,4S)-4-fluoro-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate (560 mg, 1.272 mmol, 1.0 equiv) in 1,4-dioxane (5 mL) was added a solution of 3.3 M HCl in 1,4-dioxane (5 mL, 16.5 mmol, 13 equiv) dropwise at 0° C. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure and the residue was triturated with Et2O. The solid was collected by filtration and dried under vacuum to give product as HCl salt (375 mg, 78.3%).
    • Step 4: (6aS,8S)-8-fluoro-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00219
  • A mixture of 2-fluoro-3-(((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy)-4-iodopyridine hydrochloride (370 mg, 0.983 mmol, 1.0 equiv) and K2CO3 (407 mg, 2.95 mmol, 3.0 equiv) in EtOH (4 mL) was stirred for 2 h at 60° C. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-30%), to afford the title compound (245 mg, 77.9%).
    • Step 5: 2-ethylhexyl 3-([5-[(3S,4S)-4-[(tert-butoxycarbonyl)amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2-yl]sulfanyl)propanoate
  • Figure US20200115389A1-20200416-C00220
  • A solution of tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (580.0 mg, 1.27 mmol, 1.0 equiv), 2-ethylhexyl 3-sulfanylpropanoate (332.29 mg, 1.52 mmol, 1.2 equiv), Pd2(dba)3 (116.1 mg, 0.127 mmol, 0.10 equiv), XantPhos (73.38 mg, 0.127 mmol, 0.10 equiv) and DIEA (491.69 mg, 3.804 mmol, 3.00 equiv) in 1,4-dioxane (12.0 mL) was stirred for 1 h at 100° C. under nitrogen atmosphere. The resulting mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%), to afford the title compound (600 mg, 79.54%).
    • Step 6: sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]-decan-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate
  • Figure US20200115389A1-20200416-C00221
  • To a stirred solution of 2-ethylhexyl 3-([5-[(3S,4S)-4-[(tert-butoxycarbonyl)amino]-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2-yl]sulfanyl)propanoate (680.0 mg, 1.14 mmol, 1.0 equiv) in CH3OH (6.80 mL) was added CH3ONa (247.04 mg, 1.372 mmol, 1.20 equiv, 30% in MeOH) dropwise at 5° C. After stirring at rt for 16 h, the reaction mixture was concentrated under vacuum and the residue was triturated with Et2O to afford the title compound (390 mg, crude)), which was used for next step without further purification.
    • Step 7: tert-butyl ((3S,4S)-8-(5-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00222
  • A solution of (6aS,8S)-8-fluoro-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (30.00 mg, 0.094 mmol, 1.0 equiv), sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate (48.64 mg, 0.112 mmol, 1.2 equiv), Pd2(dba)3 (25.75 mg, 0.028 mmol, 0.30 equiv), XantPhos (16.27 mg, 0.028 mmol, 0.30 equiv) and DIEA (36.34 mg, 0.281 mmol, 3.00 equiv) in dioxane (0.90 mL) was stirred for 1 h at 80° C. under nitrogen atmosphere. After cooling to rt, the reaction mixture was diluted with water, extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with MeOH/CH2Cl2 (0-10%), to afford the title compound (32 mg, 56.4%).
    • Step 8: (3-((S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00223
  • To a solution tert-butyl ((3S,4S)-8-(5-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (26 mg, 0.043 mmol, 1.00 equiv) in DCM (1.2 mL) was added TFA (0.4 mL, 5.23 mmol, 122 equiv) dropwise at 5° C. After stirring at rt for 1 h, the reaction mixture was concentrated under vacuum and the residue was purified by Prep-HPLC to give the title compound (3.1 mg, 14.30%). MS (ES, m/z): [M+1]+=503.2.
    • Example 4 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00224
  • The title compound was synthesized by the method described in Example 3 using (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid in Step 1. MS (ES, m/z): [M+1]+=503.3.
    • Example 5 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00225
    • Step 1: 1-tert-butyl 2-methyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]pyrrolidine-1,2-dicarboxylate
  • Figure US20200115389A1-20200416-C00226
  • To a stirred solution of 1-tert-butyl 2-methyl (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate (6.0 g, 24.46 mmol, 1.0 equiv) and imidazole (2.5 g, 36.72 mmol, 1.50 equiv) in DCM (60 mL) was added TBS-Cl (5.53 g, 36.69 mmol, 1.50 equiv) in portions at 0-5° C. After stirring overnight at room temperature, the reaction mixture was quenched with MeOH and water, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-10%), to afford the title compound (9.0 g, 102.3%).
    • Step 2: tert-butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00227
  • To a stirred mixture of 1-tert-butyl 2-methyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-pyrrolidine-1,2-dicarboxylate (3.0 g, 8.344 mmol, 1.0 equiv) in THF (30 mL) was added LiAlH4 (475 mg, 12.516 mmol, 1.50 equiv) in portions at 0° C. under nitrogen atmosphere and the resulting mixture was stirred for 2 h at room temperature under nitrogen atmosphere. After cooling to 0° C., the reaction mixture was quenched with sat. aq. Na2SO4 solution. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%), to afford the title compound (1.6 g, 57.8%).
    • Step 3: tert-butyl (2S, 4S)-4-[(tert-butyldimethylsilyl)oxy]-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00228
  • To a stirred mixture of 2-fluoro-4-iodopyridin-3-ol (400 mg, 1.674 mmol, 1.0 equiv), tert-butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate (555 mg, 1.674 mmol, 1.00 equiv) and PPh3 (658 mg, 2.511 mmol, 1.50 equiv) in THF (4 mL) was added DEAD (437 mg, 2.51 mmol, 1.50 equiv) dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature under nitrogen atmosphere, then quenched with water at 0° C. and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-30%), to afford the title compound (735 mg, 79.4%).
    • Step 4: (3S, 5S)-5-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidin-3-ol hydrochloride
  • Figure US20200115389A1-20200416-C00229
  • To a stirred solution of tert-butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate (750 mg, 1.357 mmol, 1.0 equiv) was added a solution of 3.0 M HCl in 1,4-dioxane (5 mL, 15 mmol, 11 equiv) dropwise at 0-5° C. After stirring at room temperature for 1 h, the reaction mixture was concentrated under reduced pressure and the residue was triturated with Et2O. The precipitates were collected by filtration and dried under reduced pressure to give the title compound (400 mg, 78.7%).
    • Step 5: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,22-d][1,4]oxazin-8-ol
  • Figure US20200115389A1-20200416-C00230
  • A mixture of (3S, 5S)-5-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidin-3-ol hydrochloride (400 mg, 1.068 mmol, 1.00 equiv) and K2CO3 (443 mg, 3.205 mmol, 3.00 equiv) in EtOH (4 mL) was stirred for 2 h at 60° C. After cooling to rt, the resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-40%), to afford the title compound (300 mg, 88.3%).
    • Step 6: (6aS,8S)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00231
  • To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (100.00 mg, 0.314 mmol, 1.0 equiv) and Ag2O (364.23 mg, 1.572 mmol, 5.0 equiv) in DMF (1.00 mL) was added MeI (133.86 mg, 0.943 mmol, 3.00 equiv) dropwise at room temperature and the resulting mixture was stirred for 4 h at 50° C. After cooling to room temperature, the reaction mixture was filtered. The filtrate was washed with H2O and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EA (2/1), to afford the title compound (89 mg, 85.2%).
    • Step 7: tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00232
  • To a stirred mixture of (6aS,8S)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (30.00 mg, 0.090 mmol, 1.0 equiv) and tert-butyl N-[(3S,4S)-8-[3-(hydroxymethyl)-5-sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (37.08 mg, 0.090 mmol, 1.0 equiv) in dioxane (0.30 mL) were added Pd2(dba)3 (24.81 mg, 0.027 mmol, 0.30 equiv), Xantphos (15.68 mg, 0.027 mmol, 0.30 equiv) and DIEA (35.02 mg, 0.271 mmol, 3.0 equiv) at room temperature under N2 atmosphere. The resulting mixture was stirred for 1 h at 80° C. under N2 atmosphere. After cooling to room temperature, the reaction mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10/1), to afford the title compound (25 mg, 45.6%).
    • Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
  • Figure US20200115389A1-20200416-C00233
  • TFA (1.3 mL) was added to a solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (130.0 mg, 0.21 mmol, 1.0 equiv) in DCM (3.0 mL) at room temperature. After stirring at rt for 2 h, the reaction solution was concentrated and the residue was purified by Prep-HPLC to give product (19 mg, 16.1%). MS (ES, m/z): [M+1]+=515.3.
    • Example 6 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00234
    • Step 1: (6aS,8R)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00235
  • Compound (6aS,8R)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine was synthesized by the method described in Example 5, Steps 1-6 using 1-(tert-butyl) 2-methyl (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate in Step 1.
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00236
  • (3-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol was synthesized by proceeding analogously as described in Example 5, Steps 7-8. MS (ES, m/z): [M+1]+=515.3.
    • Example 7 Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
  • Figure US20200115389A1-20200416-C00237
  • The title compound was synthesized by the method as described in Example 5, Steps 7-8 using (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol in Step 7. MS (ES, m/z): [M+1]+=501.3.
    • Example 8 Synthesis of (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
  • Figure US20200115389A1-20200416-C00238
  • The title compound was synthesized by proceeding analogously as described in Example 7. MS (ES, m/z): [M+1]+=501.3.
    • Example 9 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00239
  • The title compound was synthesized by proceeding analogously as described in Example 5, Steps 2-8 using 1-tert-butyl 2-methyl (2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylate in Step 2. MS (ES, m/z): [M+1]+=515.3.
    • Example 10 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00240
  • The title compound was synthesized by proceeding analogously as described in Example 5 Steps 2-8 using tert-butyl (2R,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate in Step 2. MS (ES, m/z): [M+1]+=515.2.
    • Example 11 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00241
    • Step 1: (6aS,8S)-4-iodo-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00242
  • To a stirred solution of (3R)-oxolan-3-yl 4-methylbenzenesulfonate (457 mg, 1.886 mmol, 3 equiv) and (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (200 mg, 0.629 mmol, 1.00 equiv) in DMF (2.00 mL) was added NaH (88 mg, 2.200 mmol, 3.5 equiv, 60%) in portions at 0° C. under nitrogen atmosphere and the resulting mixture was stirred overnight at room temperature under nitrogen atmosphere. After cooling to 0° C., the reaction was quenched with water and the resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by Prep-TLC (EtOAc 100%) to afford the title compound (70 mg, 28.7%).
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00243
  • The title compound was synthesized from (6aS,8S)-4-iodo-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine by proceeding analogously as described in Example 5, Steps 7-8. MS (ES, m/z): [M+1]+=571.3.
    • Example 12 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((R)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00244
  • The title compound was synthesized from (3S)-oxolan-3-yl 4-methylbenzenesulfonate by proceeding analogously as described in Example 11. MS (ES, m/z): [M+1]+=571.3.
    • Example 13 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00245
    • Step 1: (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,22-d][1,4]oxazin-8-yl trifluoromethanesulfonate
  • Figure US20200115389A1-20200416-C00246
  • To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-8-ol (400 mg, 1.257 mmol, 1.00 equiv) and DIEA (244 mg, 1.886 mmol, 1.50 equiv) in DCM (4.00 mL) was added Tf2O (426 mg, 1.509 mmol, 1.20 equiv) dropwise at 5° C. The reaction solution was stirred at 5° C. for 30 min and then concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-40%) to afford the title compound (300 mg, 53.0%) as a white solid.
    • Step 2: (6aS,8S)-4-iodo-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00247
  • To a stirred solution of oxetan-3-ol (99 mg, 1.336 mmol, 2.00 equiv) in DMF (3.00 mL) was added 60% NaH (67 mg, 1.67 mmol, 2.50 equiv) at 5° C. The mixture was stirred at this temperature for 1 h. (6aS,8R)-4-Iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl trifluoromethanesulfonate (300.00 mg, 0.666 mmol, 1.00 equiv) was added at 20° C. The resulting mixture was allowed to warm to 50° C. and stirred for 10 min. The reaction was quenched with water at 5° C. and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%) to afford the title compound (20 mg, 8.0%) as a white solid.
    • Step 3: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00248
  • The title compound was synthesized by proceeding analogously as described in Example 5 Steps 7-8 using (6aS,8S)-4-iodo-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine in Step 7. MS (ES, m/z): [M+1]+=557.3.
    • Example 14 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00249
    • Step 1: (6aS,8S)-4-iodo-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00250
  • To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-8-ol (60 mg, 0.189 mmol, 1.00 equiv) and DIEA (49 mg, 0.377 mmol, 2.00 equiv) in DME (1.00 mL) was added bromo(methoxy)methane (35.35 mg, 0.283 mmol, 1.50 equiv) dropwise at room temperature under N2 atmosphere. The resulting mixture was stirred for 4 h at room temperature under N2 atmosphere and then quenched with H2O. The resulting mixture was extracted with EA and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (1/1) to afford the title compound (50 mg, 73.2%) as a light yellow solid.
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethoxy)-6a, 7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00251
  • The title compound was synthesized by proceeding analogously as described in Example 5 Steps 7-8 using tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-(methoxymethoxy)-6a, 7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate in Step 7. MS (ES, m/z): [M+1]+=545.2.
    • Example 15 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(2-methoxyethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00252
  • The title compound was synthesized by proceeding analogously as described in Example 14 using 2-bromoethyl methyl ether in Step 1. MS (ES, m/z): [M+1]+=559.3.
    • Example 16 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(cyclopropylmethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00253
  • The title compound was synthesized by proceeding analogously as described in Example 14 using (bromomethyl)cyclopropane r in Step 1. MS (ES, m/z): [M+1]+=555.4.
    • Example 17 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin]-4′-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00254
    • Step 1: (S)-4′-iodo-6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazine]
  • Figure US20200115389A1-20200416-C00255
  • Compound (S)-4′-iodo-6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine] was synthesized by proceeding analogously as described in Example 1, Steps 1-4 using 5-tert-butyl 6-methyl (6S)-5-azaspiro[2.4]heptane-5,6-dicarboxylate in Step 1.
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin]-4′-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00256
  • The title compound was synthesized by proceeding analogously as described in Example 1, Steps 5-8.MS (ES, m/z): [M+1]+=511.3.
    • Example 18 and 19 Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-8-ol and (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
  • Figure US20200115389A1-20200416-C00257
      • stereochemistry of the tertiary alcohol arbitrarily assigned in 18 and 19
    Step 1: (S)-4-iodo-6a,7-dihydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8(9H)-one
  • Figure US20200115389A1-20200416-C00258
  • To a stirred solution of oxalyl chloride (209.47 mg, 1.650 mmol, 1.5 equiv) in DCM (1.4 mL) was added DMSO (257.89 mg, 3.301 mmol, 3.0 equiv) in DCM (0.2 mL) dropwise at −78° C. under nitrogen atmosphere and stirred at this temperature for 30 min. To the above solution was added a solution of (6aS)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (350.00 mg, 1.100 mmol, 1.00 equiv) in DCM (2.0 mL) at −78° C. After stirring at −78° C. for 30 min, DIEA (853.1 mg, 6.6 mmol, 6.0 equiv) was added dropwise at −78° C. The resulting mixture was stirred for additional 30 min at −78° C., then warmed to room temperature over 30 min. After stirring at rt for 10 min, the reaction mixture was cooled to 5° C. and quenched by addition of sat. NH4Cl aq. solution at 5° C. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to afford the title compound (250 mg, 71.8%).
    • Step 2: 2-ethylhexyl 3-(((S)-8-oxo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]-oxazin-4-yl)thio)propanoate
  • Figure US20200115389A1-20200416-C00259
  • A solution of (S)-4-iodo-6a,7-dihydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8(9H)-one (220.00 mg, 0.696 mmol, 1.00 equiv), 2-ethylhexyl 3-sulfanylpropanoate (182.37 mg, 0.835 mmol, 1.20 equiv), Pd2(dba)3 (63.73 mg, 0.070 mmol, 0.10 equiv), XantPhos (40.27 mg, 0.070 mmol, 0.10 equiv) and DIEA (269.85 mg, 2.088 mmol, 3.00 equiv) in dioxane (4.40 mL) was stirred for 1 h at 100° C. under nitrogen atmosphere. The resulting mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%), to afford the title compound (280 mg, 99%).
    • Step 3: 2-ethylhexyl 3-(((6aS)-8-hydroxy-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
  • Figure US20200115389A1-20200416-C00260
  • To a stirred solution of 2-ethylhexyl 3-(((S)-8-oxo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (160 mg, 0.394 mmol, 1.00 equiv) in THF (1.60 mL) was added 2.0 M bromo(methyl)magnesium (0.24 mL, 0.48 mmol, 1.22 equiv) dropwise at 5° C. under nitrogen atmosphere and the resulting mixture was stirred at 5° C. for 1 h. The reaction was quenched by addition of sat. NH4Cl aq. solution at 5° C. and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%), to afford the title compound (90 mg, 54.1%).
    • Step 4: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-8-ol and (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
  • Figure US20200115389A1-20200416-C00261
  • The title compounds were synthesized from 2-ethylhexyl 3-(((6aS)-8-hydroxy-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate by proceeding analogously as described in Example 1, Steps 6-8. MS (ES, m/z): [M+1]+=515.3.
    • Example 20 Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile
  • Figure US20200115389A1-20200416-C00262
    • Step 1: (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate
  • Figure US20200115389A1-20200416-C00263
  • To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (400.00 mg, 1.257 mmol, 1.00 equiv) in DCM (6.00 mL) were added TEA (190.86 mg, 1.886 mmol, 1.50 equiv) and MsCl (172.85 mg, 1.509 mmol, 1.20 equiv) at room temperature. After stirring for 16 h at room temperature, the reaction mixture was cooled to 0° C. and quenched with water. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%) to afford the title compound (450 mg, 90.3%).
    • Step 2: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile
  • Figure US20200115389A1-20200416-C00264
  • To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate (300.00 mg, 0.757 mmol, 1.00 equiv) in DMF (5.00 mL) was added NaCN (55.66 mg, 1.136 mmol, 1.50 equiv) at room temperature. After stirring at 75° C. for 16 h, the reaction mixture was cooled at room temperature and quenched with water. The mixture was then extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%), to afford the title compound (140 mg, 56.5%).
    • Step 3: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]-oxazine-8-carbonitrile
  • Figure US20200115389A1-20200416-C00265
  • The compound was synthesized from (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile by proceeding analogously as described in Example 5, Steps 7-8. [M+1]+=510.2.
    • Example 21 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methylsulfonyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00266
    • Step 1: 1-tert-butyl 2-methyl (2S, 4R)-4-(methanesulfonyloxy)pyrrolidine-1,2-dicarboxylate
  • Figure US20200115389A1-20200416-C00267
  • To a stirred solution of 1-tert-butyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (9 g, 36.7 mmol, 1.0 equiv) and TEA (7.43 g, 73.4 mmol, 2.0 equiv) in DCM (100 mL) was added MsCl (5 g, 43.6 mmol, 1.2 equiv) dropwise at 0° C. and the resulting mixture was stirred for 1 h at 0° C. The reaction was quenched with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-50%), to afford the title compound (10.5 g, 88.5%).
    • Step 2: 1-(tert-butyl) 2-methyl (2R,4R)-4-methoxypyrrolidine-1,2-dicarboxylate
  • Figure US20200115389A1-20200416-C00268
  • A solution of 1-tert-butyl 2-methyl (2S,4R)-4-(methanesulfonyloxy)pyrrolidine-1,2-dicarboxylate (4.30 g, 13.298 mmol, 1.00 equiv) in dry DMF (20.00 mL) was added NaSCH3 (1.07 g, 15.27 mmol, 1.07 equiv) at 30° C. After stirring overnight at rt, the reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EA (1/1) to afford the title compound (4 g, 109.2%).
    • Step 3: tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylthio)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00269
  • To a stirred mixture of 1-tert-butyl 2-methyl (2S,4S)-4-(methylsulfanyl)pyrrolidine-1,2-dicarboxylate (3.70 g, 13.44 mmol, 1.0 equiv) in THF (37.0 mL) was added LiAlH4 (0.76 g, 20.03 mmol, 1.5 equiv) in portions at 0° C. After stirring at room temperature for 2 h, the reaction mixture was quenched with Na2SO4.10H2O at room temperature. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure to give the title compound (2.6 g, 78.2%).
    • Step 4: tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00270
  • To a stirred solution of tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfanyl)-pyrrolidine-1-carboxylate (3.70 g, 14.959 mmol, 1.00 equiv) in DCM (40 mL) at room temperature was added m-CPBA (77%12.91 g, 57.60 mmol, 3.85 equiv) in portions over 5 h. The resulting mixture was diluted with DCM and washed with sat. aq. NaHCO3 solution and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH (20/1), to afford the title compound (1 g, 23.9%).
    • Step 5: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methylsulfonyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00271
  • The title compound was synthesized tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate by the method described in Example 1, Steps 2-8. MS (ES, m/z): [M+1]+=563.3.
    • Example 22 Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-8-yl carbamate
  • Figure US20200115389A1-20200416-C00272
    • Step 1: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate
  • Figure US20200115389A1-20200416-C00273
  • To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (150.0 mg, 0.472 mmol, 1.0 equiv) in DCM (1.80 mL) was added trichloroethanecarbonyl isocyanate (222.08 mg, 1.179 mmol, 2.5 equiv) dropwise at 5° C. and the resulting mixture was stirred at this temperature for about 30 min. To the above solution, K2CO3 (129.88 mg, 0.940 mmol, 2.0 equiv) and MeOH (1.80 mL) were added at room temperature and the resulting mixture was stirred for additional 6 h at room temperature. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%) to afford the title compound (100 mg, 58.7%).
    • Step 2: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[,2-d][1,4]-oxazin-8-yl carbamate
  • Figure US20200115389A1-20200416-C00274
  • The title compound was synthesized from tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate by proceeding analogously as described in Example 5, Steps 7-8. MS (ES, m/z): [M+1]+=544.3.
    • Example 23 Synthesis of (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate
  • Figure US20200115389A1-20200416-C00275
  • The title compound was synthesized from ((6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol by as described in example 22. MS (ES, m/z): [M+1]+=544.2.
    • Example 24 Synthesis of (6-(((6aS,8S)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00276
    • Step 1: (6aS,8S)-4-iodo-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00277
  • To a stirred solution of pyrazole (17.18 mg, 0.252 mmol, 1.0 equiv) in DMF (0.75 mL) was added NaH (20.19 mg, 0.505 mmol, 2.0 equiv, 60%) in portions at 5° C. and the resulting mixture was stirred at 5° C. for 1 h. To the above mixture was added (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate (100.00 mg, 0.252 mmol, 1.00 equiv) at room temperature and the resulting mixture was stirred at 50° C. After cooling to 0° C., the reaction was quenched by addition of water and then extracted with EtOAc. The combined organic layers were washed with water, brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%), to afford the title compound (60 mg, 64.5%).
    • Step 2: (6-(((6aS,8S)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00278
  • The title compound was synthesized from (6aS,8S)-4-iodo-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine by proceeding analogously described in Example 5, Steps 7-8. MS (ES, m/z): [M+1]+=551.3
    • Example 25 Synthesis of (6-(((6aS,8R)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00279
  • The title compound was synthesized from (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate by the method described in Example 24. MS (ES, m/z): [M+1]+=551.3.
    • Example 26 and 27 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((R)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00280
  • The title compounds were synthesized by proceeding analogously as described in Example 5, Steps 2-8 using tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate in Step 2. MS (ES, m/z): [M+1]+=501.2.
    • Example 28 Synthesis of 4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
  • Figure US20200115389A1-20200416-C00281
    • Step 1: 4-(tert-butoxycarbonyl)thiomorpholine-3-carboxylic acid
  • Figure US20200115389A1-20200416-C00282
  • To a stirred solution of thiomorpholine-3-carboxylic acid (3000 mg, 20.382 mmol, 1.00 equiv) and Et3N (4125 mg, 40.764 mmol, 2.00 equiv) in DCM (50.00 mL) was added Boc2O (6672 mg, 30.57 mmol, 1.50 equiv) in portions at room temperature under N2 atmosphere.
  • The resulting mixture was stirred for 16 h at room temperature under N2 atmosphere and then diluted with water and extracted with DCM. The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10/1) to afford the title compound (3.2 g, 63.5%) as light yellow oil.
    • Step 2: tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate
  • Figure US20200115389A1-20200416-C00283
  • To a stirred solution of 4-(tert-butoxycarbonyl)thiomorpholine-3-carboxylic acid (2000 mg, 8.087 mmol, 1.00 equiv) in THF (20 mL) was added 1M BH3-THF (16.18 mL, 16.180 mmol, 2.00 equiv) dropwise at 0° C. under N2 atmosphere. The resulting mixture was stirred for 16 h at 45° C. under N2 atmosphere and then quenched with MeOH at 0° C. The resulting mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10/1) to afford the title compound (1.8 g, 95.4%) as light yellow oil.
    • Step 3: tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate 1,1-dioxide
  • Figure US20200115389A1-20200416-C00284
  • A solution of tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate (500 mg, 2.143 mmol, 1.00 equiv) and m-CPBA (77%, 851 mg, 3.78 mmol, 1.77 equiv) in DCM (10 mL) was stirred for 16 h at room temperature under N2 atmosphere. The reaction was quenched with saturated NaHCO3 (5 mL) at room temperature. The resulting mixture was extracted with DCM. The combined organic layers were washed with saturated NaHCO3, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10/1) to afford the title compound (400 mg, 70.4%) as light yellow oil.
    • Step 4: 3-(hydroxymethyl)thiomorpholine 1,1-dioxide; trifluoroacetic acid
  • Figure US20200115389A1-20200416-C00285
  • To a stirred solution of tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate 1,1-dioxide (180 mg, 0.678 mmol, 1.00 equiv) in DCM (5.0 mL) was added TFA (3.868 g, 33.921 mmol, 50.00 equiv) at room temperature. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure to afford the title compound (170 mg, 89.74%) as a white solid.
    • Step 5: 4-iodo-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
  • Figure US20200115389A1-20200416-C00286
  • To a stirred solution of 3-(hydroxymethyl)thiomorpholine 1,1-dioxide trifluoroacetic acid (180 mg, 0.645 mmol, 1.00 equiv) and 2-fluoro-4-iodopyridin-3-ol (154 mg, 0.645 mmol, 1.00 equiv) in toluene (3.0 mL) were added PPh3 (254 mg, 0.967 mmol, 1.50 equiv) and DEAD (168 mg, 0.967 mmol, 1.50 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 16 h at 60° C. under nitrogen atmosphere and then concentrated under reduced pressure. The residue was purified by Prep-TLC (PE/EtOAc 5:1) to afford the title compound (45 mg, 19.1%) as a light yellow solid.
    • Step 6: 4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-pyrazin-2-yl)thio)-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
  • Figure US20200115389A1-20200416-C00287
  • The title compounds were synthesized by proceeding analogously as described in Example 5, Steps 7-8 using 4-iodo-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide in Step 7. MS (ES, m/z): [M+1]+=549.2.
    • Example 29 and 30 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][41,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [29] and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [30]
  • Figure US20200115389A1-20200416-C00288
    • Step 1: 1-(tert-butyl) 2-methyl (S)-4-(methoxymethylene)pyrrolidine-1,2-dicarboxylate
  • Figure US20200115389A1-20200416-C00289
  • To a stirred mixture of 1-(tert-butyl) 2-methyl (S)-4-oxopyrrolidine-1,2-dicarboxylate (4.00 g, 16.443 mmol, 1.00 equiv) and K2CO3 (1.50 g, 10.853 mmol, 0.66 equiv) in MeOH (80.0 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (9.48 g, 49.330 mmol, 3.00 equiv) at 0° C. under nitrogen atmosphere. After stirring for 12 h at room temperature, the reaction mixture was poured into water and the resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (3:1), to afford the title compound (1.45 g, 32.5%) as a light-yellow oil.
    • Step 2: 1-(tert-butyl) 2-methyl (2S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
  • Figure US20200115389A1-20200416-C00290
  • To a stirred solution of 1-(tert-butyl) 2-methyl (S)-4-(methoxymethylene)pyrrolidine-1,2-dicarboxylate (1.45 g, 5.344 mmol, 1.00 equiv) and 10% Pd/C (145 mg) in MeOH (20.0 mL) was added MgO (220 mg, 5.46 mmol, 1.02 equiv) at room temperature under hydrogen atmosphere. After stirring for 2 h at room temperature, the resulting mixture was filtered. The filtrate was concentrated under reduced pressure to afford the title compound (1.35 g, 92.42%) as a light-yellow oil which was used directly in next step without any further purification.
    • Step 3: tert-butyl (2S)-2-(hydroxymethyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00291
  • To a stirred solution of 1-(tert-butyl) 2-methyl (2S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (180 mg, 0.659 mmol, 1.00 equiv) in THF (4.0 mL) was added LiAlH4 (37 mg, 0.975 mmol, 1.50 equiv) at room temperature. After stirring for 2 h at room temperature, the resulting mixture was diluted with DCM and quenched with water at 0° C. After filtration, the filter cake was washed with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1) to afford the title compound (90 mg, 55.7%) as a light-yellow oil.
    • Step 4: tert-butyl (2S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00292
  • To a stirred solution of tert-butyl (2S)-2-(hydroxymethyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylate (90 mg, 0.367 mmol, 1.00 equiv) and 2-fluoro-4-iodopyridin-3-ol (88 mg, 0.367 mmol, 1.00 equiv) in THF (2.00 mL) were added PPh3 (144 mg, 0.550 mmol, 1.50 equiv) and DEAD (96 mg, 0.55 mmol, 1.50 equiv) at room temperature under nitrogen atmosphere. After stirring for 16 h at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-60%) to afford the title compound (115 mg, 67.2%) as a light-yellow oil.
    • Step 5: 2-fluoro-4-iodo-3-(((2S)-4-(methoxymethyl)pyrrolidin-2-yl)methoxy)pyridine hydrogen chloride
  • Figure US20200115389A1-20200416-C00293
  • To a stirred solution of tert-butyl (2S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate (115 mg, 0.247 mmol, 1.00 equiv) in dioxane (1.0 mL) was added HCl (4.0 M in dioxane, 0.62 mL, 2.48 mmol, 10.00 equiv) at room temperature. After stirring for 5 h at room temperature, the reaction mixture was concentrated under reduced pressure to afford the title compound (110 mg, crude) as a light yellow solid, which was used directly in next step without further purification. MS (ES, m/z): [M+1]+=367.0.
    • Step 6: (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00294
  • To a stirred solution of 2-fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-methoxy)pyridine hydrogen chloride (110 mg, 0.273 mmol, 1.00 equiv) in EtOH (3.0 mL) was added K2CO3 (208 mg, 1.50 mmol, 5.51 equiv) at room temperature. After stirring for 2 h at 60° C., the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-60%) to afford the title compound (80 mg, 2 steps 93.5%) as a light-yellow oil.
    • Step 7: tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00295
  • To a stirred mixture of (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido-[3,2-b]pyrrolo[1,2-d][1,4]oxazine (80 mg, 0.231 mmol, 1.00 equiv), sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxy-methyl)pyrazine-2-thiolate (100 mg, 0.231 mmol, 1.0 equiv), Pd2(dba)3 (63 mg, 0.069 mmol, 0.30 equiv) and XantPhos (40 mg, 0.069 mmol, 0.30 equiv) in dioxane (1.50 mL) was added DIEA (90 mg, 0.693 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere. After stirring for 1 h at 80° C., the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH/DCM (0-10%) to afford the title compound (110 mg, 75.7%) as a yellow solid.
    • Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)methanol [29] and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [30]
  • Figure US20200115389A1-20200416-C00296
  • To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (70.00 mg, 0.111 mmol, 1.00 equiv) in DCM (1.0 mL) was added TFA (0.20 mL, 2.61 mmol, 23.5 equiv) at room temperature. After stirring for 2 h at room temperature, the reaction mixture was concentrated under reduced pressure. The mixture was purified by Prep-HPLC to afford 50 mg of crude product. The crude product (50 mg) was further purified by Chiral-HPLC to afford the title compound [29] (9.9 mg, 16.8%), MS (ES, m/z): [M+1]+=529.3 and [30] (5.5 mg, 9.4%), MS (ES, m/z): [M+1]+=529.3; as a white solid.
    • Example 31 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00297
    • Step 1: tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00298
  • To a stirred solution of (2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid (180 g, 694.171 mmol, 1.00 equiv) in THF (1.8 L) was added BH3-Me2S (173.00 mL, 1824.073 mmol, 2.63 equiv) dropwise at 0° C. under N2 atmosphere. The resulting mixture was stirred for 16 h at room temperature under N2 atmosphere. The reaction was quenched with MeOH (200 mL) at 0° C. and the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (1/1), to afford the title compound (160 g, 94%) as a colorless oil.
    • Step 2: tert-butyl (2S,4S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00299
  • To a stirred solution of tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylate (7.0 g, 28.534 mmol, 1.00 equiv), 2-fluoro-4-iodopyridin-3-ol (6.8 g, 28.534 mmol, 1.00 equiv) and PPh3 (11.2 g, 42.7 mmol, 1.50 equiv) in THF (140.00 mL) was added DEAD (7.5 g, 43 mmol, 1.5 equiv) dropwise at rt under N2 atmosphere and the resulting mixture was stirred for 16 h at room temperature. The reaction mixture was then concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE/EA (5/1), to afford the title compound (11.5 g, 86.4%) as a light-yellow oil.
    • Step 3: 2-fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)methoxy)pyridine dihydrochloride
  • Figure US20200115389A1-20200416-C00300
  • A solution of tert-butyl (2S,4S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate (11.5 g, 24.663 mmol, 1.00 equiv) in 1,4-dioxane (20.0 mL) and 4.0 M HCl in 1,4-dioxane (50.0 mL) was stirred for 3 h at room temperature under N2 atmosphere. The resulting mixture was concentrated under reduced pressure to afford the title compound (14 g, crude) as a light-yellow oil, which was used for next step without further purification.
    • Step 4: (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00301
  • A mixture of crude 2-fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-methoxy)pyridine dihydrochloride (14.0 g, 31.88 mmol, 1.00 equiv) and K2CO3 (15.9 g, 115 mmol, 3.6 equiv) in EtOH (280.0 mL) was stirred for 3 h at 60° C. After cooled at rt, the resulting mixture was filtered and the filter cake was washed with EtOAc. The combined filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (2/1), to afford the title compound (6.6 g, 2 steps 77%) as a light yellow solid.
    • Step 5: ((6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl)-methanol
  • Figure US20200115389A1-20200416-C00302
  • To a stirred mixture of (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (250 mg, 0.722 mmol, 1.00 equiv) and NaI (357 mg, 2.383 mmol, 3.3 equiv) in CH3CN (5.00 mL) was added SiCl4 (405 mg, 2.383 mmol, 3.30 equiv) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 80° C. under nitrogen atmosphere. The mixture was allowed to cool to room temperature, diluted with water, and the pH of the solution was adjusted to pH=8 with saturated NaHCO3 aq solution. The resulting mixture was extracted with DCM and the organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1), to afford the title compound (200 mg, 83.4%) as a yellow solid.
    • Step 6: (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00303
  • To a stirred solution of ((6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl)methanol (75 mg, 0.226 mmol, 1.00 equiv) and DIEA (88 mg, 0.68 mmol, 3.0 equiv) in DCM (3.75 mL) was added bromo(methoxy)methane (85 mg, 0.68 mmol, 3.0 equiv) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 24 h at room temperature under nitrogen atmosphere. The reaction solution was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1), to afford the title compound (65 mg, 76.5%) as a yellow solid.
    • Step 7: tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetra hydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00304
  • To a stirred mixture of sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate (55 mg, 0.127 mmol, 1.00 equiv), (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (48 mg, 0.128 mmol, 1 equiv) and XantPhos (22 mg, 0.038 mmol, 0.30 equiv) in dioxane (2.0 mL) were added DIEA (82 mg, 0.63 mmol, 5 equiv) and Pd2(dba)3 (35 mg, 0.038 mmol, 0.30 equiv) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 1 h at 80° C. under nitrogen atmosphere and then diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10:1), to afford the title compound (45 mg, 53.8%) as a brown solid.
    • Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00305
  • To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-((methoxy-methoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (35 mg, 0.053 mmol, 1.00 equiv) in DCM (1.80 mL) was added dropwise TFA (0.15 mL) at room temperature. The resulting mixture was stirred for 2 h at room temperature and then basified to pH=8 with ammonia hydroxide aq. solution. The organic solvent was removed under vacuum and the residue was purified by Prep-HPLC to afford the title compound (7 mg, 23.6%) as a white solid. MS (ES, m/z): [M+1]+=559.3.
    • Example 32 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((2-methoxyethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00306
  • The title compound was synthesized by proceeding analogously as described in Example 31, Steps 6-8 using 1-bromo-2-methoxyethane in Step 6. MS (ES, m/z): [M+1]+=573.3.
    • Example 33 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((cyclopropylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00307
  • The title compound was synthesized by proceeding analogously as described in Example 31, Steps 6-8 using (bromomethyl)cyclopropane in Step 6. MS (ES, m/z): [M+1]+=569.3
    • Example 34 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((oxetan-3-ylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00308
  • The title compound was synthesized by proceeding analogously as described in Example 31, Steps 6-8 using 3-(bromomethyl)oxetane in Step 6. MS (ES, m/z): [M+1]+=585.3
    • Example 35 Synthesis of formic acid; (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-2-amino-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00309
    • Step 1: 2-fluoro-4-iodo-6-nitropyridin-3-ol
  • Figure US20200115389A1-20200416-C00310
  • To a stirred solution of 2-fluoro-4-iodopyridin-3-ol (100 mg, 0.418 mmol, 1.00 equiv) and Bu4NNO3 (191 mg, 0.628 mmol, 1.50 equiv) in DCM (2.0 mL) was added TFAA (0.10 mL, 0.595 mmol, 1.42 equiv) dropwise at 0° C. under nitrogen atmosphere and the resulting mixture was stirred for 1 h at 0° C. The reaction was quenched with saturated NH4Cl (aq.) at 0° C. and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (5:1), to afford the title compound (10 mg, 8.4%) as a yellow solid.
    • Step 2: tert-butyl (S)-2-(((2-fluoro-4-iodo-6-nitropyridin-3-yl)oxy)methyl)pyrrolidine-1-carboxylate
  • Figure US20200115389A1-20200416-C00311
  • To a stirred solution of 2-fluoro-4-iodo-6-nitropyridin-3-ol (170 mg, 0.599 mmol, 1.00 equiv), tert-butyl(2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (180 mg, 0.898 mmol, 1.50 equiv) and PPh3 (235 mg, 0.9 mmol, 1.5 equiv) in THF (2 mL) was added DIAD (181 mg, 0.9 mmol, 1.5 equiv) dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred overnight at 60° C. under nitrogen atmosphere and then quenched with water at room temperature. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-30%) to afford the title compound (50 mg, 17.9%) as a yellow oil.
    • Step 3: (S)-2-fluoro-4-iodo-6-nitro-3-(pyrrolidin-2-ylmethoxy)pyridine hydrochloride
  • Figure US20200115389A1-20200416-C00312
  • Into a 8 mL sealed tube were added tert-butyl (S)-2-(((2-fluoro-4-iodo-6-nitropyridin-3-yl)oxy)methyl) pyrrolidine-1-carboxylate (50 mg, 0.107 mmol, 1.00 equiv) and a solution of 4 M HCl in 1,4-dioxane (0.50 mL, 2.0 mmol, 18.69 equiv) at 0° C. The reaction solution was stirred for 1 h at room temperature and then concentrated under reduced pressure. The residue was triturated with Et2O to give the crude title product (30 mg) as a yellow oil which was used in the next step directly without further purification.
    • Step 4: (S)-4-iodo-2-nitro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00313
  • Into an 8 mL sealed tube were added (S)-2-fluoro-4-iodo-6-nitro-3-(pyrrolidin-2-ylmethoxy)pyridine hydrochloride (30 mg, crude), K2CO3 (34 mg, 0.246 mmol) and EtOH (0.30 mL) at room temperature. The resulting mixture was stirred for 2 h at 60° C. and then allowed to cool down to room temperature. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (5:1) to afford the title compound (13 mg, 2 steps 34.6%) as a yellow solid.
    • Step 5: (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-2-amine
  • Figure US20200115389A1-20200416-C00314
  • A mixture of (S)-4-iodo-2-nitro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (13 mg, 0.037 mmol, 1.0 equiv), NH4Cl (4 mg, 0.075 mmol, 2.0 equiv) and Fe (4 mg, 0.075 mmol, 2.0 equiv) in EtOH (0.10 mL) and H2O (0.10 mL) was stirred for 2 h at 60° C. The mixture was allowed to cool down to room temperature and filtered. The filter cake was washed with EtOAc and the filtrate was washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-100%), to afford the title compound (9 mg, 75.8%) as a yellow solid.
    • Step 6: formic acid; (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-2-amino-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00315
  • The title compound was synthesized by proceeding analogously as described in Example 5, Steps 7-8 using (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-2-amine in Step 7. MS (ES, m/z): [M+1]+=500.3.
    • Example 36 and 37 Synthesis of (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [36] and (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [37]
  • Figure US20200115389A1-20200416-C00316
    • Step 1: 2-ethylhexyl 3-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
  • Figure US20200115389A1-20200416-C00317
  • To a stirred mixture of (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (500 mg, 1.444 mmol, 1.00 equiv), 2-ethylhexyl 3-sulfanylpropanoate (378 mg, 1.733 mmol, 1.20 equiv), Pd2(dba)3(130 mg, 0.142 mmol, 0.10 equiv) and XantPhos (85 mg, 0.147 mmol, 0.10 equiv) in 1,4-dioxane (7.5 mL) was added DIEA (560 mg, 4.333 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere and the resulting mixture was stirred for 2 h at 85° C. After cooling to rt, the reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-60%), to afford the title compound (500 mg, 79.3%) as a light-yellow oil.
    • Step 2: sodium (6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiolate
  • Figure US20200115389A1-20200416-C00318
  • To a stirred solution of 2-ethylhexyl 3-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (500 mg, 1.145 mmol, 1.00 equiv) in MeOH (10.0 mL) was added NaOMe (68 mg, 1.260 mmol, 1.10 equiv) at room temperature. After stirring for 5 h at room temperature, the reaction mixture was concentrated under vacuum and the residue was triturated with Et2O to afford the title compound (220 mg, 70%) as a yellow solid.
    • Step 3: (3-chloro-6-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00319
  • To a stirred mixture of sodium (6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiolate (100 mg, 0.365 mmol, 1.00 equiv), (6-bromo-3-chloropyrazin-2-yl)methanol (90 mg, 0.40 mmol, 1.10 equiv), Pd2(dba)3 (33 mg, 0.036 mmol, 0.10 equiv) and XantPhos (21 mg, 0.036 mmol, 0.10 equiv) in 1,4-dioxane (2 mL) was added DIEA (141 mg, 1.09 mmol, 3.0 equiv) at room temperature under nitrogen atmosphere. After stirring for 2 h at 85° C., the reaction mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-60%), to afford the title compound (105 mg, 72.9%) as a light yellow oil.
    • Step 4: (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-(methoxy methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8R)-8-(methoxy methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00320
  • To a stirred mixture of (3-chloro-6-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (50 mg, 0.127 mmol, 1.00 equiv) and (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine trihydrochloride (50 mg, 0.159 mmol, 1.25 equiv) in ACN (2.0 mL) was added DIEA (82 mg, 0.63 mmol, 5.0 equiv) at room temperature and the resulting mixture was stirred at 80° C. for 48 h. After cooling to room temperature, the reaction mixture was filtered and the filter cake was washed with MeOH and the combined filtrate was concentrated and the residue was purified by Prep-HPLC to afford the title compounds. MS (ES, m/z): [M+1]+=562.3.
    • Example 38 Synthesis of (3-((S)-5-amino-13-oxa-9-azadispiro[3.1.56.24]tridecan-9-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00321
  • A solution of (3-chloro-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (35 mg, 0.089 mmol, 1.00 equiv), (S)-13-oxa-9-azadispiro[3.1.56.24]tridecan-5-amine dihydrochloride (29 mg, 0.106 mmol, 1.20 equiv) and DIEA (57 mg, 0.443 mmol, 5.00 equiv) in CH3CN (0.56 mL) was stirred for 16 h at 80° C. The reaction mixture was purified by Pre-HPLC to afford the title compound (9.8 mg, 18.4%) as yellow solid. MS (ES, m/z): [M+1]+=555.2.
    • Example 39 and 40 Synthesis of (3-((S)-5-amino-13-oxa-9-azadispiro[3.1.56.24]tridecan-9-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [39]
  • Figure US20200115389A1-20200416-C00322
  • The title compound was synthesized by proceeding analogously as described in Examples 36 and 37, from (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine and (S)-13-oxa-9-azadispiro[3.1.56.24]tridecan-5-amine dihydrochloride. MS (ES, m/z): [M+1]+=585.3.
    • (3-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((methoxymethoxy)methoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol [40]
  • Figure US20200115389A1-20200416-C00323
  • was isolated as a side product.
    • Example 41 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(hydroxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00324
    • Step 1: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(hydroxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00325
  • During synthesis of Example 31, compound 42 was also isolated as side product. MS (ES, m/z): [M+1]+=515.3.
    • Example 42 Synthesis of (3S,4S)-8-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00326
    • Step 1: (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00327
  • A mixture of (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (90 mg, 0.239 mmol, 1.00 equiv), sodium 5-chloropyrazine-2-thiolate (61 mg, 0.36 mmol, 1.51 equiv) (see WO2016/203406), Pd2(dba)3 (22 mg, 0.024 mmol, 0.10 equiv), Xantphos (14 mg, 0.024 mmol, 0.10 equiv) and DIEA (93 mg, 0.72 mmol, 3.0 equiv) in THF (2 mL) was stirred for 0.5 h at 60° C. under nitrogen atmosphere. The residue was purified by silica gel column chromatography to afford the title compound (93 mg, 98.5%) as brown oil. MS (ES, m/z): [M+1]+=395.2.
    • Step 2: (3S,4S)-8-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00328
  • A solution of (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (40 mg, 0.101 mmol, 1.00 equiv), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (42 mg, 0.173 mmol, 1.70 equiv) and DIEA (65 mg, 0.50 mmol, 5.00 equiv) in CH3CN (0.40 mL) was stirred for 16 h at 100° C. The residue was purified by Pre-HPLC to afford the title compound (16 mg, 29.9%) as off-white solid. MS (ES, m/z): [M+1]+=529.3
    • Example 43 Synthesis of (3S,4S)-8-(5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00329
  • The title compound was synthesized by proceeding analogously as described in Example 42. MS (ES, m/z): [M+1]+=499.3.
    • Example 44 Synthesis of (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00330
    • Step 1: 6-chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine
  • Figure US20200115389A1-20200416-C00331
  • A mixture of (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (90.00 mg, 0.239 mmol, 1.00 equiv), sodium 3-amino-5-chloropyrazine-2-thiolate (60 mg, 0.359 mmol, 1.5 equiv) (see WO2015/107494), Pd2(dba)3 (22 mg, 0.024 mmol, 0.1 equiv), Xantphos (14 mg, 0.024 mmol, 0.1 equiv) and DIEA (93 mg, 0.72 mmol, 3.0 equiv) in THF (2.00 mL) was stirred for 0.5 h at 60° C. under nitrogen atmosphere. The residue was purified by silica gel column chromatography and to afford the title compound (93 mg, 98.9%) as a brown oil.
    • Step 2: (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00332
  • A solution of 6-chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a, 7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine (40 mg, 0.1 mmol, 1.00 equiv), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (42 mg, 0.17 mmol, 1.76 equiv) and DIEA (65 mg, 0.5 mmol, 5.1 equiv) in CH3CN (0.40 mL) was stirred for 16 h at 100° C. The residue was purified by Pre-HPLC to afford the title compound (16 mg, 30%) as off-white solid. MS (ES, m/z): [M+1]+=544.3.
    • Example 45 Synthesis of (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Figure US20200115389A1-20200416-C00333
  • The title compound was synthesized by proceeding analogously as described in Example 44. MS (ES, m/z): [M+1]+=514.3
    • Example 46 Synthesis of (S)-1′-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
  • Figure US20200115389A1-20200416-C00334
  • A solution of (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (40 mg, 0.10 mmol, 1.0 equiv), (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine trihydrochloride (48 mg, 0.15 mmol, 1.5 equiv) and DIEA (65 mg, 0.50 mmol, 5.00 equiv) in CH3CN (0.40 mL) was stirred for 16 h at 100° C. The reaction solution was purified by Pre-HPLC to afford the title compound (12.0 mg, 21.2%) as off-white solid, MS (ES, m/z): [M+1]+=562.3.
    • Example 47 Synthesis of (S)-1′-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
  • Figure US20200115389A1-20200416-C00335
  • A solution of 6-chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine (40 mg, 0.098 mmol, 1.00 equiv), (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine trihydrochloride (46 mg, 0.147 mmol, 1.50 equiv) and DIEA (63 mg, 0.487 mmol, 5.0 equiv) in CH3CN (0.40 mL) was stirred for 16 h at 100° C. The reaction solution was purified by Pre-HPLC to afford the title compound (16.0 mg, 28.4%) as an off-white solid. MS (ES, m/z): [M+1]+=577.3.
    • Example 48 Synthesis of (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo-[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00336
  • To a stirred solution of (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine trihydrochloride (28 mg, 0.09 mmol, 1.53 equiv) and DIEA (38 mg, 0.294 mmol, 5.0 equiv) in ACN (0.5 mL) was added (3-chloro-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (25 mg, 0.059 mmol, 1.00 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred overnight at 100° C. and the mixture was allowed to cool down to room temperature. The crude product was purified by Prep-HPLC to afford the title compound (6.5 mg, 18.67%) as a white solid. MS (ES, m/z): [M+1]+=592.3.
    • Example 49 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-5-methylpyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00337
  • The title compound was synthesized by proceeding analogously as described in Example 31. MS (ES, m/z): [M+1]+=573.3.
    • Example 50 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00338
    • Step 1: (3-chloro-6-(((6aS)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido-[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00339
  • Into a mixture of (6aS)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (1.00 g, 2.658 mmol, 1.00 equiv) and sodium 5-chloro-6-(hydroxymethyl)pyrazine-2-thiolate (0.78 g, 3.93 mmol, 1.48 equiv) in THF (10.00 mL) were added XantPhos (0.15 g, 0.26 mmol, 0.10 equiv) and DIEA (1.02 g, 7.892 mmol, 2.97 equiv) at room temperature. Pd2(dba)3 (0.12 g, 0.13 mmol, 0.05 equiv) was then added to the solution under nitrogen atmosphere and the resulting mixture was stirred for 1 h at 60° C. under nitrogen atmosphere. The resulting mixture was cooled to rt and filtered and the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE/EA (0-100%) to afford product (790 mg, 69.9%).
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy) methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00340
  • Into a mixture of (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (730 mg, 3.002 mmol, 1.72 equiv) and DIEA (1.30 g, 10.06 mmol, 5.77 equiv) in ACN (5 mL) was added (3-chloro-6-(((6aS)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio) pyrazin-2-yl)methanol (740 mg, 1.742 mmol, 1.00 equiv) at room temperature. The resulting mixture was stirred for 16 h at 60° C. under nitrogen atmosphere and then purified by Prep-HPLC and chiral HPLC to afford product. MS (ES, m/z): [M+1]+=559.3.
    • Example 51 and 52 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00341
    • Step 1: (6aR)-4-iodo-8-((methoxymethoxy)methyl)-6a7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
  • Figure US20200115389A1-20200416-C00342
  • The title compound was synthesized by proceeding analogously as described in Examples 29-30, steps 1-6.
    • Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro-[4.5]decan-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00343
  • A mixtures of title compounds was synthesized by proceeding analogously as described in Example 31, steps 5-8. The material was then purified by HPLC to give compounds 51 and 52. Compound 51: MS (ES, m/z): [M+1]+=559.3. Compound 52: MS (ES, m/z): [M+1]+=559.3.
    • Example 53 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00344
    • Step 1: ((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-4-yl)boronic acid
  • Figure US20200115389A1-20200416-C00345
  • To a stirred solution of (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (100 mg, 0.289 mmol, 1.00 equiv), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (110 mg, 0.433 mmol, 1.5 equiv), AcOK (57 mg, 0.581 mmol, 2.0 equiv) in toluene (2 mL) was added Pd(dppf)Cl2 (12 mg, 0.0164 mmol, 0.057 equiv) at room temperature under N2 atmosphere. The resulting mixture was stirred for 16 h at 100° C. under N2 atmosphere and the resulting mixture was used directly in next step without further purification.
    • Step 2: tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate
  • Figure US20200115389A1-20200416-C00346
  • To the mixture of ((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)boronic acid in toluene from last step were added K2CO3 (120 mg, 0.87 mmol, 3.00 equiv), tert-butyl ((3S,4S)-8-(5-bromo-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (132 mg, 0.290 mmol, 1.00 equiv), Pd(dppf)Cl2 (12.00 mg, 0.064 mmol, 0.057 equiv) and H2O (0.2 mL) under N2. After stirring for 3 h at 100° C., the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA, to afford the title compound (70 mg, 40.7%, 2 steps) as a light-yellow oil. MS (ES, m/z): [M+1]=597.3.
    • Step 3: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00347
  • A mixture of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (70 mg, 0.117 mmol, 1.00 equiv) in DCM (3 mL) and TFA (1 mL) was stirred at room temperature for 3 h. The resulting mixture was concentrated and purified by Prep-HPLC to afford the title compound (17 mg, 29.3%). MS (ES, m/z): [M+H]+=497.3.
    • Example 54 Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
  • Figure US20200115389A1-20200416-C00348
  • The title compound was synthesized by proceeding analogously as described in Example 54. MS (ES, m/z): [M+H]+=527.3.
    • Biological Assays SHP2 Allosteric Inhibition Assay
  • SHP2 possesses two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and C-terminal tail. At the basal state, SHP2 is auto-inhibited and access of substrates to the catalytic site is blocked by the intermolecular interactions between the SH2 domains and the PTP domain. When bis-tyrosyl-phosphorylated peptides bind to SH2 domain of SHP2, the PTP domain becomes available for substrate recognition and reaction catalysis and SHP2 is allosterically activated. SHP2 catalytic activity can be measured using a fluorogenic artificial substrate DiFMUP.
  • The phosphatase reactions were carried out at room temperature in 384-well black polystyrene plates (Greiner Bio-One, Cat #784076) using assay buffers containing 60 mM HEPES, pH 7.2, 75 mM NaCl, 75 mM KCl, 1 mM EDTA, 0.05% P-20, and 5 mM DTT.
  • 0.33 nM of SHP2 was co-incubated with of 0.5 μM of bisphos-IRS 1 peptide (sequence: H2N-LN(pY)IDLDLV(dPEG8)LST(pY)ASINFQK-amide) and various concentrations of compounds for 30-60 min at room temperature. Then the reaction was initiated by addition of the surrogate substrate DiFMUP (Invitrogen, Cat # D6567, 100 uM final).
  • The real-time conversion of DiFMUP to DiFMU (6, 8-difluoro-7-hydroxyl-4-methyl-coumarin) was measured every 5 min for 30 min using a microplate reader (CLARIOstar, BMG Labtech) with excitation and emission wavelengths of 340 nm and 450 nm, respectively. Initial reaction rates were determined by linear fitting of the data and the inhibitor dose response curves were analyzed using normalized IC50 regression curve fitting with control-based normalization.
  • The IC50 value for compounds as numbered in compound Table 1 above are provided below in Table 4 below, where the IC50 was measured as 100 nM or less.
  • TABLE 4
    Compound Shp2
    # from Table 1 Structure IC50(nM)
     1
    Figure US20200115389A1-20200416-C00349
         		3
     2
    Figure US20200115389A1-20200416-C00350
         		4
     3
    Figure US20200115389A1-20200416-C00351
         		13
     4
    Figure US20200115389A1-20200416-C00352
         		5
     5
    Figure US20200115389A1-20200416-C00353
         		8
     6
    Figure US20200115389A1-20200416-C00354
         		6
     7
    Figure US20200115389A1-20200416-C00355
         		6
     8
    Figure US20200115389A1-20200416-C00356
         		8
     9
    Figure US20200115389A1-20200416-C00357
         		8
    10
    Figure US20200115389A1-20200416-C00358
         		10
    11
    Figure US20200115389A1-20200416-C00359
         		14
    12
    Figure US20200115389A1-20200416-C00360
         		12
    13
    Figure US20200115389A1-20200416-C00361
         		8
    14
    Figure US20200115389A1-20200416-C00362
         		5
    15
    Figure US20200115389A1-20200416-C00363
         		10
    16
    Figure US20200115389A1-20200416-C00364
         		3
    17
    Figure US20200115389A1-20200416-C00365
         		2
    18
    Figure US20200115389A1-20200416-C00366
         		one of 21 and 22 is 13 and the other is 8
    19
    Figure US20200115389A1-20200416-C00367
    20
    Figure US20200115389A1-20200416-C00368
         		11
    21
    Figure US20200115389A1-20200416-C00369
         		13
    22
    Figure US20200115389A1-20200416-C00370
         		6
    23
    Figure US20200115389A1-20200416-C00371
         		8
    24
    Figure US20200115389A1-20200416-C00372
         		10
    25
    Figure US20200115389A1-20200416-C00373
         		11
    26 and 27
    Figure US20200115389A1-20200416-C00374
         		one of 26 and 27 is 10 and the other is 8
    Figure US20200115389A1-20200416-C00375
    28
    Figure US20200115389A1-20200416-C00376
         		13
    29
    Figure US20200115389A1-20200416-C00377
         		3.6
    30
    Figure US20200115389A1-20200416-C00378
         		3.8
    31
    Figure US20200115389A1-20200416-C00379
         		4.2
    32
    Figure US20200115389A1-20200416-C00380
         		4
    33
    Figure US20200115389A1-20200416-C00381
         		2.3
    34
    Figure US20200115389A1-20200416-C00382
         		6.2
    35
    Figure US20200115389A1-20200416-C00383
         		18
    36 and 37
    Figure US20200115389A1-20200416-C00384
         		One of 36 and 37 is 2.7 and the other is 4.2
    Figure US20200115389A1-20200416-C00385
    38
    Figure US20200115389A1-20200416-C00386
         		5.7
    39
    Figure US20200115389A1-20200416-C00387
         		7.0
    40
    Figure US20200115389A1-20200416-C00388
         		5.9
    41
    Figure US20200115389A1-20200416-C00389
         		5.0
    42
    Figure US20200115389A1-20200416-C00390
         		5.9
    43
    Figure US20200115389A1-20200416-C00391
         		4.5
    44
    Figure US20200115389A1-20200416-C00392
         		5.9
    45
    Figure US20200115389A1-20200416-C00393
         		9.4
    46
    Figure US20200115389A1-20200416-C00394
         		3.9
    47
    Figure US20200115389A1-20200416-C00395
         		8.4
    48
    Figure US20200115389A1-20200416-C00396
         		3.3
    49
    Figure US20200115389A1-20200416-C00397
         		12
    50
    Figure US20200115389A1-20200416-C00398
         		3.5
    51
    Figure US20200115389A1-20200416-C00399
         		4.9
    52
    Figure US20200115389A1-20200416-C00400
         		3.7
    • p-ERK Cellular Assay
  • Detroit562 cells were seeded in 96-well plate and cultured overnight (30,000 cells per well, 200 ul total volume). Following morning, cells were treated with compounds of the disclosure, with starting concentration at 10 uM and ½ log dilution down to 1 nM for 2 hours at 37° C. DMSO treatment serves as control. p-ERK was then measured using AlphaLISAR SureFireR Ultra™ p-ERK 1/2 (Thr202/Tyr204) Assay Kit (PerkinElmer, ALSU-PERK-A500) following instruction. Briefly, medium was removed and add 50 ul 1× lysis buffer was added, followed by 10 minutes incubation on a plate shaker at room temperature. Then 10 ul of lysate was transferred to a white 384-well plate, and 5 ul Acceptor mix, and 5 ul Donor mix were added (both prepared according to manufacturer's instruction). The plate was wrapped with foil, shaken for 1-2 minutes on a plate reader and incubated for >2 hours. Signal was then measured on a CLARIOstar® plate reader. Percentage inhibition was calculated with DMSO treatment as 100% of signal, and IC50 is calculated by Graphpad Prism 7.
    • Formulation Examples
  • The following are representative pharmaceutical formulations containing a compound of Formula (I).
    • Tablet Formulation
  • The following ingredients are mixed intimately and pressed into single scored tablets.
  • Ingredient Quantity per tablet (mg)
    Compound of the disclosure 400
    cornstarch 50
    croscarmellose sodium 25
    lactose 120
    magnesium stearate 5
    • Capsule Formulation
  • The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
  • Ingredient Quantity per capsule (mg)
    Compound of the disclosure 200
    lactose spray dried 148
    magnesium stearate 2
    • Injectable Formulation
  • Compound of the disclosure (e.g., compound 1) in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL
    • Inhalation Composition
  • To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
    • Topical Gel Composition
  • To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropyl cellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration.
    • Ophthalmic Solution Composition
  • To prepare a pharmaceutical ophthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g of NaCl in 100 mL of purified water and filtered using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
    • Nasal Spray Solution
  • To prepare a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 ul of spray for each application.

Claims (51)

1. A compound of Formula (I):
Figure US20200115389A1-20200416-C00401
wherein:
A and E are independently selected from a bond, CH2, O, NH, S, and S(O)2;
Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, —NRrC(O)C(O)Rs or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)Rc, —S(O)2Rd, —NReC(O)Rf, —NRgSO2Rh, —OC(O)NRiRj, —C(O)NRkRm, —S(O)2NRnRo, —NRpRq, or —NRrC(O)C(O)Rs and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each Rc, Rd, Rf, Rh, and Rs are independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and each Ra, Rb, Re, Rg, Ri, Rj, Rk, Rm, Rn, Ro, Rp, Rq, and Rr are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; or, independently of each other, each Ri and Rj, Rk and Rm, Rn and Ro, and Rp and Rq, together with the nitrogen atom to which they are attached form optionally substituted heterocyclyl;
R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxylalkyl, amino, and aminoalkyl;
or one of R1 and R2 and R3 and R4, when attached to the same carbon, combine to form oxo, alkyldienyl, 3 to 6 membered cycloalkylene, or 4 to 6 membered optionally substituted heterocyclylene;
R5 and R6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl, or wherein one of R5 and R6 is optionally substituted heterocyclyl and then the other R5 and R6 is selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxylalkyl, amino, and aminoalkyl;
L is bond, O, S, S(O), S(O)2, or CR7R8 where R7 and R8 are independently hydrogen or alkyl;
Z1 is a group of formula (a) or (b):
Figure US20200115389A1-20200416-C00402
wherein:
R9 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
R10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, —CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxy, cyano, or alkoxycarbonyl;
R13 is hydrogen, alkyl, halo, hydroxy, amino, or haloalkyl;
R14 is hydrogen, alkyl, or haloalkyl;
R11 and R15 are selected from amino and aminoalkyl;
R12 and R16 are selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
or R11 and R12, and R15 and R16 together with the carbon atom to which they are attached form a ring of formula (c):
Figure US20200115389A1-20200416-C00403
wherein:
e is 0, 1, or 2;
k is 0, 1, or 2 provided e+k is 1, 2, or 3;
q is 0, 1, 2, or 3;
R17 and R18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
each R19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
when two R19 groups are attached to the same carbon atom, the two R19 groups together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene;
ring D is absent or present; wherein:
(i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2, or NH; and the other of Q and W is CH2; and
(ii) when ring D is present, then Q and W are independently N or C provided only one of Q and W is N; and ring D is phenyl or a 5 or 6 membered heteroaryl ring which, including Q and W, contains one to three heteroatoms independently selected from N, O, and S and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy, and optionally substituted heterocyclyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)ORb where Rb is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
3. (canceled)
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein Z is —Y-M (wherein Y is bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O—Ra where Ra is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
5. (canceled)
6. (canceled)
7. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl, and heteroaryl are optionally substituted with one to three halo), —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, —OC(O)NRiRj, —S(O)2NRnRo, —NRpRq, or —Y-M (wherein Y is bond, O, or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are substituted with —O(alk)yRa, —O(alk)ORb, —S(O)2Rd, or —NRpRq and cycloalkyl, heterocyclyl, and heteroaryl are optionally further substituted with 1 to 3 halo).
8. The compound of claim 2, or a pharmaceutically acceptable salt thereof wherein Z is methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxymethyl, or oxetan-3-ylmethyloxymethyl.
9. (canceled)
10. The compound of claim 7, or a pharmaceutically acceptable salt thereof wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethyloxy, methoxyethyloxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethyloxymethyl, ethoxymethyloxymethyl, methoxyethyloxymethyl, cyclopropylmethyloxy, or oxetan-3-ylmethyloxymethyl.
11. (canceled)
12. The compound of claim 1, or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of formula (II):
Figure US20200115389A1-20200416-C00404
13. The compound of claim 7, and or a pharmaceutically acceptable salt thereof is wherein the compound has a structure of Formula (IIA):
Figure US20200115389A1-20200416-C00405
14. (canceled)
15. (canceled)
16. The compound of claim 13, or a pharmaceutically acceptable salt thereof wherein E is O and A is CH2 or bond.
17. (canceled)
18. The compound of claim 2, or a pharmaceutically acceptable salt thereof has a structure of formula (IIB):
Figure US20200115389A1-20200416-C00406
19-23. (canceled)
24. The compound of claim 16, or a pharmaceutically acceptable salt thereof wherein L is S.
25-27. (canceled)
28. The compound of claim 24, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxyalkyl.
29. The compound of claim 28, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxymethyl.
30-33. (canceled)
34. The compound of claim 29, or a pharmaceutically acceptable salt thereof wherein R11 and R12 together with the carbon atom to which they are attached form a ring of formula (c):
Figure US20200115389A1-20200416-C00407
35. The compound of claim 34, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
Figure US20200115389A1-20200416-C00408
36. The compound of claim 29, or a pharmaceutically acceptable salt thereof wherein R11 and R12 together with the carbon atom to which they are attached form a ring of formula (c):
Figure US20200115389A1-20200416-C00409
37. The compound of claim 36, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
Figure US20200115389A1-20200416-C00410
Figure US20200115389A1-20200416-C00411
38. The compound of claim 29, or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, and amino.
39. The compound of claim 38, or a pharmaceutically acceptable salt thereof wherein one of R1, R2, R3, and R4 is hydrogen and the remaining three of R1, R2, R3, and R4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, and amino.
40. (canceled)
41. The compound of claim 39, or a pharmaceutically acceptable salt wherein R5 is hydrogen, alkyl, halo, or amino and R6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, or cyano.
42. The compound of claim 41, or a pharmaceutically acceptable salt thereof wherein R5 and R6 are hydrogen.
43. The compound of claim 1 selected from:
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((R)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol;
(6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((R)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(2-methoxyethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(cyclopropylmethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin]-4′-yl)thio)pyrazin-2-yl)methanol;
(6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol;
(6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol;
(6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methylsulfonyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate;
(6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate;
(6-(((6aS,8S)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)methanol;
(6-(((6aS,8R)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((R)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((2-methoxyethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((cyclopropylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((oxetan-3-ylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((S)-2-amino-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-13-oxa-9-azadispiro[3.1.56.24]tridecan-9-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-13-oxa-9-azadispiro[3.1.56.24]tridecan-9-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-5-methylpyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol; and
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol;
or a pharmaceutically acceptable salt thereof.
44. A compound selected from:
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((2-methoxyethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((S)-5-amino-13-oxa-9-azadispiro[3.1.56.24]tridecan-9-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-(((methoxymethoxy)methoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3S,4S)-8-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine;
(3S,4S)-8-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine;
(S)-1′-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine;
(S)-1′-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro-[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine;
(3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-5-methylpyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol;
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol; and
(3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol; or
a pharmaceutically acceptable salt thereof.
45-49. (canceled)
50. The compound of claim 18, or a pharmaceutically acceptable salt thereof wherein L is S.
51. The compound of claim 50, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxyalkyl.
52. The compound of claim 51, or a pharmaceutically acceptable salt thereof wherein R10 is hydroxymethyl.
53. The compound of claim 52, or a pharmaceutically acceptable salt thereof wherein R11 and R12 together with the carbon atom to which they are attached form a ring of formula (c):
Figure US20200115389A1-20200416-C00412
54. The compound of claim 53, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
Figure US20200115389A1-20200416-C00413
55. The compound of claim 52, or a pharmaceutically acceptable salt thereof wherein R11 and R12 together with the carbon atom to which they are attached form a ring of formula (c):
Figure US20200115389A1-20200416-C00414
56. The compound of claim 55, or a pharmaceutically acceptable salt thereof wherein ring of formula (c) is:
Figure US20200115389A1-20200416-C00415
Figure US20200115389A1-20200416-C00416
57. The compound of claim 52, or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, and R4 are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, and amino.
58. The compound of claim 57, or a pharmaceutically acceptable salt thereof wherein one of R1, R2, R3, and R4 is hydrogen and the remaining three of R1, R2, R3, and R4 are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy, and amino.
59. The compound of claim 58, or a pharmaceutically acceptable salt wherein R5 is hydrogen, alkyl, halo, or amino and R6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, or cyano.
60. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
61. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 44 and a pharmaceutically acceptable excipient.
62. A method of treating cancer which method comprises administering to the patient in need of such treatment pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
63. A method of treating cancer which method comprises administering to the patient in need of such treatment pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 44 and a pharmaceutically acceptable excipient.
64. The method of claim 63 wherein the cancer is selected from lung, stomach, liver, colon, kidney, breast, pancreatitis, juvenile myelomonocytic leukemias, neurolastoma, melanoma, and acute myeloid leukemia.
US16/573,900 2018-09-18 2019-09-17 Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors Abandoned US20200115389A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US16/573,900 US20200115389A1 (en) 2018-09-18 2019-09-17 Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
US15/930,309 US10894797B2 (en) 2018-09-18 2020-05-12 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US17/025,790 US11518772B2 (en) 2018-09-18 2020-09-18 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US17/074,337 US11034705B2 (en) 2018-09-18 2020-10-19 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US18/051,679 US20230167134A1 (en) 2018-09-18 2022-11-01 Fused tricyclic ring derivatives as src homology-2 phosphate inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862733061P 2018-09-18 2018-09-18
US201862749655P 2018-10-23 2018-10-23
US201962810911P 2019-02-26 2019-02-26
US201962883121P 2019-08-06 2019-08-06
US201962883120P 2019-08-06 2019-08-06
US16/573,900 US20200115389A1 (en) 2018-09-18 2019-09-17 Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/930,309 Continuation US10894797B2 (en) 2018-09-18 2020-05-12 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors

Publications (1)

Publication Number Publication Date
US20200115389A1 true US20200115389A1 (en) 2020-04-16

Family

ID=68084982

Family Applications (6)

Application Number Title Priority Date Filing Date
US16/573,900 Abandoned US20200115389A1 (en) 2018-09-18 2019-09-17 Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
US17/277,293 Active US11459340B2 (en) 2018-09-18 2019-09-17 Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US15/930,309 Active 2039-10-10 US10894797B2 (en) 2018-09-18 2020-05-12 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US17/025,790 Active US11518772B2 (en) 2018-09-18 2020-09-18 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US17/074,337 Active US11034705B2 (en) 2018-09-18 2020-10-19 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US18/051,679 Pending US20230167134A1 (en) 2018-09-18 2022-11-01 Fused tricyclic ring derivatives as src homology-2 phosphate inhibitors

Family Applications After (5)

Application Number Title Priority Date Filing Date
US17/277,293 Active US11459340B2 (en) 2018-09-18 2019-09-17 Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US15/930,309 Active 2039-10-10 US10894797B2 (en) 2018-09-18 2020-05-12 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US17/025,790 Active US11518772B2 (en) 2018-09-18 2020-09-18 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US17/074,337 Active US11034705B2 (en) 2018-09-18 2020-10-19 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US18/051,679 Pending US20230167134A1 (en) 2018-09-18 2022-11-01 Fused tricyclic ring derivatives as src homology-2 phosphate inhibitors

Country Status (16)

Country Link
US (6) US20200115389A1 (en)
EP (2) EP3853233A1 (en)
JP (2) JP2022501431A (en)
KR (2) KR20210060555A (en)
CN (2) CN112996795A (en)
AU (2) AU2019344897B2 (en)
BR (1) BR112021005082A2 (en)
CA (2) CA3113233A1 (en)
CL (1) CL2021000628A1 (en)
CO (1) CO2021004436A2 (en)
CR (1) CR20210175A (en)
MX (1) MX2021003158A (en)
PH (1) PH12021550604A1 (en)
SG (1) SG11202102679QA (en)
TW (1) TWI827677B (en)
WO (2) WO2020061103A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10934302B1 (en) 2018-03-21 2021-03-02 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2022271919A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
WO2022271964A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and shp2 inhibitors combination therapy
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
US11629145B2 (en) 2016-10-24 2023-04-18 D. E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030167A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20190111079A (en) 2017-01-23 2019-10-01 레볼루션 메디슨즈, 인크. Bicyclic Compounds as Allosteric SHP2 Inhibitors
WO2018136264A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
BR112020007058A2 (en) * 2017-10-12 2020-10-06 Revolution Medicines, Inc. pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
MX2020006273A (en) 2017-12-15 2020-09-14 Revolution Medicines Inc Polycyclic compounds as allosteric shp2 inhibitors.
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN113365988B (en) * 2019-01-31 2023-10-03 贝达药业股份有限公司 SHP2 inhibitor and application thereof
WO2021043077A1 (en) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound and preparation method therefor and use thereof
CN116425742A (en) 2019-11-08 2023-07-14 锐新医药公司 Bicyclic heteroaryl compounds and uses thereof
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
MX2022016355A (en) 2020-06-18 2023-04-03 Revolution Medicines Inc Methods for delaying, preventing, and treating acquired resistance to ras inhibitors.
WO2022042331A1 (en) * 2020-08-25 2022-03-03 四川科伦博泰生物医药股份有限公司 Heterocyclic compound, and preparation method therefor and use thereof
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP4259147A1 (en) * 2020-12-11 2023-10-18 Erasca, Inc. Combination therapies for the treatment of cancer
EP4259639A1 (en) * 2020-12-11 2023-10-18 Erasca, Inc. Combination therapies for the treatment of cancer
WO2022125967A2 (en) * 2020-12-11 2022-06-16 Erasca, Inc. Combination therapies for the treatment of cancer
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
KR20230171917A (en) * 2020-12-18 2023-12-21 젠자임 코포레이션 How to make SHP2 inhibitors
WO2022206684A1 (en) * 2021-03-31 2022-10-06 南京明德新药研发有限公司 Series of se-containing pyrazine compounds and application thereof
PE20240089A1 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc RAS INHIBITORS FOR CANCER TREATMENT
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
KR20240004960A (en) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. RAS inhibitors
WO2022271966A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023044065A1 (en) * 2021-09-17 2023-03-23 Erasca, Inc. Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
CA3233995A1 (en) * 2021-10-06 2023-04-13 Leslie Harris BRAIL Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024042361A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Family Cites Families (382)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (en) 1976-09-06 1985-09-13 喜徳 喜谷 Cis platinum(2) complex of 1,2-diaminocyclohexane isomer
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS62135834A (en) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd Method for processing silver halide color photographic sensitive material
JPS62135830A (en) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material and method for processing it
JPS62135832A (en) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd Method for processing silver halide color photographic sensitive material
JPS62135835A (en) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd Method for processing silver halide color photographic sensitive material
JPS62136654A (en) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd Processing method for silver halide photographic sensitive material
JPS62136651A (en) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material and processing method therefor
JPS62136650A (en) 1985-12-11 1987-06-19 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material and processing method therefor
JPS62206545A (en) 1986-03-07 1987-09-11 Fuji Photo Film Co Ltd Silver halide photographic sensitive material
GB8729614D0 (en) 1987-12-18 1988-02-03 Beecham Group Plc Novel compounds
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
US5360459A (en) 1991-05-13 1994-11-01 The Lubrizol Corporation Copper-containing organometallic complexes and concentrates and diesel fuels containing same
JPH05196976A (en) 1991-11-18 1993-08-06 Toshiba Corp Organic nonlinear optical element
JPH05181221A (en) 1991-12-27 1993-07-23 Konica Corp Silver halide photographic sensitive material
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
FR2687932A1 (en) 1992-02-27 1993-09-03 Oreal OIL-IN-WATER DISPERSION CAPABLE OF FORMING COMPOSITE FILMS.
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998006709A1 (en) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Cyclic urea compounds, their production and use as herbicides
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
FR2761687B1 (en) 1997-04-08 2000-09-15 Centre Nat Rech Scient QUINOLEIN DERIVATIVES, ESPECIALLY HAVING ANTIVIRAL PROPERTIES, THEIR PREPARATIONS AND THEIR BIOLOGICAL APPLICATIONS
JP2000072695A (en) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd Cyclic compound
WO2000076984A2 (en) 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
MXPA02001160A (en) 1999-08-04 2002-07-02 Millennium Pharm Inc Melanocortin-4 receptor binding compounds and methods of use thereof.
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE60024651T2 (en) 1999-09-28 2006-09-28 Eisai Co., Ltd. CHINUCLIDIN COMPOUNDS AND MEDICAMENTS CONTAINING THESE AS ACTIVE ACTIVE SUBSTANCES
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4548761B2 (en) 2000-06-15 2010-09-22 富士フイルムホールディングス株式会社 Lubricant composition
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
DE10032633A1 (en) 2000-07-05 2002-01-17 Bayer Ag Method for finding protoporphyrinogen oxidase inhibitors
JP2002122954A (en) 2000-08-08 2002-04-26 Fuji Photo Film Co Ltd Photosensitive silver halide photographic emulsion, silver halide photographic material containing the same and method for enhancing sensitivity of photosensitive silver halide photographic emulsion
AU2001279955A1 (en) 2000-08-18 2002-03-04 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
AU2001294865A1 (en) 2000-09-30 2002-04-15 Loctite Low shrinkage thermosetting resin compositions and methods of use therefor
US6963001B2 (en) 2000-09-30 2005-11-08 Henkel Corporation Low shrinkage thermosetting resin compositions and methods of use therefor
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2433950A1 (en) 2001-01-16 2002-07-18 Timothy Davenport Therapeutic chromone compounds
CN100509794C (en) 2001-01-16 2009-07-08 阿斯特拉曾尼卡有限公司 Therapeutic heterocyclic compounds
SE0103646D0 (en) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic chroman compounds
US7148237B2 (en) 2001-03-01 2006-12-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity
ATE438615T1 (en) 2001-04-06 2009-08-15 Biocryst Pharm Inc BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
FR2831536A1 (en) 2001-10-26 2003-05-02 Aventis Pharma Sa NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS KDR INHIBITORS
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
BRPI0308208B8 (en) 2002-03-05 2021-05-25 Axys Pharm Inc cathepsin cysteine protease inhibitor compounds and pharmaceutical compositions comprising the same
EP1487850A2 (en) 2002-03-15 2004-12-22 Nuevolution A/S A building block forming a c-c or a c-hetero atom bond upon reaction
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
GB0306430D0 (en) 2003-03-20 2003-04-23 Bp Chem Int Ltd Polymerisation and oligomerisation catalysts
CA2525547C (en) 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
JPWO2004101529A1 (en) 2003-05-19 2006-07-13 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
JP4231379B2 (en) 2003-10-15 2009-02-25 富士フイルム株式会社 Lubricant composition
JP2005170939A (en) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd Prophylactic/therapeutic agent for diabetes
DE10355066A1 (en) 2003-11-25 2005-06-23 Basf Ag Process for asymmetric synthesis
US7632946B2 (en) 2004-02-06 2009-12-15 Abbott Laboratories Naphthyridine-based antibacterial compositions
JP4829506B2 (en) 2004-02-17 2011-12-07 石原産業株式会社 Thioamide compounds or salts thereof, and cytokine production inhibitors containing them
CA2562244A1 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
EP1595888A1 (en) 2004-05-11 2005-11-16 Degussa AG Cycloolefin phosphine ligands and their use in catalysis
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
GB0415879D0 (en) 2004-07-15 2004-08-18 Bp Chem Int Ltd Polymerisation catalyst
GB0418022D0 (en) 2004-08-12 2004-09-15 Bp Chem Int Ltd Polymerisation and oligomerisation catalyst
JP5143558B2 (en) 2004-09-02 2013-02-13 ジェネンテック，インコーポレイティド Pyridyl inhibitors of hedgehog signaling
GB0420396D0 (en) 2004-09-14 2004-10-13 Bp Chem Int Ltd Polyolefins
WO2006038594A1 (en) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N-type calcium channel inhibitor
GB2436261B (en) 2004-12-11 2010-06-09 Merck Patent Gmbh Liquid crystal compounds,liquid crystal medium and liquid crystal display
JP2008527030A (en) 2005-01-19 2008-07-24 バイオリポックス エービー Indoles useful for the treatment of inflammation
JP4749000B2 (en) 2005-02-22 2011-08-17 富士フイルム株式会社 Grease composition
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20080134938A1 (en) 2005-03-15 2008-06-12 Fujifilm Corporation Surface Treatment Method Employing Discotic Compound, (Lubricant) Composition to Be Used Surface Treatments, and Surface-Treated Articles
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2006230366A1 (en) 2005-03-31 2006-10-05 Lightwave Logic, Inc. Heterocyclical chromophore architectures with novel electronic acceptor systems
ATE524182T1 (en) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-SUBSTITUTED PYRAZINE SULPHONAMIDES AS CRTH2 INHIBITORS
AU2006239632B2 (en) 2005-04-25 2012-03-15 Merck Patent Gmbh Novel AZA- heterocycles serving as kinase inhibitors
EP1883687A1 (en) 2005-05-09 2008-02-06 Technische Universität Braunschweig Light emitting compound for electroluminescent applications
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TW200726764A (en) 2005-06-27 2007-07-16 Bristol Myers Squibb Co N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007011721A1 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
JP2007056213A (en) 2005-08-26 2007-03-08 Fujifilm Corp Composition for sintered oil-containing bearing oil, bearing device and sliding member using the same
US8710233B2 (en) 2005-10-19 2014-04-29 Gruenenthal Gmbh Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations
FR2892859B1 (en) 2005-10-27 2008-06-06 Commissariat Energie Atomique METHOD OF GRAFTING MOLECULES OF INTEREST ON INORGANIC SURFACES, SURFACES OBTAINED AND APPLICATIONS
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida Inhibition of cell proliferation
WO2007064869A2 (en) 2005-12-01 2007-06-07 Yale University Catalysts for aryl sulfide synthesis and method of producing aryl sulfides
JP2008007634A (en) 2006-06-29 2008-01-17 Fujifilm Corp Lubricant composition
AU2007288188A1 (en) 2006-08-23 2008-02-28 Xtl Biopharmaceuticals Ltd. 4-thio substituted quinoline and naphthyridine compounds
KR101436179B1 (en) 2006-09-02 2014-09-01 메르크 파텐트 게엠베하 Particle beam process for the alignment of reactive mesogens
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
US7956020B2 (en) 2007-03-29 2011-06-07 Fujifilm Corporation Lubricant composition, mechanical element, and method for producing triazine derivatives
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
CA2934114A1 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
US8063165B2 (en) 2007-06-18 2011-11-22 Bridgestone Corporation Functional polymers prepared with sulfur-containing initiators
JP2009013314A (en) 2007-07-06 2009-01-22 Toyo Ink Mfg Co Ltd Photocurable type ink
CA2982520A1 (en) 2007-08-21 2009-02-26 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
US8143276B2 (en) 2007-08-22 2012-03-27 Xtl Biopharmaceuticals Ltd. 4-thio substituted quinoline and naphthyridine compounds
DE102008035718A1 (en) 2007-08-29 2009-03-05 Merck Patent Gmbh liquid-crystal display
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
BRPI0818501A2 (en) 2007-10-08 2015-04-22 Advinus Therapeutics Private Ltd Acetamide derivatives as glycokinase activators, their process and medicinal applications
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
KR20100095430A (en) 2007-11-02 2010-08-30 메틸진 인크. Inhibitors of histone deacetylase
WO2009078813A1 (en) 2007-12-19 2009-06-25 Nanyang Technological University Method of forming oseltamivir and derivatives thereof
EP2098226A1 (en) 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA interaction inhibitors for use in the treatment of heart diseases
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
JP5847580B2 (en) 2008-07-28 2016-01-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Liquid crystal display
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010072302A1 (en) 2008-12-22 2010-07-01 Merck Patent Gmbh Liquid crystal display
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
DE102010006691A1 (en) 2009-02-06 2010-10-28 Merck Patent Gmbh Liquid-crystalline medium and liquid-crystal display
WO2010094029A2 (en) 2009-02-16 2010-08-19 University Of South Florida Asymmetric cyclopropanation with succinimidyl diazoacetate
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP2010217692A (en) 2009-03-18 2010-09-30 Konica Minolta Holdings Inc Display element
EA022753B1 (en) 2009-04-02 2016-02-29 Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii Imidazothiadiazoles useful as inhibitors of kinases
WO2010115098A2 (en) 2009-04-03 2010-10-07 The Scripps Research Institute Palladium-catalyzed ortho-fluorination
DE102010012900A1 (en) 2009-04-23 2010-11-25 Merck Patent Gmbh liquid-crystal display
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
EP2443121A2 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
CA2766033C (en) 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2292720A1 (en) 2009-09-08 2011-03-09 Merck Patent GmbH Liquid-crystal display
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
KR20110088098A (en) 2010-01-28 2011-08-03 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
KR20110101444A (en) 2010-03-08 2011-09-16 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20110104765A (en) 2010-03-17 2011-09-23 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
HUE028983T2 (en) 2010-05-06 2017-01-30 Vertex Pharma Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
CN103201267B (en) 2010-07-29 2016-08-17 里格尔药品股份有限公司 AMPK-activity heterocyclic compound and its using method
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012020357A1 (en) 2010-08-09 2012-02-16 Advinus Therapeutics Ltd. Acetamide compounds, their process and pharmaceutical application
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
EP2606033A1 (en) 2010-08-20 2013-06-26 Grünenthal GmbH Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
EP2627358B1 (en) 2010-10-14 2024-03-27 Tagworks Pharmaceuticals B.V. Pretargeting kit, method and agents used therein
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
US20120108819A1 (en) 2010-10-28 2012-05-03 Basf Se N-Heterocyclic Carbene Complexes, Their Preparation And Use
EP2632929A4 (en) 2010-10-28 2014-03-26 Basf Se N-heterocyclic carbene complexes, their preparation and use
KR20120045905A (en) 2010-11-01 2012-05-09 한국화학연구원 Heterocyclic ring fused pyrido compounds and process for preparing them
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US9427482B2 (en) 2010-12-21 2016-08-30 Koninklijke Philips N.V. Agents for clearing biomolecules from circulation
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
JP5618815B2 (en) 2010-12-24 2014-11-05 富士フイルム株式会社 Actinic ray-sensitive or radiation-sensitive resin composition, actinic ray-sensitive or radiation-sensitive film and pattern formation method using the composition
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
CN103502218B (en) 2011-03-04 2016-08-17 生命科技公司 Compounds and methods for for conjugating biomolecules
DE102012003796A1 (en) 2011-03-18 2012-09-20 Merck Patent Gmbh Liquid crystalline medium
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103459554B (en) 2011-03-29 2018-07-10 默克专利股份有限公司 Liquid crystal media
WO2013058825A1 (en) 2011-04-07 2013-04-25 Cornell University Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same
EP2522369A1 (en) 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
AU2012257418B2 (en) 2011-05-16 2017-08-03 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
JP5782836B2 (en) 2011-05-27 2015-09-24 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND COMPOUND
JP6266509B2 (en) 2011-06-03 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー Z-selective ring-closing metathesis reaction
US9520565B2 (en) 2011-06-28 2016-12-13 Merck Patent Gmbh Indaceno derivatives as organic semiconductors
EP2729550B1 (en) 2011-07-07 2018-02-21 Merck Patent GmbH Liquid-crystalline medium
EP2729513A2 (en) 2011-07-08 2014-05-14 Merck Patent GmbH Conjugated polymers
ES2731471T3 (en) 2011-09-09 2019-11-15 Lantheus Medical Imaging Inc Compositions, methods and systems for the synthesis and use of imaging agents
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
EP2615083A1 (en) 2012-01-10 2013-07-17 Studiengesellschaft Kohle mbH Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst
JP5814141B2 (en) 2012-01-23 2015-11-17 ユー・ディー・シー アイルランド リミテッド Synthesis method, compound synthesized using the synthesis method, and organic electroluminescence device
US10934487B2 (en) 2012-02-22 2021-03-02 Merck Patent Gmbh Liquid crystalline medium
JP2015518504A (en) 2012-04-03 2015-07-02 スリーエム イノベイティブ プロパティズ カンパニー Crosslinkable composition containing photobase generator
EP2838893B1 (en) 2012-04-20 2019-03-13 Bayer Cropscience AG N-cycloalkyl-n-[(heterocyclylphenyl)methylene]-(thio)carboxamide derivatives
FR2992317B1 (en) 2012-06-22 2016-05-13 Diverchim PROCESS FOR THE PREPARATION OF CHIRAL PEPTIDES
US8575283B1 (en) 2012-06-28 2013-11-05 Formosa Plastics Corporation, U.S.A. Heterocyclic organic compounds as electron donors for polyolefin catalysts
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
BR112015004637B1 (en) 2012-09-04 2022-04-05 Shanghai Hengrui Pharmaceutical Co., Ltd. Imidazoline derivatives, their uses and their preparation processes, and pharmaceutical composition
EP2897962A1 (en) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
KR101677866B1 (en) 2012-10-29 2016-11-18 코니카 미놀타 가부시키가이샤 Phase difference film, circularly polarizing plate, and image forming device
MX2015006082A (en) 2012-11-16 2015-08-12 Basf Se Lubricant compositions comprising epoxide compounds to improve fluoropolymer seal compatibility.
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
US9580653B2 (en) 2012-12-12 2017-02-28 Merck Patent Gmbh Liquid-crystalline medium
JP6335428B2 (en) 2012-12-21 2018-05-30 出光興産株式会社 Organic electroluminescence device and electronic device
US20150340627A1 (en) 2013-01-03 2015-11-26 Merck Patent Gmbh Materials for electronic devices
JP6322587B2 (en) 2013-02-08 2018-05-09 株式会社Ｊｏｌｅｄ Organic electroluminescence device
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst Modulators of vasopressin receptors with therapeutic potential
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014134141A1 (en) 2013-02-26 2014-09-04 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
WO2014141129A2 (en) 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
US9290528B1 (en) 2013-03-15 2016-03-22 University Of Kentucky Research Foundation Light-activated compounds
JP5902641B2 (en) 2013-03-27 2016-04-13 富士フイルム株式会社 Optical interference pigment and method for producing the same
WO2014165827A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
EP2984692B1 (en) 2013-04-08 2018-01-31 Merck Patent GmbH Organic electroluminescence device with thermally activated delayed fluorescence (tadf) material
CN105102581A (en) 2013-04-08 2015-11-25 默克专利有限公司 Organic electroluminescent device
US9522881B2 (en) 2013-04-26 2016-12-20 Indiana University Research And Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
JP2014232188A (en) 2013-05-29 2014-12-11 コニカミノルタ株式会社 Cellulose acylate film, circularly polarizing plate and image display device
US9862789B2 (en) 2013-07-03 2018-01-09 University Of Connecticut Polymerization of diene monomers
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
WO2015003094A2 (en) 2013-07-03 2015-01-08 Indiana University Research & Technology Corporation Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
CN104371744B (en) 2013-08-02 2019-01-01 默克专利股份有限公司 Liquid crystal media
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
KR101628288B1 (en) 2013-09-30 2016-06-08 주식회사 엘지화학 Composition for manufacturing optical elements with negative optical dispersion and optically anisotropic body manufactured therefrom
EP2857405A1 (en) 2013-10-01 2015-04-08 Studiengesellschaft Kohle mbH Process for the trans-selective hydroboration of internal alkynes
KR20160063366A (en) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Heteroaryl compounds as btk inhibitorsand uses thereof
JP6522313B2 (en) 2013-10-24 2019-05-29 出光興産株式会社 Organic electroluminescent device and electronic device
JP6088995B2 (en) 2013-10-24 2017-03-01 出光興産株式会社 Organic electroluminescence device and electronic device
KR101537860B1 (en) 2013-11-22 2015-07-20 롯데케미칼 주식회사 Polycarbonate composite increased gamma-radiation resistant property and molded article using same
JP6215674B2 (en) 2013-11-29 2017-10-18 出光興産株式会社 Organic electroluminescence device and electronic device
JP6309834B2 (en) 2013-12-11 2018-04-11 株式会社Adeka Coloring composition
JP2015163671A (en) 2013-12-13 2015-09-10 株式会社Adeka Radical-polymerizable composition
US10131841B2 (en) 2013-12-16 2018-11-20 Merck Patent Gmbh Liquid-crystalline medium
US10020455B2 (en) 2014-01-07 2018-07-10 Arizona Board Of Regents On Behalf Of Arizona State University Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues
JP6510539B2 (en) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン Substituted benzoxazines and related compounds
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
KR20150091942A (en) 2014-02-04 2015-08-12 삼성전자주식회사 Organometallic compound and organic light emitting diode including the same
JP6313604B2 (en) 2014-02-05 2018-04-18 富士フイルム株式会社 Actinic ray-sensitive or radiation-sensitive resin composition, actinic ray-sensitive or radiation-sensitive film, mask blank provided with actinic ray-sensitive or radiation-sensitive film, pattern formation method, and electronic device manufacturing method
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
EP3901145A1 (en) 2014-05-13 2021-10-27 F. Hoffmann-La Roche AG Deuterated heterocyclic compounds and their use in the synthesis of imaging agents
ES2824105T3 (en) 2014-05-16 2021-05-11 Olaplex Inc Keratin Treatment Methods and Formulations
MX361606B (en) 2014-05-19 2018-12-11 Merial Inc Anthelmintic compounds.
EP3152192A1 (en) 2014-06-05 2017-04-12 Merck Patent GmbH Novel quinoline derivatives and their use in neurodegenerative diseases
SG11201700349SA (en) 2014-07-16 2017-02-27 Agency Science Tech & Res Donor-acceptor polymers
US9818959B2 (en) 2014-07-29 2017-11-14 Arizona Board of Regents on behlaf of Arizona State University Metal-assisted delayed fluorescent emitters containing tridentate ligands
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
WO2016031785A1 (en) 2014-08-26 2016-03-03 出光興産株式会社 Organic electroluminescent element and electronic device
US10205190B2 (en) 2014-08-28 2019-02-12 Samsung Electronics Co., Ltd. Composite electrolyte including polymeric ionic liquid and inorganic particles and lithium battery including the same
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
JP2017537940A (en) 2014-12-10 2017-12-21 マサチューセッツ インスティテュート オブ テクノロジー Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
KR102384224B1 (en) 2014-12-30 2022-04-08 삼성전자주식회사 Condensed-cyclic compound and organic light emitting device including the same
WO2016145383A1 (en) 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
KR102434696B1 (en) 2015-03-13 2022-08-22 삼성전자주식회사 Organometallic compound and organic light emitting device including the same
KR20180005178A (en) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 Substituted quinazoline compounds and methods for their use
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US9815859B2 (en) 2015-05-07 2017-11-14 Bristol-Myers Squibb Company Tricyclic sulfones as RORγ modulators
US9458308B1 (en) 2015-05-12 2016-10-04 Lotte Chemical Corporation Polycarbonate resin composition with increased gamma-radiation resistant property and molded article using the same
US9879039B2 (en) 2015-06-03 2018-01-30 Arizona Board Of Regents On Behalf Of Arizona State University Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN107922388B (en) 2015-06-19 2020-12-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
ES2741746T3 (en) 2015-06-19 2020-02-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
FR3037952B1 (en) 2015-06-24 2019-01-25 Compagnie Generale Des Etablissements Michelin PROCESS FOR THE SYNTHESIS OF AROMATIC OXIMES
EP3112440B1 (en) 2015-07-02 2019-07-24 Merck Patent GmbH Liquid-crystal medium
EP3325447A1 (en) 2015-07-22 2018-05-30 Araxes Pharma LLC Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
GB201514015D0 (en) 2015-08-07 2015-09-23 Arnér Elias S J And Dept Of Health And Human Services Novel pyridazinones and their use in the treatment of cancer
GB201514018D0 (en) 2015-08-07 2015-09-23 Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic Novel tricyclic compounds and their use in the treatment of cancer
WO2017026516A1 (en) 2015-08-12 2017-02-16 持田製薬株式会社 Isothiazole derivative
EP3133078B1 (en) 2015-08-18 2019-01-30 Samsung Electronics Co., Ltd. Organometallic compound and organic light-emitting device including the same
KR101796227B1 (en) 2015-08-21 2017-11-10 삼성디스플레이 주식회사 Organic light-emitting device
US10240085B2 (en) 2015-08-27 2019-03-26 Samsung Electronics Co., Ltd. Thin film and organic light-emitting device including the same
KR102542465B1 (en) 2015-09-22 2023-06-12 삼성전자주식회사 Organometallic compound and organic light emitting device including the same
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
SE541053C2 (en) 2015-09-30 2019-03-19 Epiroc Rock Drills Ab System and method for drilling plan generation, drilling rig, computer program and computer program product
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC Method for screening inhibitors of ras
EP3162875B1 (en) 2015-10-30 2018-05-23 Merck Patent GmbH Polymerisable compounds and the use thereof in liquid-crystal displays
EP3974424A1 (en) 2015-11-02 2022-03-30 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
KR20170069342A (en) 2015-12-10 2017-06-21 삼성디스플레이 주식회사 Organic light-emitting device
CN106892924B (en) 2015-12-17 2021-01-08 四川科伦博泰生物医药股份有限公司 Short-acting benzodiazepine derivatives, method for the production thereof and use thereof
KR102579752B1 (en) 2015-12-22 2023-09-19 삼성디스플레이 주식회사 Organic light emitting device
KR20170075118A (en) 2015-12-22 2017-07-03 삼성디스플레이 주식회사 Organic light emitting device
US10336772B2 (en) 2015-12-28 2019-07-02 Samsung Electronics Co., Ltd. Bicarbazole compound, material for organic light-emitting device including bicarbazole compound, and organic light-emitting device including bicarbazole compound
KR102396293B1 (en) 2015-12-29 2022-05-11 삼성디스플레이 주식회사 Organic light-emitting device
KR102419178B1 (en) 2015-12-29 2022-07-11 삼성디스플레이 주식회사 Organic light-emitting device
WO2017117239A1 (en) 2015-12-30 2017-07-06 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
EP3190164B1 (en) 2016-01-05 2019-07-24 Samsung Electronics Co., Ltd Composition, thin film including the composition, and organic light-emitting device including the composition or the thin film
KR102633852B1 (en) 2016-01-25 2024-02-07 삼성디스플레이 주식회사 Carbazole-based compound and organic light emitting device comprising the same
EP3414231B1 (en) 2016-02-08 2020-08-19 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
KR102628850B1 (en) 2016-03-07 2024-01-25 삼성디스플레이 주식회사 Condensed cyclic compound and organic light emitting device comprising the same
CA3015817A1 (en) 2016-03-09 2017-09-14 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
ES2947636T3 (en) 2016-03-16 2023-08-14 Kura Oncology Inc Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-MLL and methods of use
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2017170263A1 (en) 2016-03-31 2017-10-05 株式会社Ｄｎｐファインケミカル Photosensitive coloring resin composition, color filter and method for producing same, and display device
KR102606277B1 (en) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 Organic light emitting device
KR102642199B1 (en) 2016-04-07 2024-03-05 삼성디스플레이 주식회사 Organic light emitting device
JP7039489B2 (en) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド KRAS G12C inhibitor
CN109475531B (en) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Heterocyclic inhibitors of PTPN11
KR20170138614A (en) 2016-06-07 2017-12-18 삼성디스플레이 주식회사 Organic light emitting device comprising the same
CN112250670B (en) * 2016-06-07 2021-06-08 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
PT3468972T (en) 2016-06-14 2020-08-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3471717A4 (en) 2016-06-20 2020-01-22 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
US20180002604A1 (en) 2016-06-30 2018-01-04 Merck Patent Gmbh Liquid-crystalline medium
CA3030167A1 (en) * 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11299673B2 (en) 2016-08-12 2022-04-12 Merck Patent Gmbh Liquid-crystal medium
KR20180019803A (en) 2016-08-16 2018-02-27 삼성디스플레이 주식회사 Organic light emitting device
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
JP6589795B2 (en) 2016-09-27 2019-10-16 信越化学工業株式会社 Sulfonium salt, resist composition and pattern forming method
US11820932B2 (en) 2016-09-28 2023-11-21 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3522247B1 (en) 2016-09-29 2023-03-22 Sumitomo Chemical Company Limited Light-emitting element
CN110312711A (en) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 Heterocyclic compound and its application method as RAS inhibitor
WO2018071620A1 (en) 2016-10-13 2018-04-19 Bristol-Myers Squibb Company Heterocyclic sulfones as ror gamma modulators
TW201819386A (en) 2016-10-24 2018-06-01 美商傳達治療有限公司 SHP2 phosphatase inhibitors and methods of use thereof
AU2017356911A1 (en) 2016-11-09 2019-06-20 Bristol-Myers Squibb Company Tricyclic sulfones as ROR gamma modulators
ES2894255T3 (en) 2016-12-22 2022-02-14 Amgen Inc Benzoisothiazole derivatives, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors to treat lung cancer pancreatic or colorectal
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018130928A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
KR20190111079A (en) 2017-01-23 2019-10-01 레볼루션 메디슨즈, 인크. Bicyclic Compounds as Allosteric SHP2 Inhibitors
WO2018136264A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CA3057582C (en) 2017-03-23 2024-01-09 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
KR102395784B1 (en) 2017-03-27 2022-05-10 삼성전자주식회사 Organometallic compound and organic light emitting device including the same
KR102461719B1 (en) 2017-05-23 2022-11-01 삼성전자주식회사 Organometallic compound, organic light emitting device including the same and a composition for diagnosing including the same
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
WO2018230595A1 (en) 2017-06-14 2018-12-20 富士フイルム株式会社 Composition, film, lens, solid state imaging element, and compound
KR20180137311A (en) 2017-06-16 2018-12-27 삼성전자주식회사 Organometallic compound, organic light emitting device including the same and a composition for diagnosing including the same
EP3645528A1 (en) 2017-06-26 2020-05-06 Esteve Pharmaceuticals, S.A. Compounds having multimodal activity against pain
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc Methods of treating epilepsy and kcnti related conditions
KR20190014187A (en) 2017-07-27 2019-02-12 삼성디스플레이 주식회사 Organometallic compound and organic light-emitting device including the same
GB201712110D0 (en) 2017-07-27 2017-09-13 Thomas Helledays Stiftelse För Medicinsk Forskning New compounds and uses
JP7346015B2 (en) 2017-09-06 2023-09-19 住友化学株式会社 light emitting element
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
JP7447002B2 (en) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド Octahydrocyclopenta[c]pyrrole allosteric inhibitor of SHP2
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
US11299676B2 (en) 2017-09-29 2022-04-12 Merck Patent Gmbh Polymerisable compounds and the use thereof in liquid-crystal displays
KR102526756B1 (en) 2017-09-29 2023-04-27 삼성전자주식회사 Organometallic compound, organic light emitting device including the same and a composition for diagnosing including the same
BR112020007058A2 (en) 2017-10-12 2020-10-06 Revolution Medicines, Inc. pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
KR102518722B1 (en) 2017-11-21 2023-04-07 삼성디스플레이 주식회사 Organometallic compound and organic light emitting device comprising the same
MX2020006273A (en) 2017-12-15 2020-09-14 Revolution Medicines Inc Polycyclic compounds as allosteric shp2 inhibitors.
CN111936484A (en) 2017-12-22 2020-11-13 拉文纳制药公司 Chromenopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
KR102595918B1 (en) 2018-01-18 2023-11-14 삼성디스플레이 주식회사 Organometallic compound, organic light emitting device comprising the same and organic emitting apparatus comprising the organic light emitting device
CN110066276B (en) 2018-01-24 2020-09-18 上海璎黎药业有限公司 Aromatic heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN110066277B (en) 2018-01-24 2021-07-23 上海璎黎药业有限公司 Aromatic heterocyclic substituted olefin compound, preparation method, pharmaceutical composition and application thereof
MA51845A (en) 2018-02-13 2020-12-23 Shanghai Blueray Biopharma Co Ltd CYCLIC COMPOUND MERGED WITH A PYRIMIDINE, ITS PREPARATION PROCESS AND ITS APPLICATION
KR20190098676A (en) 2018-02-13 2019-08-22 삼성디스플레이 주식회사 Organic light emitting device and display apparatus comprising the same
EP3755699A1 (en) 2018-02-21 2020-12-30 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
CN111902415A (en) 2018-03-02 2020-11-06 大冢制药株式会社 Pharmaceutical compounds
EP3537495A1 (en) 2018-03-08 2019-09-11 Samsung Display Co., Ltd. Organic light-emitting device
EP3537493A1 (en) 2018-03-09 2019-09-11 Samsung Display Co., Ltd Electronic apparatus
EP3768664A4 (en) 2018-03-21 2021-12-15 Chengdu SYNBLic Therapeutics Inc., Ltd. Shp2 inhibitors and uses thereof
RU2020134302A (en) 2018-03-21 2022-04-22 Рилэй Терапьютикс, Инк. SHP2 PHOSPHATASE INHIBITORS AND METHODS OF THEIR APPLICATION
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
CN108794485B (en) 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 Toll-like receptor modulators, pharmaceutical composition, preparation method and application thereof
MX2020011528A (en) 2018-05-02 2021-02-09 Navire Pharma Inc Substituted heterocyclic inhibitors of ptpn11.
CN110492006B (en) 2018-05-14 2020-06-12 江苏三月光电科技有限公司 Electroluminescent device based on boron-containing organic compound
CN108840886A (en) 2018-06-22 2018-11-20 南京工业大学 A kind of platinum complex blue light material and organic luminescent device
BR112021001292A2 (en) 2018-07-24 2021-05-11 Otsuka Pharmaceutical Co., Ltd heterobicyclic compounds to inhibit shp2 activity
CN108863982B (en) 2018-08-04 2022-02-01 南昌航空大学 Organic electrosynthesis method of phenothiazine/phenoxazine compounds
WO2020033286A1 (en) 2018-08-06 2020-02-13 Purdue Research Foundation Novel sesquiterpenoid analogs
BR112021002327A2 (en) 2018-08-10 2021-05-04 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4,5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h) derivatives -one and related compounds as ptpn11(shp2) inhibitors for cancer treatment
KR20210060555A (en) 2018-09-18 2021-05-26 니캉 테라퓨틱스 인코포레이티드 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
WO2020065453A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
BR112021005593A2 (en) 2018-09-29 2021-06-29 Novartis Ag manufacture of compounds and compositions for inhibiting shp2 activity
EP3863636A1 (en) 2018-10-08 2021-08-18 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US11629145B2 (en) 2016-10-24 2023-04-18 D. E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
US10934302B1 (en) 2018-03-21 2021-03-02 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11034705B2 (en) * 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
WO2022271919A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
WO2022271964A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and shp2 inhibitors combination therapy

Also Published As

Publication number Publication date
CA3113233A1 (en) 2020-03-26
SG11202102679QA (en) 2021-04-29
JP2022501431A (en) 2022-01-06
CA3113234A1 (en) 2020-03-26
US20210040122A1 (en) 2021-02-11
US11034705B2 (en) 2021-06-15
TWI827677B (en) 2024-01-01
PH12021550604A1 (en) 2022-02-14
US20210380604A1 (en) 2021-12-09
TW202026299A (en) 2020-07-16
CN112996795A (en) 2021-06-18
CL2021000628A1 (en) 2021-09-20
EP3853233A1 (en) 2021-07-28
JP2022501430A (en) 2022-01-06
AU2019344899A1 (en) 2021-04-15
BR112021005082A2 (en) 2021-06-08
WO2020061101A1 (en) 2020-03-26
US10894797B2 (en) 2021-01-19
JP7337174B2 (en) 2023-09-01
US20230167134A1 (en) 2023-06-01
CO2021004436A2 (en) 2021-04-30
KR20210060555A (en) 2021-05-26
CR20210175A (en) 2021-06-01
US20210188876A1 (en) 2021-06-24
US11518772B2 (en) 2022-12-06
US20200277308A1 (en) 2020-09-03
CN113227103A (en) 2021-08-06
US11459340B2 (en) 2022-10-04
AU2019344897B2 (en) 2024-01-18
AU2019344897A1 (en) 2021-04-15
KR20210060556A (en) 2021-05-26
WO2020061103A1 (en) 2020-03-26
MX2021003158A (en) 2021-07-16
EP3853234A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
US11518772B2 (en) Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10435389B2 (en) Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
ES2741746T3 (en) Compounds and compositions to inhibit SHP2 activity
TWI694076B (en) Triazolopyrimidine compounds and uses thereof
EA031573B1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
TW202317589A (en) Alkylidene derivatives as kras inhibitors
IL303661A (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
WO2022187527A1 (en) Quinazoline nitrile derivatives as kras inhibitors
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
EA044940B1 (en) DERIVATIVES OF CONDENSED TRICYCLIC RING AS PHOSPHATASE INHIBITORS WITH SRC2 HOMOLOGY DOMAIN
WO2023250029A1 (en) Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2023249968A1 (en) Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2023249970A1 (en) Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2024091409A1 (en) Tricyclic derivatives as kras inhibitors
US20230303509A1 (en) Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2024054625A2 (en) Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
WO2024045066A1 (en) Alkylidene carbamate as kras inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: NIKANG THERAPEUTICS, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FU, JIPING;LOU, YAN;HE, YIGANG;REEL/FRAME:051614/0453

Effective date: 20200103

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION